Melanin concentrating hormone receptor antagonists

Abstract

Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula I wherein W, X, Y, Z, R3-R6, and R11 are as defined in the specification, are provided. Also provided are methods of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of Formula I.

Description

BACKGROUND OF THE INVENTION

In 1999, 61% of adults, 13% of children aged 6 to 11 years and 14% of adolescents aged 12 to 19 years in the United States were overweight. Increases in occurrence of overweight and obesity has been seen in all age, racial and ethnic groups, and in both men and women.

Epidemiological studies show an increase in mortality associated with overweight and obesity. Individuals who are obese (body mass index (“BMI”)>30) have a 50-100% increased risk of premature death from all causes compared to individuals with a BMI in the range of 20 to 25. BMI is calculated according to the formula: $\mathrm{BMI}=\frac{\mathrm{Weight}\mathrm{in}\mathrm{pounds}}{{\left(\mathrm{Height}\mathrm{in}\mathrm{inches}\right)}^2}\times 703$

An estimated 300,000 deaths a year in the United States may be attributable to obesity. Overweight and obesity are associated with an increased risk for coronary heart disease; type 2 diabetes; endometrial, colon, postmenopausal breast, and other cancers; and certain musculoskeletal disorders, such as knee osteoarthritis.

Both modest and large weight gains are associated with significantly increased risk of disease. For example, a weight gain of 11 to 18 pounds increases a person's risk of developing type 2 diabetes to twice that of individuals who have not gained weight, while those who gain 44 pounds or more have four times the risk of type 2 diabetes. A gain of approximately 10 to 20 pounds results in an increased risk of coronary heart disease (nonfatal myocardial infarction and death) of 1.25 times in women and 1.6 times in men. Higher levels of body weight gain of 22 pounds in men and 44 pounds in women result in an increased coronary heart disease risk of 1.75 and 2.65, respectively. In women with a BMI of 34 or greater, the risk of developing endometrial cancer is increased by more than six times. Overweight and obesity are also known to exacerbate many chronic conditions such as hypertension and elevated cholesterol. Overweight and obese individuals also may suffer from social stigmatization, discrimination, and poor body image. Although obesity-associated morbidities occur most frequently in adults, important consequences of excess weight as well as antecedents of adult disease occur in overweight children and adolescents. Overweight children and adolescents are more likely to become overweight or obese adults; this concern is greatest among adolescents. Type 2 diabetes, high blood lipids, and hypertension as well as early maturation and orthopedic problems also occur with increased frequency in overweight youth. A common consequence of childhood overweight is psychosocial-specifically discrimination. See The Surgeon General's Call To Action To Prevent and Decrease Overweight and Obesity, U.S. Dept. of Health and Human Services, 2001. Thus, the need exists for methods of controlling weight and treating obesity.

Melanin-concentrating hormone (MCH) is a cyclic, 19-amino acid hypothalamic neuropeptide derived from a larger pro-hormone precursor of MCH, Pmch. Pmch-deficient mice are lean, hypophagic, and have an increased metabolic rate. Transgenic mice over-expressing Pmch are hyperphagic and develop mild obesity. Consequently, MCH has been implicated in the regulation of energy homeostasis, through actions on motor activity, metabolism, food intake and neuroendocrine function.

Two receptors have been identified in MCH, and are designated MCH 1 receptor and MCH 2 receptor. The MCH 1 and MCH 2 receptors are G protein-coupled receptors (GPCRs) believed to be responsible for the actions of MCH. G proteins are heterotrimeric proteins that control cellular responses to stimuli by cycling between a GTP-bound active state, which regulates the activity of a number of effector proteins, and a GDP-bound inactive state. GPCRs accelerate activation of the G protein by increasing the GDP/GTP exchange rate.

MCH 1 receptor-deficient mice have normal body weights, yet are lean and have reduced fat mass. Surprisingly, MCH 1 receptor-deficient mice are hyperphagic when maintained on regular chow, and their leanness is a consequence of hyperactivity and altered metabolism. Consistent with the hyperactivity, MCH 1 receptor-deficient mice are less susceptible to diet-induced obesity. Importantly, chronic central infusions of MCH induce hyperphagia and mild obesity in wild-type mice, but not in MCH 1 receptor-deficient mice. Marsh et al., Proc. Nat. Acad. Sci., 99(5), 3241 (2002).

Because MCH has been shown to be an important regulator of food intake and energy balance, compounds capable of modulating the activity of MCH receptors, particularly MCH 1 receptors, are highly desirable for the treatment of eating disorders and metabolic disorders.

PCT Publication No. WO 02/04433 describes phenylcycloalkylmethylamino and phenylalkenylamino derivatives as modulators of MCH 1 receptors useful in the treatment of certain metabolic, feeding and sexual disorders.

U.S. Pat. No. 6,472,394 describes the use of amide derivatives of 1,4-disubstituted piperidine as MCH antagonists for the treatment of obesity and diabetes.

SUMMARY OF THE INVENTION

Among the several objects of certain embodiments of the present invention, therefore, may be noted the provision of melanin concentrating hormone receptor antagonists; the provision of pharmaceutical compositions comprising melanin concentrating hormone receptor antagonists; the provision of methods of treating, preventing, or otherwise ameliorating melanin concentrating hormone-mediated disorders in a subject; the provision of methods for treating, preventing or otherwise ameliorating obesity in a subject; and the provision of methods of achieving sustained body weight loss in a subject.

Briefly therefore, the present invention is directed to a melanin concentrating hormone receptor antagonist of Formula I as defined herein.

The present invention is also directed to pharmaceutical compositions comprising a compound of Formula I, as defined herein, and a pharmaceutically acceptable carrier, adjuvant, or diluent.

The present invention is also directed to a method of inhibiting a GPCR, comprising contacting a compound of Formula I, as defined herein, with a GPCR, wherein the compound of Formula I is present at a concentration sufficient to inhibit the binding of a GPCR ligand in vitro. This method includes inhibiting a GPCR in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to inhibit the binding of a ligand to the GCPR in vitro. Examples of GPCRs which may be inhibited according to the present invention include, but are not limited to the following GPCR families: Acetylcholine muscarinic, Adenosine, adrenergic, adrenergic, alpha-adrenergic, angiotensin, AR, Cannabinoid, DA, dopamine, His, imidazoline, Leukotriene, mAch, MCH, Opioid, serotonergic, serotonin, and Somatostatin.

Inhibition of the binding of a GPCR ligand to GPCRs is useful in the treatment of numerous disorders, including digestive tract disorders; mucolytic asthma; arrhythmia; ischemia; reperfusion injury; bronchospasm associated with asthma, emphysema and chronic bronchitis; acute and chronic respiratory diseases, including cystic fibrosis; cardiostimulant; chronic bronchitis; neurological depression; heart failure; benign prostate hypertrophy; diabetes; muscle spasm; myocardial infarction; stroke; Alzheimer's disease; anorexia; cachexia; multiple sclerosis; hyperprolactinemia; psychotropism; mydriasis in ocular examination and surgery; deficitary and productive schizophrenia, psychasthenia and non-endogenous depression; kidney disease; vasodilation; chronic gastritis; glaucoma; depression; rhinitis, including allergic rhinitis; pain, including cancer pain, musculoskeletal pain, post-operative pain; eye disease; dyspepsia; cough; ulcer, including gastrointestinal, gastric and esophageal ulcers; helicobacter pylori prophylaxis infection; oesophagitis; allergies, including non-asthma allergies; cold; asthma; conjuctivitis; urticaria; diarrhea; Creutzfeldt-Jakob disease; dysmenorrhoea; drug addiction and drug overdose; septic shock treatment; cerebral ischaemia; drug posoning; head trauma; inflammation; pruritus; tardive dyskinesia; emesis; anxiety; motility dysfunction; cluster headaches; hypertension; cancer; irritable bowel syndrome; hemotherapy-induced nausea and vomiting; thrombosis; dementia; opiate-induced nausea and vomiting; bipolar depression; migraine; sleep disorders; traumatic shock; gastritis; gastro-oesophageal reflux; psychosis; Parkinson disease; Dependence treatment; Pre-eclampsia; Raynaud's disease; Vasospasm; haemostasis; nausea and vomiting; spasms; post-operative nausea and vomiting; alcoholism, alcohol addiction; bulimia; nicotine addiction; obsessive-compulsive disorder; panic disorder; post-traumatic stress disorder; premenstrual syndrome; and dermatitis, including allergic dermatitis.

The present invention is also directed to methods of inhibiting the binding of MCH to MCH receptors comprising contacting a compound of Formula I with cells expressing MCH receptors, wherein the compound is present at a concentration sufficient to inhibit MCH binding to MCH receptors in vitro. This method includes inhibiting the binding of MCH to MCH receptors in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to inhibit the binding of MCH to the MCH receptors in vitro. The amount of a compound of Formula I that would be sufficient to inhibit the binding of MCH to the MCH receptor in vitro may be readily determined via a MCH receptor binding assay, such as the assay described hereinbelow in Example 24.

The present invention is also directed to methods for altering the signal-transducing activity of MCH receptors, particularly the MCH receptor-mediated release of intracellular calcium, said method comprising exposing cells expressing such receptors to an effective amount of a compound of the invention. This method includes altering the signal-transducing activity of MCH receptors in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to alter the signal-transducing activity of MCH receptors in vitro. The amount of a compound that would be sufficient to alter the signal-transducing activity of MCH receptors may be determined via a MCH receptor signal transduction assay, such as the calcium mobilization assay described hereinbelow in Example 23.

The present invention is also directed to methods of using compounds of Formula I and appropriately labeled derivatives thereof as standards and reagents in determining the ability of a potential pharmaceutical to bind to MCH receptor.

The present invention is also directed to methods of treating, preventing, or otherwise ameliorating melanin concentrating hormone-mediated disorders in a subject, the method comprising administering a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically-acceptable carrier, adjuvant, or diluent to said subject.

The present invention is also directed to methods of treating or preventing obesity in a subject, the method comprising administering a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically-acceptable carrier, adjuvant, or diluent to said subject.

The present invention is also directed to methods of treating or preventing conditions such as feeding disorders, including obesity, bulimia and bulimia nervosa; sexual or reproductive disorders; depression and anxiety; epileptic seizure; hypertension; cerebral hemorrhage; congestive heart failure; sleep disturbances; or any condition in which antagonism of an MCH receptor is beneficial.

The present invention is also directed to methods of treating eating disorders, particularly obesity and bulimia nervosa, comprising administering to a subject in need of such treatment a compound of Formula I in combination with leptin, a leptin receptor agonist, or a melanocortin receptor 4 (MC4) agonist.

The present invention is also directed to methods of using compounds of Formula I as positive controls in assays for activity of GPCRs, particularly MCH.

The present invention is also directed to methods of using appropriately labeled compounds of Formula I as probes for the localization of GPCRs, particularly MCH, in tissue sections.

Other objects and features will be in part apparent and in part pointed out hereinafter.

Abbreviations and Definitions

The term “alkyl”, where used alone or within other terms such as “haloalkyl”, “alkylsulfonyl”, “alkoxyalkyl” and “hydroxyalkyl”, is a linear or branched radical having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are “lower alkyl” radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, sec-butyl, and tert-butyl), pentyl (e.g., n-pentyl and iso-amyl), hexyl, and the like.

The term “cycloalkyl” is a saturated carbocyclic radical having three to twelve carbon atoms. The cycloalkyl radical may be mono-, bi-, or tricyclic. More preferred cycloalkyl radicals are “lower cycloalkyl” radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term “alkenyl” is a linear or branched radical having at least one carbon-carbon double bond and having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkyl radicals are “lower alkenyl” radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, butenyl and 4-methylbutenyl. The terms “alkenyl” and “lower alkenyl” also are radicals having “cis” and “trans” orientations, or alternatively, “E” and “Z” orientations.

The term “cycloalkenyl” is a partially unsaturated carbocyclic radical having three to twelve carbon atoms. The cycloalkenyl radicals may be mono-, bi-, or tricyclic. More preferred cycloalkenyl radicals are “lower cycloalkenyl” radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl.

The term “alkynyl” is a linear or branched radical having at least one carbon-carbon triple bond and having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are “lower alkynyl” radicals having two to about ten carbon atoms. Most preferred are lower alkynyl radicals having two to about six carbon atoms. Examples of such radicals include propargyl, butynyl, and the like.

The terms “carboxy” or “carboxyl”, whether used alone or with other terms, such as “carboxyalkyl”, is —CO₂H.

The term “carboxyalkyl” is an alkyl radical as defined above substituted with a carboxy radical. More preferred are “lower carboxyalkyl” radicals, which are lower alkyl radicals as defined above substituted with a carboxy radical, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl, carboxyethyl and carboxypropyl.

The term “halo” is a halogen such as fluorine, chlorine, bromine or iodine.

The term “haloalkyl” is an alkyl radical as defined above wherein any one or more of the carbon atoms is substituted with halo as defined above. Specifically included are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. More preferred haloalkyl radicals are “lower haloalkyl” having one to six carbon atoms. Examples of lower haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.

The terms “alkoxy” and “alkyloxy” are linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are “lower alkoxy” radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The “alkoxy” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. More preferred haloalkoxy radicals are “lower haloalkoxy” radicals having one to six carbon atoms and one or more halo radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.

The term “alkoxyalkyl” is an alkyl radical having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and polyalkoxyalkyl radicals. More preferred alkoxyalkyl radicals are “lower alkoxyalkyl” radicals having two to twelve carbon atoms. Examples of such radicals include methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, dimethoxymethyl, dimethoxyethyl, methoxy(ethoxy)ethyl, dimethoxypropyl, and methoxy(ethoxy)propyl.

The term “alkoxycarbonyl” is a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical, i.e., an ester radical. More preferred are “lower alkoxycarbonyl” radicals with alkyl portions having one to six carbons. Examples of such lower alkoxycarbonyl radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl.

The term “hydroxyalkyl” is a linear or branched alkyl radical having one to about ten carbon atoms, any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are “lower hydroxyalkyl” radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl.

The term “alkylamino” is an amino group that has been substituted with one or two alkyl radicals. Preferred are “lower N-alkylamino” radicals having alkyl portions having one to six carbon atoms. Suitable lower alkylamino may be mono- or dialkylamino, such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino or the like.

The term “alkylaminoalkyl” is a radical having one or more alkyl radicals attached to the nitrogen atom of an aminoalkyl radical.

The term “alkylaminocarbonyl” is an aminocarbonyl group that has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are “N-alkylaminocarbonyl” “N,N-dialkylaminocarbonyl” radicals. More preferred are “lower N-alkylaminocarbonyl” and “lower N,N-dialkylaminocarbonyl” radicals with lower alkyl portions as defined above.

The term “alkylthio” is a radical containing an alkyl radical of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are “lower alkylthio” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio.

The term “alkylthioalkyl” is a radical containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkyl radicals are “lower alkylthioalkyl” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkyl radicals include methylthiomethyl, methylthioethyl, ethylthioethyl, and ethylthiopropyl.

The term “alkylsulfinyl” is a radical containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent —S(═O)— radical. More preferred alkylsulfinyl radicals are “lower alkylsulfinyl” radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl.

The term “aminoalkyl” is an alkyl radical substituted with one or more amino radicals. More preferred are “lower aminoalkyl” radicals of one to six carbon atoms. Examples of such radicals include aminomethyl, aminoethyl, and the like.

The term “aminocarbonyl” is an amide group of the formula —C(═O)NH₂.

The term “carbonyl”, whether used alone or with other terms, such as “alkoxycarbonyl”, is —(C═O)—.

The term “aryl”, alone or in combination, is a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused, and wherein at least one of the rings is aromatic. The term “aryl” includes aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl, alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkoxy, aralkoxy, hydroxyl, amino, halo, nitro, alkylamino, acyl, cyano, carboxy, aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl.

The terms “heterocyclyl” and “heterocyclo” are saturated or partially unsaturated heteroatom-containing ring-shaped radicals having one, two, or three rings wherein such rings may be attached together in a pendent manner or may be fused, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl and heterocyclo radicals include saturated 3- to 6-membered heteromonocylic radicals containing one to four nitrogen atoms (e.g., pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3- to 6-membered heteromonocyclic group containing one to two oxygen atoms and one to three nitrogen atoms (e.g., morpholinyl, etc.); saturated 3- to 6-membered heteromonocyclic group containing one to two sulfur atoms and one to three nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclyl and heterocyclo radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole.

The term “heteroaryl” is an aromatic heteroatom-containing ring-shaped radical having one, two, or three rings wherein at least one ring is aromatic. Examples of heteroaryl radicals include unsaturated 3- to 6-membered heteromonocyclic group containing one to four nitrogen atoms, e.g., pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclyl group containing one to five nitrogen atoms, e.g., indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3- to 6-membered heteromonocyclic group containing an oxygen atom, e.g., pyranyl, furyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing a sulfur atom, e.g., thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing one to two oxygen atoms and one to three nitrogen atoms, e.g., oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing one to two oxygen atoms and one to three nitrogen atoms (e.g., benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3- to 6-membered heteromonocyclic group containing one to two sulfur atoms and one to three nitrogen atoms, e.g., thiazolyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing one to two sulfur atoms and one to three nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term “heteroaryl” also includes radicals where heteroaryl radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said heterocyclyl group may be substituted at a substitutable position with one or more substituents selected independently from alkyl, hydroxyl, halo, alkoxy, oxo, amino and alkylamino.

The terms “heterocyclylalkyl” and “heterocycloalkyl” are saturated and partially unsaturated heterocyclyl-substituted alkyl radicals, such as pyrrolidinylmethyl, and heteroaryl-substituted alkyl radicals, such as pyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.

The term “acyl” is a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals.

The term “alkanoyl” or “alkylcarbonyl” are alkyl radicals as defined herein attached to a carbonyl radical. Examples of such alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, and trifluoroacetyl.

The terms “arylcarbonyl” (also called “aroyl”) and “aralkylcarbonyl” include radicals having aryl or aralkyl radicals, as defined herein, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted phenylcarbonyl, naththoyl, and benzylcarbonyl. The aryl in said aroyl and aralkylcarbonyl radicals may be additionally substituted.

The term “aralkoxy” is an aralkyl radical as defined herein attached through an oxygen atom to other radicals.

The term “aralkoxyalkyl” is an aralkoxy radical as defined herein attached through an oxygen atom to an alkyl radical.

The terms “aralkyl” and “arylalkyl” are aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. The terms benzyl and phenylmethyl are interchangeable.

The term “aralkylamino” is an aralkyl radical as defined herein attached through an amino nitrogen atom to other radicals. The terms “N-arylaminoalkyl” and “N-aryl-N-alkyl-aminoalkyl” are amino groups which have been substituted with one aryl radical or one aryl and one alkyl radical, respectively, and having the amino group attached to an alkyl radical. Examples of such radicals include N-phenylaminomethyl and N-phenyl-N-methylaminomethyl.

The term “aralkylthio” is an aralkyl radical attached to a sulfur atom.

The term “aralkylthioalkyl” is an aralkylthio radical attached through a sulfur atom to an alkyl radical.

The term “arylamino” is an amino group that has been substituted with one or two aryl radicals. An example of such arylamino radicals is N-phenylamino. The “arylamino” radicals may be further substituted on the aryl ring portion of the radical.

The term “aryloxyalkyl” is a radical having an aryl radical attached to an alkyl radical through a divalent oxygen atom.

The term “arylthioalkyl” is a radical having an aryl radical attached to an alkyl radical through a divalent sulfur atom.

The term “sulfonyl”, whether used alone or linked to other terms such as alkylsulfonyl, is a divalent —SO₂— radical.

The term “alkylsulfonyl” is an alkyl radical attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are “lower alkylsulfonyl” radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The “alkylsulfonyl” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals.

The terms “sulfamyl”, “aminosulfonyl” and “sulfonamidyl” are —SO₂NH₂.

The term “pharmaceutically acceptable” is used adjectivally herein to mean that the modified noun is appropriate for use in a pharmaceutical product; that is the “pharmaceutically-acceptable” material is relatively safe and/or non-toxic, though not necessarily providing a separable therapeutic benefit by itself. Pharmaceutically-acceptable cations include metallic ions and organic ions. More preferred metallic ions include, but are not limited to, appropriate alkali metal salts, alkaline earth metal salts and other physiologically-acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, in their usual valences. Preferred organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplary pharmaceutically acceptable acids include without limitation hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid, oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.

The term “prodrug” refers to a chemical compound that can be converted into a therapeutic compound by metabolic or simple chemical processes within the body of the subject.

The term “subject” for purposes of treatment or prevention includes any human or animal subject who is in need of treatment. The subject can be a domestic livestock species, a laboratory animal species, a zoo animal or a companion animal. In one embodiment, the subject is a mammal. In another embodiment, the mammal is a human being.

The term “PBS” stands for phosphate buffered saline.

The term “HEPES” stands for N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid.

The term “BSA” stands for bovine serum albumin.

The term “STI” stands for soybean trypsin inhibitor.

The term “Pefabloc” stands for (4-(2-aminoethyl)benzenesulfonylfluoride, HCl salt.

The term “Phosphoramidon” stands for N-α-L-rhamnopyranosyloxy(hydroxyphosphinyl)-L-leucyl-L-tryptophan.

The term “FCC” stands for flash column chromatography.

The term “K_i” stands for inhibitory rate constant.

The term “FLIPR” stands for fluorometric imaging plate reader.

The term “HEK 293” stands for the human embryonic kidney 293 cell line.

The term “Boc” stands for tert-butoxycarbonyl.

The term “DIC” stands for diisopropylcarbodiimide.

The term “DCM” stands for dichloromethane.

The term “DBU” stands for 1,8-diazabicyclo[5.4.0]undec-7-ene.

The term “phosgene” stands for COCl₂.

The term “DCE” stands for dichloroethane.

The term “DMF” stands for dimethylformamide.

The term “EtOAc” stands for ethyl acetate.

The term “HOBt” stands for 1-Hydroxybenzotriazole hydrate.

The term “MeOH” stands for methanol.

The term “TFA” stands for trifluoroacetic acid.

The MCH receptor antagonists employed in the present invention can exist in tautomeric, geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-geometric isomers, E- and Z-geometric isomers, R- and S-enantiomers, diastereomers, d- and l-isomers, the racemic mixtures thereof and other mixtures thereof. Pharmaceutically acceptable salts of such tautomeric, geometric or stereoisomeric forms are also included within the invention. The terms “cis” and “trans”, as used herein, denote a form of geometric isomerism in which two carbon atoms connected by a double bond and each substituted by a hydrogen and another group, will each have a hydrogen atom on the same side of the double bond (“cis”) or on opposite sides of the double bond (“trans”). Some of the compounds described herein contain alkenyl groups, and are meant to include both cis and trans or “E” and “Z” geometric forms. Furthermore, some of the compounds described herein contain one or more stereocenters and are meant to include R, S, and mixtures or R and S forms for each stereocenter present.

The MCH receptor antagonists utilized in the present invention may be in the form of free bases or pharmaceutically-acceptable acid addition salts thereof. The term “pharmaceutically-acceptable salts” are salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt may vary, provided that it is pharmaceutically acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds for use in the present methods may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of use in the present methods include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound of any Formula set forth herein.

The MCH receptor antagonists useful in the practice of the present invention can be formulated into pharmaceutical compositions and administered by any means that will deliver a therapeutically effective dose. Such compositions can be administered orally, parenterally, by inhalation spray, rectally, intradermally, transdermally, or topically, in dosage unit formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, e.g., Hoover, Remington's Pharmaceutical Sciences, (1975), and Liberman & Lachman, Eds., Pharmaceutical Dosage Forms, (1980).

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are useful in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, and polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the compounds discussed herein can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols, which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of active ingredient that can be combined with the carrier materials to produce a single dosage of the MCH receptor antagonist will vary depending upon the patient and the particular mode of administration. In general, the pharmaceutical compositions may contain an MCH receptor antagonist in the range of about 1 to about 250 mg, more typically, in the range of about 10 to about 200 mg and still more typically, between about 25 to about 150 mg. A daily dose of about 0.01 to about 80 mg/kg body weight, or more typically, between about 0.5 to about 50 mg/kg body weight and even more typically, from about 1 to about 25 mg/kg body weight, may be appropriate. The daily dose can be administered in one to about four doses per day.

The MCH receptor antagonists are administered in such amount as will be therapeutically effective in the treatment or control of the disorder or condition being treated. It will be appreciated that the amount of active ingredients contained in an individual dose of each dosage form need not in itself constitute an effective amount, as the necessary effective amount could be reached by administration of a number of individual doses. Those skilled in the art will appreciate that the quantity of active MCH receptor antagonist to be administered will vary depending upon the age, sex, and body weight of the subject to be treated, the type of disease, or syndrome to be treated, the particular method and scheduling of administration, and what other MCH receptor antagonist, if any, is co-administered. Dosage amounts for an individual patient may thus be above or below the typical dosage ranges. Generally speaking, the MCH receptor antagonist can be employed in any amount known to be effective at treating, preventing or controlling the disorder or condition being treated. The doses may be single doses or multiple doses per day, with the number of doses taken per day and the time allowed between doses varying depending on the individual needs of the patient. Optimization of treatment, including dosage amount, method and time of administration, is thus best determined by a skilled practitioner through close monitoring of patients on an individual basis. Those skilled in the art will appreciate that dosages may also be determined with guidance from Goodman & Goldman, The Pharmacological Basis of Therapeutics, 9th Ed. (1996), App. II, pp. 1707-1711 and from Goodman & Goldman, The Pharmacological Basis of Therapeutics, 10th Ed. (2001), App. II, pp. 475-493.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

In one embodiment of the present invention, the MCH receptor antagonist is a compound of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, having the following structure:

• • wherein:
  • W is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano;
  • X is selected from the group consisting of —OR¹, —NR¹R¹⁰, and —SR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)—, —CH₂N(R⁹)—, and —N(R¹²)C(O)N(R⁹)—;
  • R¹ is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, and heteroarylalkyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, arylcycloalkyl, and heteroarylalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R³ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano;
  • R⁴ is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and heteroarylalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, alkoxycarbonyl, and halo;
  • R⁵ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano;
  • R⁸ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano;
  • R¹¹ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; and
  • R¹² is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano;
  • X is selected from the group consisting of —OR¹, —NR¹R¹⁰, and —SR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)—, —C(O)N(R⁹)—, and —N(R¹²)C(O)N(R⁹)—;
  • R¹ is selected from the group consisting of lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl, lower aralkyl, heteroaryl, and lower heteroarylalkyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, lower arylcycloalkyl, and lower heteroarylalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R³ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano;
  • R⁴ is selected from the group consisting of a bond, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower heteroarylalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, lower alkoxycarbonyl, and halo;
  • R⁵ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano;
  • R⁸ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano;
  • R¹¹ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; and
  • R¹² is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • X is selected from the group consisting of —OR¹, —NR¹R¹⁰, and —SR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)—, —C(O)N(R⁹)—, and —N(R¹²)C(O)N(R⁹)—;
  • R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R² is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R² together with R⁸ and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R² or the ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R³ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • R⁴ is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro;
  • R⁵ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁶ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁷ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • R⁸ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R⁸ together with R² and the nitrogen to which they are attached may form an isoindolinyl ring;
  • R⁹ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R¹⁰ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • R¹¹ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; and
  • R¹² is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • W is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano;
  • X is —OR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)—, —C(O)N(R⁹)—, and —N(R¹²)C(O)N(R⁹)—;
  • R¹ is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, and heteroarylalkyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, arylcycloalkyl, and heteroarylalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R³ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano;
  • R⁴ is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and heteroarylalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, alkoxycarbonyl, and halo;
  • R⁵ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano;
  • R⁸ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano;
  • R¹¹ is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; and
  • R¹² is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano;
  • X is —OR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)—, —C(O)N(R⁹)—, and —N(R¹²)C(O)N(R⁹)—;
  • R¹ is selected from the group consisting of lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl, lower aralkyl, heteroaryl, and lower heteroarylalkyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, lower arylcycloalkyl, and lower heteroarylalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R³ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano;
  • R⁴ is selected from the group consisting of a bond, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower heteroarylalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, lower alkoxycarbonyl, and halo;
  • R⁵ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano;
  • R⁸ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano;
  • R¹¹ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; and
  • R¹² is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug-thereof, wherein:

• • W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • X is —OR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)—, —C(O)N(R⁹)—, and —N(R¹²)C(O)N(R⁹)—;
  • R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R² is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R² together with R⁸ and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R² or the ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R³ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • R⁴ is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro;
  • R⁵ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁶ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁷ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • R⁸ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R⁸ together with R² and the nitrogen to which they are attached may form an isoindolinyl ring;
  • R⁹ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R¹⁰ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • R¹¹ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; and
  • R¹² is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula II:

• • wherein:
  • W is selected from the group consisting of hydrogen, hydroxy, alkyl, and alkoxy;
  • X is selected from the group consisting of —OR¹, —NR¹R¹⁰, and —SR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)—, —C(O)N(R⁹)—, and —N(R¹²)C(O)N(R⁹)—;
  • R¹ is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R⁴ is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, alkyl, and aryl;
  • R⁸ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; and
  • R¹² is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl;
  • or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula II, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, and lower alkoxy;
  • X is selected from the group consisting of —OR¹, —NR¹R¹⁰, and —SR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)—, —C(O)N(R⁹)—, and —N(R¹²)C(O)N(R⁹)—;
  • R¹ is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R⁴ is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, lower alkyl, and aryl;
  • R⁸ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and
  • R¹² is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula II, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, and hexyloxy;
  • X is selected from the group consisting of —OR¹, —NR¹R¹⁰, and —SR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)O R², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)—, —C(O)N(R⁹)—, and —N(R¹²)C(O)N(R⁹);
  • R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R² is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R² together with R⁸ and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R² or the ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R³ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • R⁴ is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro;
  • R⁵ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁶ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁷ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl;
  • R⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁸ together with R² and the nitrogen to which they are attached may form an isoindolinyl ring;
  • R⁹ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R¹⁰ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl; and
  • R¹² is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula III:

• • wherein:
  • X is selected from the group consisting of —OR¹ and —SR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;

R² is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;

• • R⁴ is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, alkyl, and aryl;
  • R⁸ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; and
  • R¹² is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl;
  • or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula III, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • X is selected from the group consisting of —OR¹ and —SR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R⁴ is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, lower alkyl, and aryl;
  • R⁸ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and
  • R¹² is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula III, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • X is selected from the group consisting of —OR¹ and —SR¹;
  • Y is selected from the group consisting of hydrogen, —N(R⁷)C(O)NR²R⁸, —N(R⁷)C(O)OR², —N(R⁷)C(O)R², —N(R⁷)SO₂R², and —NR²R⁷;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R² is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R² together with R⁸ and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R² or the ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R³ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • R⁴ is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro;
  • R⁵ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, wherein R⁵ together with R⁶ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁶ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁷ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl;
  • R⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁸ together with R² and the nitrogen to which they are attached may form an isoindolinyl ring;
  • R⁹ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R¹⁰ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl; and
  • R¹² is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula IV:

• • wherein:
  • X is selected from the group consisting of —OR¹ and —SR¹;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R⁴ is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, alkyl, and aryl;
  • R⁸ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R⁵ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; and
  • R¹² is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl;
  • or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula IV, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • X is selected from the group consisting of —OR¹ and —SR¹;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R⁴ is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, lower alkyl, and aryl;
  • R⁸ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • R⁹ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R¹⁰ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and
  • R¹² is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula IV, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • X is selected from the group consisting of —OR¹ and —SR¹;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R² is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R² together with R⁸ and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R² or ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R³ is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano;
  • R⁴ is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro;
  • R⁵ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁶ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁷ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl;
  • R⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁸ together with R² and the nitrogen to which they are attached may form an isoindolinyl ring;
  • R⁹ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R¹⁰ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl; and
  • R¹² is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula V:

• • wherein:
  • X is selected from the group consisting of —OR¹ and —SR¹;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R⁴ is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, alkyl, and aryl;
  • R⁸ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and
  • R⁹ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula V, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • X is selected from the group consisting of —OR¹ and —SR¹;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R⁴ is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, lower alkyl, and aryl;
  • R⁸ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and
  • R⁹ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula V, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • X is selected from the group consisting of —OR¹ and —SR¹;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R² is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R² together with R⁸ and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R² or the ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R⁴ is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro;
  • R⁵ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁶ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁷ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl;
  • R⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁸ together with R² and the nitrogen to which they are attached may form an isoindolinyl ring; and
  • R⁹ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula VI:

• • wherein:
  • X is selected from the group consisting of —OR¹ and —SR¹;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R⁴ is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, alkyl, and aryl; and
  • R⁹ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula VI, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • X is selected from the group consisting of —OR¹ and —SR¹;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R² is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R⁴ is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁷ is selected from the group consisting of hydrogen, lower alkyl, and aryl;
  • R⁸ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and
  • R⁹ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula VI, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • X is selected from the group consisting of —OR¹ and —SR¹;
  • Z is selected from the group consisting of —CH═CH—, —CH₂N(R⁹)—, —C(O)N(R⁹)—, and —NHC(O)NR⁹—;
  • R¹ is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R² is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R² together with R⁸ and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R² or the ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro;
  • R⁴ is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R⁴ together with R⁹ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R⁴ or the ring formed with R⁹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro;
  • R⁵ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁶ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁷ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl;
  • R⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁸ together with R² and the nitrogen to which they are attached may form an isoindolinyl ring; and
  • R⁹ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R⁹ together with R⁴ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring.

In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula VII:

• • wherein:
  • R¹ is selected from the group consisting of cycloalkyl and aryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, and halo;
  • R² is selected from the group consisting of alkyl, aryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, aryloxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen and alkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen and alkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; and
  • R⁸ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and aryl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system;
  • or a pharmaceutically-acceptable salt, tautomer or prodrug thereof.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula VII, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • R¹ is selected from the group consisting of lower cycloalkyl and aryl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, and halo;
  • R² is selected from the group consisting of lower alkyl, aryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R² together with R⁸ and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R² or the unsaturated fused heterocyclic ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, aryloxy, and halo;
  • R⁵ is selected from the group consisting of hydrogen and lower alkyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring;
  • R⁶ is selected from the group consisting of hydrogen and lower alkyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; and
  • R⁸ is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, and aryl, or R⁸ together with R² and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula VII, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • R¹ is selected from the group consisting of cyclopentyl, cyclohexyl, phenyl, naphthyl, and biphenyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, hydroxy, methoxy, ethoxy, propoxy, chloro, bromo, and fluoro;
  • R² is selected from the group consisting of methyl, ethyl, propyl, butyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, phenylethyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, phenylethenyl, phenylpropenyl, phenylcyclopropyl, biphenylcyclopropyl, and naphthylcyclopropyl, or R² together with R⁸ and the nitrogen to which they are attached may form a ring selected from the group consisting of dihydroisoindolyl, dihydroindolyl, tetrahydroisoquinolinyl, and tetrahydroquinolinyl, wherein R² or the ring formed with R⁸ is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, hydroxy, methoxy, ethoxy, propoxy, phenoxy, naphthyloxy, biphenylyloxy, chloro, bromo, and fluoro;
  • R⁵ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or R⁵ together with R⁶ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring;
  • R⁶ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or R⁶ together with R⁵ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; and
  • R⁸ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and biphenyl, or R⁸ together with R² and the nitrogen to which they are attached may form a ring selected from the group consisting of dihydroisoindolyl, dihydroindolyl, tetrahydroisoquinolinyl, and tetrahydroquinolinyl.

In another embodiment, the MCH receptor antagonist consists of compounds of Formula VII, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein:

• • R¹ is selected from the group consisting of phenyl, and naphthyl, wherein R¹ is optionally substituted with one or more substituents selected from the group consisting of methyl, chloro, and fluoro;
  • R² is selected from the group consisting of methyl, ethyl, phenyl, naphthyl, biphenyl, benzyl, phenylethyl, cyclopentylethyl, phenylethenyl, phenylcyclopropyl, or R² together with R⁸ and the nitrogen to which they are attached may form a dihydroisoindolyl ring, wherein R² or the ring formed with R⁶ is optionally substituted with one or more substituents selected from the group consisting of methyl, propyl, methoxy, phenoxy, chloro, bromo, and fluoro;
  • R⁵ is hydrogen or R⁵ together with R⁶ and the nitrogen to which they are attached form a pyrrolidinyl ring;
  • R⁶ is hydrogen or R⁶ together with R⁵ and the nitrogen to which they are attached form a pyrrolidinyl ring; and
  • R⁸ is selected from the group consisting of hydrogen, methyl, and phenyl, or R⁸ together with R² and the nitrogen to which they are attached may form a dihydroisoindolyl ring.

In another embodiment, the compound of Formula I is selected from the group of compounds listed in Table 1.

TABLE 1
Compound
No. Structure
1
    4-[(3,4-dimethylphenyl)oxy]-3-
    {[(phenylamino)carbonyl]amino}-N-(2-(1-
    pyrrolidinyl)ethyl)benzamide
    MS m/z 473 (M + H); MW 472
5
    4-[(3,4-dimethylphenyl)oxy]-3-[(3-
    phenylpropanoyl)amino]-N-(2-(1-
    pyrrolidinyl)ethyl)benzamide
    MS m/z 486 (M + H); MW 485
6
    4-[(3,4-dimethylphenyl)oxy]-3-
    ({[(phenylmethyl)amino]carbonyl}amino)-N-
    (2-(1-pyrrolidinyl)ethyl)benzamide
    MS m/z 487 (M + H); MW 486
8
    4-(phenyloxy)-N-(2-(1-
    pyrrolidinyl)ethyl)benzamide
    MS m/z 311.4 (M + H); MW 310.4
10
    3-acetylamino-4-(3,4-dimethylphenoxy)-N-(2-
    pyrrolidin-1-yl-ethyl)benzamide
    MS m/z 396 (M + H); MW 395
11
    4-(3,4-dimethylphenoxy)-3-propionylamino-N-
    (2-pyrrolidin-1-yl-ethyl)benzamide
    MS m/z 400 (M + H); MW 409
12
    3-(3-cyclopentylpropionylamino)-4-(3,4-
    dimethylphenoxy)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 478 (M + H); MW 477
13
    4-(3,4-dimethylphenoxy)-3-
    phenylacetylarnino-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 472 (M + H); MW 471
15
    4-(3,4-dimethylphenoxy)-3-(3-phenyl-
    acryloylamino)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 484 (M + H); MW 483
16
    4-(3,4-dimethylphenoxy)-3-[(2-phenyl-
    cyclopropanecarbonyl)amino]-N-(2-
    pyrrolidin-1-yl-ethyl)benzamide
    MS m/z 498 (M + H); MW 497
17
    naphthalene-2-carboxylic acid [2-(3,4-
    dimethylphenoxy)-5-(2-pyrrolidin-1-yl-
    ethylcarbamoyl)phenyl]amide
    MS m/z 508 (M + H); MW 507
18
    4-(3,4-dimethylphenoxy)-3-(3-ethylureido)-
    N-(2-pyrrolidin-1-yl-ethyl)benzamide
    MS m/z 425 (M + H); MW 424
20
    N-(2-aminoethyl)-4-(3,4-dimethylphenoxy)-3-
    (3-phenylpropionylamino)benzamide
    MS m/z 432 (M + H); MW 431
22
    4-methoxy-3-(3-phenylpropionylamino)-N-(2-.
    pyrrolidin-1-yl-ethyl)benzamide
    MS m/z 508 (M + H); MW 507
27
    4-(naphthalen-2-yl-oxy)-3-(3-
    phenylpropionylamino)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 502 (M + H); MW 501
30
    4-(3,4-dimethylphenoxy)-3-[3-(2-
    methoxyphenyl)ureido]-N-(2-pyrroliidin-1-yl-
    ethyl)benzamide
    MS m/z 503 (M + H); MW 502
31
    3-[3-(2,4-dichlorophenyl)ureido]-4-(3,4-
    dimethylphenoxy)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 542 (M + H); MW 541
32
    4-(3,4-dimethylphenoxy)-3-[3-(4-
    phenoxyphenyl)ureido]-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 565 (M + H); MW 564
33
    3-(3-biphenyl-4-yl-ureido)-4-(3,4-
    dimethylphenoxy)-N-(2-pyrrolidin-1-yl-
    MS m/z 549 (M + H); MW 548
34
    4-(3,4-dimethylphenoxy)-3-[3-(4-
    isopropylphenyl)ureido]-N-(2-pyrrolidin-1-
    yl-ethyl)benzamide
    MS m/z 515 (M + H); MW 514
35
    4-(3,4-dimethylphenoxy)-3-[3-(2,6-
    dimethylphenyl)ureido]-N-(2-pyrrolidin-1-
    yl-ethyl)benzamide
    MS m/z 501 (M + H); MW 500
36
    4-(3,4-dimethylphenoxy)-3-(3-naphthalen-1-
    yl-ureido)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 523 (M + H); MW 522
37
    3-[3-(2,6-diisopropylphenyl)ureido]-4-(3,4-
    dimethylphenoxy)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 557 (M + H); MW 556
38
    3-[3-(4-bromophenyl)ureido]-4-(3,4-
    dimethylpherioxy)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 553 (M + H); MW 552
39
    4-(3,4-dimethylphenoxy)-3-[3-(3-
    fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 491 (M + H); MW 490
40
    4-(3,4-dimethylphenoxy)-3-[3-(3-
    methoxyphenyl)ureido]-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 503 (M + H); MW 502
41
    3-[3-(2-chlorophenyl)ureido]-4-(3,4-
    dimethylphenoxy)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 507 (M + H); MW 506
42
    4-(3,4-dimethylphenoxy)-3-(3,3-
    diphenylureido)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 549 (M + H); MW 548
43
    4-(3,4-dimethylphenoxy)-3-(3-methyl-3-
    phenylureido)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 487 (M + H); MW 486
50
    1,3-dihydroisoindole-2-carboxylic acid [2-
    (3,4-dimethylphenoxy)-5-(2-pyrrolidin-1-yl-
    ethylcarbamoyl)phenyl]amide
    MS m/z 499 (M + H); MW 498
51
    4-(4-fluoro-3-methylphenoxy)-3-[3-(3-
    fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 495 (M + H); MW 494
52
    4-(3,4-dichlorophenoxy)-3-[3-(3-
    fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 531 (M + H); MW 530
53
    4-(3,4-difluorophenoxy)-3-[3-(3-
    fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 499 (M + H); MW 498
54
    4-(4-fluorophenoxy)-3-[3-(3-
    fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 481 (M + H); MW 480
55
    4-(3-fluorophenoxy)-3-[3-(3-
    fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 481 (M + H); MW 480
56
    3-[3-(3-fluorophenyl)ureido]-N-(2-
    pyrrolidin-1-yl-ethyl)-4-p-
    tolyloxybenzamide
    MS m/z 477 (M + H); MW 476
57
    3-[3-(3-fluorophenyl)ureidol-N-(2-
    pyrrolidin-1-yl-ethyl)-4-m-
    tolyloxybenzamide
    MS m/z 477 (M + H); MW 476
58
    3-[3-(3,5-difluorophenyl)ureido]-4-(3,4-
    dimethylphenoxy)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 509 (M + H); MW 508
59
    3-[3-(3,5-dichlorophenyl)ureido]-4-(3,4-
    dimethylphenoxy)-N-(2-pyrrolidin-1-yl-
    ethyl)benzamide
    MS m/z 541 (M + H); MW 540
61
    3-[3-(3-fluorophenyl)ureido]-4-phenoxy-N-
    (2-pyrrolidin-1-yl-ethyl)benzamide
    MS m/z 463 (M + H); MW 462
63
    1-(2-(3,4-dimethylphenoxy)-5-(2-pyrrolidin-
    1-yl-methylpyrrolidine-1-carbonyl)phenyl]-
    3-phenylurea
    MS m/z 513 (M + H); MW 512
64
    1-{2-(3,4-dimethylphenoxy)-5-[(2-
    pyrrolidin-1-yl-ethylamino)-methyl]phenyl}-
    3-(3-fluorophenyl)urea
    MS m/z 477 (M + H); MW 476
65
    1-[2-(3,4-dimethylphenoxy)-5-(2-pyrrolidin-
    1-yl-methylpyrrolidine-1-carbonyl)phenyl]-
    3-phenylurea
    MS m/z 513 (M + H); MW 512
66
    4-(3,4-dichlorophenoxy)-3-[3-(3,5-
    difluorophenyl)ureido]-N-(2-pyrrolidin-1-
    yl-ethyl)benzamide
    MS m/z 549 (M + H); MW 548

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

TABLE 2
Compound
No.	R2a	R2b	R2c	R2d	R2e
200	H	CH3	CH3	H	H
201	H	CH3	CH3	CH3	H
202	H	CH3	CH3	OCH3	H
203	H	CH3	CH3	Cl	H
204	H	CH3	CH3	Br	H
205	H	CH3	CH3	F	H
206	H	CH3	CH3	H	CH3
207	H	CH3	CH3	CH3	CH3
208	H	CH3	CH3	H	OCH3
209	H	CH3	CH3	CH3	OCH3
210	H	CH3	CH3	OCH3	OCH3
211	H	CH3	CH3	Cl	OCH3
212	H	CH3	CH3	Br	OCH3
213	H	CH3	CH3	F	OCH3
214	H	CH3	CH3	H	Cl
215	H	CH3	CH3	CH3	Cl
216	H	CH3	CH3	OCH3	Cl
217	H	CH3	CH3	Cl	Cl
218	H	CH3	CH3	Br	Cl
219	H	CH3	CH3	F	Cl
220	H	CH3	CH3	H	Br
221	H	CH3	CH3	CH3	Br
222	H	CH3	CH3	OCH3	Br
223	H	CH3	CH3	Cl	Br
224	H	CH3	CH3	Br	Br
225	H	CH3	CH3	F	Br
226	H	CH3	CH3	H	F
227	H	CH3	CH3	CH3	F
228	H	CH3	CH3	OCH3	F
229	H	CH3	CH3	Cl	F
230	H	CH3	CH3	Br	F
231	H	CH3	CH3	F	F
232	H	CH3	OCH3	H	H
233	H	CH3	OCH3	CH3	H
234	H	CH3	OCH3	OCH3	H
235	H	CH3	OCH3	Cl	H
236	H	CH3	OCH3	Br	H
237	H	CH3	OCH3	F	H
238	H	CH3	OCH3	H	CH3
239	H	CH3	OCH3	CH3	CH3
240	H	CH3	OCH3	OCH3	CH3
241	H	CH3	OCH3	Cl	CH3
242	H	CH3	OCH3	Br	CH3
243	H	CH3	OCH3	F	CH3
244	H	CH3	OCH3	H	OCH3
245	H	CH3	OCH3	OCH3	OCH3
246	H	CH3	OCH3	H	Cl
247	H	CH3	OCH3	CH3	Cl
248	H	CH3	OCH3	OCH3	Cl
249	H	CH3	OCH3	Cl	Cl
250	H	CH3	OCH3	Br	Cl
251	H	CH3	OCH3	F	Cl
252	H	CH3	OCH3	H	Br
253	H	CH3	OCH3	CH3	Br
254	H	CH3	OCH3	OCH3	Br
255	H	CH3	OCH3	Cl	Br
256	H	CH3	OCH3	Br	Br
257	H	CH3	OCH3	F	Br
258	H	CH3	OCH3	H	F
259	H	CH3	OCH3	CH3	F
260	H	CH3	OCH3	OCH3	F
261	H	CH3	OCH3	Cl	F
262	H	CH3	OCH3	Br	F
263	H	CH3	OCH3	F	F
264	H	CH3	Cl	H	H
265	H	CH3	Cl	CH3	H
266	H	CH3	Cl	OCH3	H
267	H	CH3	Cl	Cl	H
268	H	CH3	Cl	Br	H
269	H	CH3	Cl	F	H
270	H	CH3	Cl	H	CH3
271	H	CH3	Cl	CH3	CH3
272	H	CH3	Cl	OCH3	CH3
273	H	CH3	Cl	Cl	CH3
274	H	CH3	Cl	Br	CH3
275	H	CH3	Cl	F	CH3
276	H	CH3	Cl	H	OCH3
277	H	CH3	Cl	CH3	OCH3
278	H	CH3	Cl	OCH3	OCH3
279	H	CH3	Cl	Cl	OCH3
280	H	CH3	Cl	Br	OCH3
281	H	CH3	Cl	F	OCH3
282	H	CH3	Cl	H	Cl
283	H	CH3	Cl	Cl	Cl
284	H	CH3	Cl	H	Br
285	H	CH3	Cl	CH3	Br
286	H	CH3	Cl	OCH3	Br
287	H	CH3	Cl	Cl	Br
288	H	CH3	Cl	Br	Br
289	H	CH3	Cl	F	Br
290	H	CH3	Cl	H	F
291	H	CH3	Cl	CH3	F
292	H	CH3	Cl	OCH3	F
293	H	CH3	Cl	Cl	F
294	H	CH3	Cl	F	F
295	H	CH3	Br	H	H
296	H	CH3	Br	CH3	H
297	H	CH3	Br	OCH3	H
298	H	CH3	Br	Cl	H
299	H	CH3	Br	Br	H
300	H	CH3	Br	F	H
301	H	CH3	Br	H	CH3
302	H	CH3	Br	CH3	CH3
303	H	CH3	Br	OCH3	CH3
304	H	CH3	Br	Cl	CH3
305	H	CH3	Br	Br	CH3
306	H	CH3	Br	F	CH3
307	H	CH3	Br	H	OCH3
308	H	CH3	Br	CH3	OCH3
309	H	CH3	Br	OCH3	OCH3
310	H	CH3	Br	Cl	OCH3
311	H	CH3	Br	Br	OCH3
312	H	CH3	Br	F	OCH3
313	H	CH3	Br	H	Cl
314	H	CH3	Br	CH3	Cl
315	H	CH3	Br	OCH3	Cl
316	H	CH3	Br	Cl	Cl
317	H	CH3	Br	Br	Cl
318	H	CH3	Br	F	Cl
319	H	CH3	Br	H	Br
320	H	CH3	Br	Br	Br
321	H	CH3	Br	H	F
322	H	CH3	Br	CH3	F
323	H	CH3	Br	OCH3	F
324	H	CH3	Br	Cl	F
325	H	CH3	Br	Br	F
326	H	CH3	Br	F	F
327	H	CH3	F	H	H
328	H	CH3	F	CH3	H
329	H	CH3	F	OCH3	H
330	H	CH3	F	Cl	H
331	H	CH3	F	Br	H
332	H	CH3	F	F	H
333	H	CH3	F	H	CH3
334	H	CH3	F	CH3	CH3
335	H	CH3	F	OCH3	CH3
336	H	CH3	F	Cl	CH3
337	H	CH3	F	Br	CH3
338	H	CH3	F	F	CH3
339	H	CH3	F	H	OCH3
340	H	CH3	F	CH3	OCH3
341	H	CH3	F	OCH3	OCH3
342	H	CH3	F	Cl	OCH3
343	H	CH3	F	Br	OCH3
344	H	CH3	F	F	OCH3
345	H	CH3	F	H	Cl
346	H	CH3	F	CH3	Cl
347	H	CH3	F	OCH3	Cl
348	H	CH3	F	Cl	Cl
349	H	CH3	F	Br	Cl
350	H	CH3	F	F	Cl
351	H	CH3	F	H	Br
352	H	CH3	F	CH3	Br
353	H	CH3	F	OCH3	Br
354	H	CH3	F	Cl	Br
355	H	CH3	F	Br	Br
356	H	CH3	F	F	Br
357	H	CH3	F	H	F
358	H	CH3	F	F	F
359	H	OCH3	CH3	H	H
360	H	OCH3	CH3	H	CH3
361	H	OCH3	CH3	H	OCH3
362	H	OCH3	CH3	H	Cl
363	H	OCH3	CH3	H	Br
364	H	OCH3	CH3	H	F
365	H	OCH3	CH3	CH3	H
366	H	OCH3	CH3	CH3	CH3
367	H	OCH3	CH3	CH3	OCH3
368	H	OCH3	CH3	CH3	Cl
369	H	OCH3	CH3	CH3	Br
370	H	OCH3	CH3	CH3	F
371	H	OCH3	CH3	OCH3	H
372	H	OCH3	CH3	OCH3	OCH3
373	H	OCH3	CH3	OCH3	Cl
374	H	OCH3	CH3	OCH3	Br
375	H	OCH3	CH3	OCH3	F
376	H	OCH3	CH3	Cl	H
377	H	OCH3	CH3	Cl	OCH3
378	H	OCH3	CH3	Cl	Cl
379	H	OCH3	CH3	Cl	Br
380	H	OCH3	CH3	Cl	F
381	H	OCH3	CH3	Br	H
382	H	OCH3	CH3	Br	OCH3
383	H	OCH3	CH3	Br	Cl
384	H	OCH3	CH3	Br	Br
385	H	OCH3	CH3	Br	F
386	H	OCH3	CH3	F	H
387	H	OCH3	CH3	F	OCH3
388	H	OCH3	CH3	F	Cl
389	H	OCH3	CH3	F	Br
390	H	OCH3	CH3	F	F
391	H	OCH3	OCH3	H	H
392	H	OCH3	OCH3	H	CH3
393	H	OCH3	OCH3	H	OCH3
394	H	OCH3	OCH3	H	Cl
395	H	OCH3	OCH3	H	Br
396	H	OCH3	OCH3	H	F
397	H	OCH3	OCH3	CH3	H
398	H	OCH3	OCH3	CH3	CH3
399	H	OCH3	OCH3	CH3	Cl
400	H	OCH3	OCH3	CH3	Br
401	H	OCH3	OCH3	CH3	F
402	H	OCH3	OCH3	OCH3	H
403	H	OCH3	OCH3	OCH3	CH3
404	H	OCH3	OCH3	OCH3	OCH3
405	H	OCH3	OCH3	OCH3	Cl
406	H	OCH3	OCH3	OCH3	Br
407	H	OCH3	OCH3	OCH3	F
408	H	OCH3	OCH3	Cl	H
409	H	OCH3	OCH3	Cl	CH3
410	H	OCH3	OCH3	Cl	Cl
411	H	OCH3	OCH3	Cl	Br
412	H	OCH3	OCH3	Cl	F
413	H	OCH3	OCH3	Br	H
414	H	OCH3	OCH3	Br	CH3
415	H	OCH3	OCH3	Br	Cl
416	H	OCH3	OCH3	Br	Br
417	H	OCH3	OCH3	Br	F
418	H	OCH3	OCH3	F	H
419	H	OCH3	OCH3	F	CH3
420	H	OCH3	OCH3	F	Cl
421	H	OCH3	OCH3	F	Br
422	H	OCH3	OCH3	F	F
423	H	OCH3	Cl	H	H
424	H	OCH3	Cl	H	CH3
425	H	OCH3	Cl	H	OCH3
426	H	OCH3	Cl	H	Cl
427	H	OCH3	Cl	H	Br
428	H	OCH3	Cl	H	F
429	H	OCH3	Cl	CH3	H
430	H	OCH3	Cl	CH3	CH3
431	H	OCH3	Cl	CH3	OCH3
432	H	OCH3	Cl	CH3	Br
433	H	OCH3	Cl	CH3	F
434	H	OCH3	Cl	OCH3	H
435	H	OCH3	Cl	OCH3	CH3
436	H	OCH3	Cl	OCH3	OCH3
437	H	OCH3	Cl	OCH3	Br
438	H	OCH3	Cl	OCH3	F
439	H	OCH3	Cl	Cl	H
440	H	OCH3	Cl	Cl	CH3
441	H	OCH3	Cl	Cl	OCH3
442	H	OCH3	Cl	Cl	Cl
443	H	OCH3	Cl	Cl	Br
444	H	OCH3	Cl	Cl	F
445	H	OCH3	Cl	Br	H
446	H	OCH3	Cl	Br	CH3
447	H	OCH3	Cl	Br	OCH3
448	H	OCH3	Cl	Br	Br
449	H	OCH3	Cl	F	H
450	H	OCH3	Cl	F	CH3
451	H	OCH3	Cl	F	OCH3
452	H	OCH3	Cl	F	Br
453	H	OCH3	Cl	F	F
454	H	OCH3	Br	H	H
455	H	OCH3	Br	H	CH3
456	H	OCH3	Br	H	OCH3
457	H	OCH3	Br	H	Cl
458	H	OCH3	Br	H	Br
459	H	OCH3	Br	H	F
460	H	OCH3	Br	CH3	H
461	H	OCH3	Br	CH3	CH3
462	H	OCH3	Br	CH3	OCH3
463	H	OCH3	Br	CH3	Cl
464	H	OCH3	Br	CH3	F
465	H	OCH3	Br	OCH3	H
466	H	OCH3	Br	OCH3	CH3
467	H	OCH3	Br	OCH3	OCH3
468	H	OCH3	Br	OCH3	Cl
469	H	OCH3	Br	OCH3	F
470	H	OCH3	Br	Cl	H
471	H	OCH3	Br	Cl	CH3
472	H	OCH3	Br	Cl	OCH3
473	H	OCH3	Br	Cl	Cl
474	H	OCH3	Br	Cl	F
475	H	OCH3	Br	Br	H
476	H	OCH3	Br	Br	CH3
477	H	OCH3	Br	Br	OCH3
478	H	OCH3	Br	Br	Cl
479	H	OCH3	Br	Br	Br
480	H	OCH3	Br	Br	F
481	H	OCH3	Br	F	H
482	H	OCH3	Br	F	CH3
483	H	OCH3	Br	F	OCH3
484	H	OCH3	Br	F	Cl
485	H	OCH3	Br	F	F
486	H	OCH3	F	H	H
487	H	OCH3	F	H	CH3
488	H	OCH3	F	H	OCH3
489	H	OCH3	F	H	Cl
490	H	OCH3	F	H	Br
491	H	OCH3	F	H	F
492	H	OCH3	F	CH3	H
493	H	OCH3	F	CH3	CH3
494	H	OCH3	F	CH3	OCH3
495	H	OCH3	F	CH3	Cl
496	H	OCH3	F	CH3	Br
497	H	OCH3	F	OCH3	H
498	H	OCH3	F	OCH3	CH3
499	H	OCH3	F	OCH3	OCH3
500	H	OCH3	F	OCH3	Cl
501	H	OCH3	F	OCH3	Br
502	H	OCH3	F	Cl	H
503	H	OCH3	F	Cl	CH3
504	H	OCH3	F	Cl	OCH3
505	H	OCH3	F	Cl	Cl
506	H	OCH3	F	Cl	Br
507	H	OCH3	F	Br	H
508	H	OCH3	F	Br	CH3
509	H	OCH3	F	Br	OCH3
510	H	OCH3	F	Br	Cl
511	H	OCH3	F	Br	Br
512	H	OCH3	F	F	H
513	H	OCH3	F	F	CH3
514	H	OCH3	F	F	OCH3
515	H	OCH3	F	F	Cl
516	H	OCH3	F	F	Br
517	H	OCH3	F	F	F
518	H	Cl	CH3	H	H
519	H	Cl	CH3	H	CH3
520	H	Cl	CH3	H	OCH3
521	H	Cl	CH3	H	Cl
522	H	Cl	CH3	H	Br
523	H	Cl	CH3	H	F
524	H	Cl	CH3	CH3	H
525	H	Cl	CH3	CH3	CH3
526	H	Cl	CH3	CH3	OCH3
527	H	Cl	CH3	CH3	Cl
528	H	Cl	CH3	CH3	Br
529	H	Cl	CH3	CH3	F
530	H	Cl	CH3	OCH3	H
531	H	Cl	CH3	OCH3	OCH3
532	H	Cl	CH3	OCH3	Cl
533	H	Cl	CH3	OCH3	Br
534	H	Cl	CH3	OCH3	F
535	H	Cl	CH3	Cl	H
536	H	Cl	CH3	Cl	OCH3
537	H	Cl	CH3	Cl	Cl
538	H	Cl	CH3	Cl	Br
539	H	Cl	CH3	Cl	F
540	H	Cl	CH3	Br	H
541	H	Cl	CH3	Br	OCH3
542	H	Cl	CH3	Br	Cl
543	H	Cl	CH3	Br	Br
544	H	Cl	CH3	Br	F
545	H	Cl	CH3	F	H
546	H	Cl	CH3	F	OCH3
547	H	Cl	CH3	F	Cl
548	H	Cl	CH3	F	Br
549	H	Cl	CH3	F	F
550	H	Cl	OCH3	H	H
551	H	Cl	OCH3	H	CH3
552	H	Cl	OCH3	H	OCH3
553	H	Cl	OCH3	H	Cl
554	H	Cl	OCH3	H	Br
555	H	Cl	OCH3	H	F
556	H	Cl	OCH3	CH3	H
557	H	Cl	OCH3	CH3	CH3
558	H	Cl	OCH3	CH3	Cl
559	H	Cl	OCH3	CH3	Br
560	H	Cl	OCH3	CH3	F
561	H	Cl	OCH3	OCH3	H
562	H	Cl	OCH3	OCH3	CH3
563	H	Cl	OCH3	OCH3	OCH3
564	H	Cl	OCH3	OCH3	Cl
565	H	Cl	OCH3	OCH3	Br
566	H	Cl	OCH3	OCH3	F
567	H	Cl	OCH3	Cl	H
568	H	Cl	OCH3	Cl	CH3
569	H	Cl	OCH3	Cl	Cl
570	H	Cl	OCH3	Cl	Br
571	H	Cl	OCH3	Cl	F
572	H	Cl	OCH3	Br	H
573	H	Cl	OCH3	Br	CH3
574	H	Cl	OCH3	Br	Cl
575	H	Cl	OCH3	Br	Br
576	H	Cl	OCH3	Br	F
577	H	Cl	OCH3	F	H
578	H	Cl	OCH3	F	CH3
579	H	Cl	OCH3	F	Cl
580	H	Cl	OCH3	F	Br
581	H	Cl	OCH3	F	F
582	H	Cl	Cl	H	H
583	H	Cl	Cl	H	CH3
584	H	Cl	Cl	H	OCH3
585	H	Cl	Cl	H	Cl
586	H	Cl	Cl	H	Br
587	H	Cl	Cl	H	F
588	H	Cl	Cl	CH3	H
589	H	Cl	Cl	CH3	CH3
590	H	Cl	Cl	CH3	OCH3
591	H	Cl	Cl	CH3	Br
592	H	Cl	Cl	CH3	F
593	H	Cl	Cl	OCH3	H
594	H	Cl	Cl	OCH3	CH3
595	H	Cl	Cl	OCH3	OCH3
596	H	Cl	Cl	OCH3	Br
597	H	Cl	Cl	OCH3	F
598	H	Cl	Cl	Cl	H
599	H	Cl	Cl	Cl	CH3
600	H	Cl	Cl	Cl	OCH3
601	H	Cl	Cl	Cl	Cl
602	H	Cl	Cl	Cl	Br
603	H	Cl	Cl	Cl	F
604	H	Cl	Cl	Br	H
605	H	Cl	Cl	Br	CH3
606	H	Cl	Cl	Br	OCH3
607	H	Cl	Cl	Br	Br
608	H	Cl	Cl	F	H
609	H	Cl	Cl	F	CH3
610	H	Cl	Cl	F	OCH3
611	H	Cl	Cl	F	Br
612	H	Cl	Cl	F	F
613	H	Cl	Br	H	H
614	H	Cl	Br	H	CH3
615	H	Cl	Br	H	OCH3
616	H	Cl	Br	H	Cl
617	H	Cl	Br	H	Br
618	H	Cl	Br	H	F
619	H	Cl	Br	CH3	H
620	H	Cl	Br	CH3	CH3
621	H	Cl	Br	CH3	OCH3
622	H	Cl	Br	CH3	Cl
623	H	Cl	Br	CH3	F
624	H	Cl	Br	OCH3	H
625	H	Cl	Br	OCH3	CH3
626	H	Cl	Br	OCH3	OCH3
627	H	Cl	Br	OCH3	Cl
628	H	Cl	Br	OCH3	F
629	H	Cl	Br	Cl	H
630	H	Cl	Br	Cl	CH3
631	H	Cl	Br	Cl	OCH3
632	H	Cl	Br	Cl	Cl
633	H	Cl	Br	Cl	F
634	H	Cl	Br	Br	H
635	H	Cl	Br	Br	CH3
636	H	Cl	Br	Br	OCH3
637	H	Cl	Br	Br	Cl
638	H	Cl	Br	Br	Br
639	H	Cl	Br	Br	F
640	H	Cl	Br	F	H
641	H	Cl	Br	F	CH3
642	H	Cl	Br	F	OCH3
643	H	Cl	Br	F	Cl
644	H	Cl	Br	F	F
645	H	Cl	F	H	H
646	H	Cl	F	H	CH3
647	H	Cl	F	H	OCH3
648	H	Cl	F	H	Cl
649	H	Cl	F	H	Br
650	H	Cl	F	H	F
651	H	Cl	F	CH3	H
652	H	Cl	F	CH3	CH3
653	H	Cl	F	CH3	OCH3
654	H	Cl	F	CH3	Cl
655	H	Cl	F	CH3	Br
656	H	Cl	F	OCH3	H
657	H	Cl	F	OCH3	CH3
658	H	Cl	F	OCH3	OCH3
659	H	Cl	F	OCH3	Cl
660	H	Cl	F	OCH3	Br
661	H	Cl	F	Cl	H
662	H	Cl	F	Cl	CH3
663	H	Cl	F	Cl	OCH3
664	H	Cl	F	Cl	Cl
665	H	Cl	F	Cl	Br
666	H	Cl	F	Br	H
667	H	Cl	F	Br	CH3
668	H	Cl	F	Br	OCH3
669	H	Cl	F	Br	Cl
670	H	Cl	F	Br	Br
671	H	Cl	F	F	H
672	H	Cl	F	F	CH3
673	H	Cl	F	F	OCH3
674	H	Cl	F	F	Cl
675	H	Cl	F	F	Br
676	H	Cl	F	F	F
677	H	Br	CH3	H	H
678	H	Br	CH3	H	CH3
679	H	Br	CH3	H	OCH3
680	H	Br	CH3	H	Cl
681	H	Br	CH3	H	Br
682	H	Br	CH3	H	F
683	H	Br	CH3	CH3	H
684	H	Br	CH3	CH3	CH3
685	H	Br	CH3	CH3	OCH3
686	H	Br	CH3	CH3	Cl
687	H	Br	CH3	CH3	Br
688	H	Br	CH3	CH3	F
689	H	Br	CH3	OCH3	H
690	H	Br	CH3	OCH3	OCH3
691	H	Br	CH3	OCH3	Cl
692	H	Br	CH3	OCH3	Br
693	H	Br	CH3	OCH3	F
694	H	Br	CH3	Cl	H
695	H	Br	CH3	Cl	OCH3
696	H	Br	CH3	Cl	Cl
697	H	Br	CH3	Cl	Br
698	H	Br	CH3	Cl	F
699	H	Br	CH3	Br	H
700	H	Br	CH3	Br	OCH3
701	H	Br	CH3	Br	Cl
702	H	Br	CH3	Br	Br
703	H	Br	CH3	Br	F
704	H	Br	CH3	F	H
705	H	Br	CH3	F	OCH3
706	H	Br	CH3	F	Cl
707	H	Br	CH3	F	Br
708	H	Br	CH3	F	F
709	H	Br	OCH3	H	H
710	H	Br	OCH3	H	CH3
711	H	Br	OCH3	H	OCH3
712	H	Br	OCH3	H	Cl
713	H	Br	OCH3	H	Br
714	H	Br	OCH3	H	F
715	H	Br	OCH3	CH3	H
716	H	Br	OCH3	CH3	CH3
717	H	Br	OCH3	CH3	Cl
718	H	Br	OCH3	CH3	Br
719	H	Br	OCH3	CH3	F
720	H	Br	OCH3	OCH3	H
721	H	Br	OCH3	OCH3	CH3
722	H	Br	OCH3	OCH3	OCH3
723	H	Br	OCH3	OCH3	Cl
724	H	Br	OCH3	OCH3	Br
725	H	Br	OCH3	OCH3	F
726	H	Br	OCH3	Cl	H
727	H	Br	OCH3	Cl	CH3
728	H	Br	OCH3	Cl	Cl
729	H	Br	OCH3	Cl	Br
730	H	Br	OCH3	Cl	F
731	H	Br	OCH3	Br	H
732	H	Br	OCH3	Br	CH3
733	H	Br	OCH3	Br	Cl
734	H	Br	OCH3	Br	Br
735	H	Br	OCH3	Br	F
736	H	Br	OCH3	F	H
737	H	Br	OCH3	F	CH3
738	H	Br	OCH3	F	Cl
739	H	Br	OCH3	F	Br
740	H	Br	OCH3	F	F
741	H	Br	Cl	H	H
742	H	Br	Cl	H	CH3
743	H	Br	Cl	H	OCH3
744	H	Br	Cl	H	Cl
745	H	Br	Cl	H	Br
746	H	Br	Cl	H	F
747	H	Br	Cl	CH3	H
748	H	Br	Cl	CH3	CH3
749	H	Br	Cl	CH3	OCH3
750	H	Br	Cl	CH3	Br
751	H	Br	Cl	CH3	F
752	H	Br	Cl	OCH3	H
753	H	Br	Cl	OCH3	CH3
754	H	Br	Cl	OCH3	OCH3
755	H	Br	Cl	OCH3	Br
756	H	Br	Cl	OCH3	F
757	H	Br	Cl	Cl	H
758	H	Br	Cl	Cl	CH3
759	H	Br	Cl	Cl	OCH3
760	H	Br	Cl	Cl	Cl
761	H	Br	Cl	Cl	Br
762	H	Br	Cl	Cl	F
763	H	Br	Cl	Br	H
764	H	Br	Cl	Br	CH3
765	H	Br	Cl	Br	OCH3
766	H	Br	Cl	Br	Br
767	H	Br	Cl	F	H
768	H	Br	Cl	F	CH3
769	H	Br	Cl	F	OCH3
770	H	Br	Cl	F	Br
771	H	Br	Cl	F	F
772	H	Br	Br	H	H
773	H	Br	Br	H	CH3
774	H	Br	Br	H	OCH3
775	H	Br	Br	H	Cl
776	H	Br	Br	H	Br
777	H	Br	Br	H	F
778	H	Br	Br	CH3	H
779	H	Br	Br	CH3	CH3
780	H	Br	Br	CH3	OCH3
781	H	Br	Br	CH3	Cl
782	H	Br	Br	CH3	F
783	H	Br	Br	OCH3	H
784	H	Br	Br	OCH3	CH3
785	H	Br	Br	OCH3	OCH3
786	H	Br	Br	OCH3	Cl
787	H	Br	Br	OCH3	F
788	H	Br	Br	Cl	H
789	H	Br	Br	Cl	CH3
790	H	Br	Br	Cl	OCH3
791	H	Br	Br	Cl	Cl
792	H	Br	Br	Cl	F
793	H	Br	Br	Br	H
794	H	Br	Br	Br	CH3
795	H	Br	Br	Br	OCH3
796	H	Br	Br	Br	Cl
797	H	Br	Br	Br	Br
798	H	Br	Br	Br	F
799	H	Br	Br	F	H
800	H	Br	Br	F	CH3
801	H	Br	Br	F	OCH3
802	H	Br	Br	F	Cl
803	H	Br	Br	F	F
804	H	Br	F	H	H
805	H	Br	F	H	CH3
806	H	Br	F	H	OCH3
807	H	Br	F	H	Cl
808	H	Br	F	H	Br
809	H	Br	F	H	F
810	H	Br	F	CH3	H
811	H	Br	F	CH3	CH3
812	H	Br	F	CH3	OCH3
813	H	Br	F	CH3	Cl
814	H	Br	F	CH3	Br
815	H	Br	F	OCH3	H
816	H	Br	F	OCH3	CH3
817	H	Br	F	OCH3	OCH3
818	H	Br	F	OCH3	Cl
819	H	Br	F	OCH3	Br
820	H	Br	F	Cl	H
821	H	Br	F	Cl	CH3
822	H	Br	F	Cl	OCH3
823	H	Br	F	Cl	Cl
824	H	Br	F	Cl	Br
825	H	Br	F	Br	H
826	H	Br	F	Br	CH3
827	H	Br	F	Br	OCH3
828	H	Br	F	Br	Cl
829	H	Br	F	Br	Br
830	H	Br	F	F	H
831	H	Br	F	F	CH3
832	H	Br	F	F	OCH3
833	H	Br	F	F	Cl
834	H	Br	F	F	Br
835	H	Br	F	F	F
836	H	F	CH3	H	H
837	H	F	CH3	H	CH3
838	H	F	CH3	H	OCH3
839	H	F	CH3	H	Cl
840	H	F	CH3	H	Br
841	H	F	CH3	H	F
842	H	F	CH3	CH3	H
843	H	F	CH3	CH3	CH3
844	H	F	CH3	CH3	OCH3
845	H	F	CH3	CH3	Cl
846	H	F	CH3	CH3	Br
847	H	F	CH3	CH3	F
848	H	F	CH3	OCH3	H
849	H	F	CH3	OCH3	OCH3
850	H	F	CH3	OCH3	Cl
851	H	F	CH3	OCH3	Br
852	H	F	CH3	OCH3	F
853	H	F	CH3	Cl	H
854	H	F	CH3	Cl	OCH3
855	H	F	CH3	Cl	Cl
856	H	F	CH3	Cl	Br
857	H	F	CH3	Cl	F
858	H	F	CH3	Br	H
859	H	F	CH3	Br	OCH3
860	H	F	CH3	Br	Cl
861	H	F	CH3	Br	Br
862	H	F	CH3	Br	F
863	H	F	CH3	F	H
864	H	F	CH3	F	OCH3
865	H	F	CH3	F	Cl
866	H	F	CH3	F	Br
867	H	F	CH3	F	F
868	H	F	OCH3	H	H
869	H	F	OCH3	H	CH3
870	H	F	OCH3	H	OCH3
871	H	F	OCH3	H	Cl
872	H	F	OCH3	H	Br
873	H	F	OCH3	H	F
874	H	F	OCH3	CH3	H
875	H	F	OCH3	CH3	CH3
876	H	F	OCH3	CH3	Cl
877	H	F	OCH3	CH3	Br
878	H	F	OCH3	CH3	F
879	H	F	OCH3	OCH3	H
880	H	F	OCH3	OCH3	CH3
881	H	F	OCH3	OCH3	OCH3
882	H	F	OCH3	OCH3	Cl
883	H	F	OCH3	OCH3	Br
884	H	F	OCH3	OCH3	F
885	H	F	OCH3	Cl	H
886	H	F	OCH3	Cl	CH3
887	H	F	OCH3	Cl	Cl
888	H	F	OCH3	Cl	Br
889	H	F	OCH3	Cl	F
890	H	F	OCH3	Br	H
891	H	F	OCH3	Br	CH3
892	H	F	OCH3	Br	Cl
893	H	F	OCH3	Br	Br
894	H	F	OCH3	Br	F
895	H	F	OCH3	F	H
896	H	F	OCH3	F	CH3
897	H	F	OCH3	F	Cl
898	H	F	OCH3	F	Br
899	H	F	OCH3	F	F
900	H	F	Cl	H	H
901	H	F	Cl	H	CH3
902	H	F	Cl	H	OCH3
903	H	F	Cl	H	Cl
904	H	F	Cl	H	Br
905	H	F	Cl	H	F
906	H	F	Cl	CH3	H
907	H	F	Cl	CH3	CH3
908	H	F	Cl	CH3	OCH3
909	H	F	Cl	CH3	Br
910	H	F	Cl	CH3	F
911	H	F	Cl	OCH3	H
912	H	F	Cl	OCH3	CH3
913	H	F	Cl	OCH3	OCH3
914	H	F	Cl	OCH3	Br
915	H	F	Cl	OCH3	F
916	H	F	Cl	Cl	H
917	H	F	Cl	Cl	CH3
918	H	F	Cl	Cl	OCH3
919	H	F	Cl	Cl	Cl
920	H	F	Cl	Cl	Br
921	H	F	Cl	Cl	F
922	H	F	Cl	Br	H
923	H	F	Cl	Br	CH3
924	H	F	Cl	Br	OCH3
925	H	F	Cl	Br	Br
926	H	F	Cl	F	H
927	H	F	Cl	F	CH3
928	H	F	Cl	F	OCH3
929	H	F	Cl	F	Br
930	H	F	Cl	F	F
931	H	F	Br	H	H
932	H	F	Br	H	CH3
933	H	F	Br	H	OCH3
934	H	F	Br	H	Cl
935	H	F	Br	H	Br
936	H	F	Br	H	F
937	H	F	Br	CH3	H
938	H	F	Br	CH3	CH3
939	H	F	Br	CH3	OCH3
940	H	F	Br	CH3	Cl
941	H	F	Br	CH3	F
942	H	F	Br	OCH3	H
943	H	F	Br	OCH3	CH3
944	H	F	Br	OCH3	OCH3
945	H	F	Br	OCH3	Cl
946	H	F	Br	OCH3	F
947	H	F	Br	Cl	H
948	H	F	Br	Cl	CH3
949	H	F	Br	Cl	OCH3
950	H	F	Br	Cl	Cl
951	H	F	Br	Cl	F
952	H	F	Br	Br	H
953	H	F	Br	Br	CH3
954	H	F	Br	Br	OCH3
955	H	F	Br	Br	Cl
956	H	F	Br	Br	Br
957	H	F	Br	Br	F
958	H	F	Br	F	H
959	H	F	Br	F	CH3
960	H	F	Br	F	OCH3
961	H	F	Br	F	Cl
962	H	F	Br	F	F
963	H	F	F	H	H
964	H	F	F	H	CH3
965	H	F	F	H	OCH3
966	H	F	F	H	Cl
967	H	F	F	H	Br
968	H	F	F	H	F
969	H	F	F	CH3	H
970	H	F	F	CH3	CH3
971	H	F	F	CH3	OCH3
972	H	F	F	CH3	Cl
973	H	F	F	CH3	Br
974	H	F	F	OCH3	H
975	H	F	F	OCH3	CH3
976	H	F	F	OCH3	OCH3
977	H	F	F	OCH3	Cl
978	H	F	F	OCH3	Br
979	H	F	F	Cl	H
980	H	F	F	Cl	CH3
981	H	F	F	Cl	OCH3
982	H	F	F	Cl	Cl
983	H	F	F	Cl	Br
984	H	F	F	Br	H
985	H	F	F	Br	CH3
986	H	F	F	Br	OCH3
987	H	F	F	Br	Cl
988	H	F	F	Br	Br
989	H	F	F	F	H
990	H	F	F	F	CH3
991	H	F	F	F	OCH3
992	H	F	F	F	Cl
993	H	F	F	F	Br
994	H	F	F	F	F
995	CH3	CH3	CH3	H	H
996	CH3	CH3	CH3	CH3	H
997	CH3	CH3	CH3	OCH3	H
998	CH3	CH3	CH3	Cl	H
999	CH3	CH3	CH3	Br	H
1000	CH3	CH3	CH3	F	H
1001	CH3	CH3	CH3	H	CH3
1002	CH3	CH3	CH3	CH3	CH3
1003	CH3	CH3	CH3	H	OCH3
1004	CH3	CH3	CH3	CH3	OCH3
1005	CH3	CH3	CH3	OCH3	OCH3
1006	CH3	CH3	CH3	Cl	OCH3
1007	CH3	CH3	CH3	Br	OCH3
1008	CH3	CH3	CH3	F	OCH3
1009	CH3	CH3	CH3	H	Cl
1010	CH3	CH3	CH3	CH3	Cl
1011	CH3	CH3	CH3	OCH3	Cl
1012	CH3	CH3	CH3	Cl	Cl
1013	CH3	CH3	CH3	Br	Cl
1014	CH3	CH3	CH3	F	Cl
1015	CH3	CH3	CH3	H	Br
1016	CH3	CH3	CH3	CH3	Br
1017	CH3	CH3	CH3	OCH3	Br
1018	CH3	CH3	CH3	Cl	Br
1019	CH3	CH3	CH3	Br	Br
1020	CH3	CH3	CH3	F	Br
1021	CH3	CH3	CH3	H	F
1022	CH3	CH3	CH3	CH3	F
1023	CH3	CH3	CH3	OCH3	F
1024	CH3	CH3	CH3	Cl	F
1025	CH3	CH3	CH3	Br	F
1026	CH3	CH3	CH3	F	F
1027	CH3	CH3	OCH3	H	H
1028	CH3	CH3	OCH3	CH3	H
1029	CH3	CH3	OCH3	OCH3	H
1030	CH3	CH3	OCH3	Cl	H
1031	CH3	CH3	OCH3	Br	H
1032	CH3	CH3	OCH3	F	H
1033	CH3	CH3	OCH3	H	CH3
1034	CH3	CH3	OCH3	CH3	CH3
1035	CH3	CH3	OCH3	OCH3	CH3
1036	CH3	CH3	OCH3	Cl	CH3
1037	CH3	CH3	OCH3	Br	CH3
1038	CH3	CH3	OCH3	F	CH3
1039	CH3	CH3	OCH3	H	OCH3
1040	CH3	CH3	OCH3	OCH3	OCH3
1041	CH3	CH3	OCH3	H	Cl
1042	CH3	CH3	OCH3	CH3	Cl
1043	CH3	CH3	OCH3	OCH3	Cl
1044	CH3	CH3	OCH3	Cl	Cl
1045	CH3	CH3	OCH3	Br	Cl
1046	CH3	CH3	OCH3	F	Cl
1047	CH3	CH3	OCH3	H	Br
1048	CH3	CH3	OCH3	CH3	Br
1049	CH3	CH3	OCH3	OCH3	Br
1050	CH3	CH3	OCH3	Cl	Br
1051	CH3	CH3	OCH3	Br	Br
1052	CH3	CH3	OCH3	F	Br
1053	CH3	CH3	OCH3	H	F
1054	CH3	CH3	OCH3	CH3	F
1055	CH3	CH3	OCH3	OCH3	F
1056	CH3	CH3	OCH3	Cl	F
1057	CH3	CH3	OCH3	Br	F
1058	CH3	CH3	OCH3	F	F
1059	CH3	CH3	Cl	H	H
1060	CH3	CH3	Cl	CH3	H
1061	CH3	CH3	Cl	OCH3	H
1062	CH3	CH3	Cl	Cl	H
1063	CH3	CH3	Cl	Br	H
1064	CH3	CH3	Cl	F	H
1065	CH3	CH3	Cl	H	CH3
1066	CH3	CH3	Cl	CH3	CH3
1067	CH3	CH3	Cl	OCH3	CH3
1068	CH3	CH3	Cl	Cl	CH3
1069	CH3	CH3	Cl	Br	CH3
1070	CH3	CH3	Cl	F	CH3
1071	CH3	CH3	Cl	H	OCH3
1072	CH3	CH3	Cl	CH3	OCH3
1073	CH3	CH3	Cl	OCH3	OCH3
1074	CH3	CH3	Cl	Cl	OCH3
1075	CH3	CH3	Cl	Br	OCH3
1076	CH3	CH3	Cl	F	OCH3
1077	CH3	CH3	Cl	H	Cl
1078	CH3	CH3	Cl	Cl	Cl
1079	CH3	CH3	Cl	H	Br
1080	CH3	CH3	Cl	CH3	Br
1081	CH3	CH3	Cl	OCH3	Br
1082	CH3	CH3	Cl	Cl	Br
1083	CH3	CH3	Cl	Br	Br
1084	CH3	CH3	Cl	F	Br
1085	CH3	CH3	Cl	H	F
1086	CH3	CH3	Cl	CH3	F
1087	CH3	CH3	Cl	OCH3	F
1088	CH3	CH3	Cl	Cl	F
1089	CH3	CH3	Cl	F	F
1090	CH3	CH3	Br	H	H
1091	CH3	CH3	Br	CH3	H
1092	CH3	CH3	Br	OCH3	H
1093	CH3	CH3	Br	Cl	H
1094	CH3	CH3	Br	Br	H
1095	CH3	CH3	Br	F	H
1096	CH3	CH3	Br	H	CH3
1097	CH3	CH3	Br	CH3	CH3
1098	CH3	CH3	Br	OCH3	CH3
1099	CH3	CH3	Br	Cl	CH3
1100	CH3	CH3	Br	Br	CH3
1101	CH3	CH3	Br	F	CH3
1102	CH3	CH3	Br	H	OCH3
1103	CH3	CH3	Br	CH3	OCH3
1104	CH3	CH3	Br	OCH3	OCH3
1105	CH3	CH3	Br	Cl	OCH3
1106	CH3	CH3	Br	Br	OCH3
1107	CH3	CH3	Br	F	OCH3
1108	CH3	CH3	Br	H	Cl
1109	CH3	CH3	Br	CH3	Cl
1110	CH3	CH3	Br	OCH3	Cl
1111	CH3	CH3	Br	Cl	Cl
1112	CH3	CH3	Br	Br	Cl
1113	CH3	CH3	Br	F	Cl
1114	CH3	CH3	Br	H	Br
1115	CH3	CH3	Br	Br	Br
1116	CH3	CH3	Br	H	F
1117	CH3	CH3	Br	CH3	F
1118	CH3	CH3	Br	OCH3	F
1119	CH3	CH3	Br	Cl	F
1120	CH3	CH3	Br	Br	F
1121	CH3	CH3	Br	F	F
1122	CH3	CH3	F	H	H
1123	CH3	CH3	F	CH3	H
1124	CH3	CH3	F	OCH3	H
1125	CH3	CH3	F	Cl	H
1126	CH3	CH3	F	Br	H
1127	CH3	CH3	F	F	H
1128	CH3	CH3	F	H	CH3
1129	CH3	CH3	F	CH3	CH3
1130	CH3	CH3	F	OCH3	CH3
1131	CH3	CH3	F	Cl	CH3
1132	CH3	CH3	F	Br	CH3
1133	CH3	CH3	F	F	CH3
1134	CH3	CH3	F	H	OCH3
1135	CH3	CH3	F	CH3	OCH3
1136	CH3	CH3	F	OCH3	OCH3
1137	CH3	CH3	F	Cl	OCH3
1138	CH3	CH3	F	Br	OCH3
1139	CH3	CH3	F	F	OCH3
1140	CH3	CH3	F	H	Cl
1141	CH3	CH3	F	CH3	Cl
1142	CH3	CH3	F	OCH3	Cl
1143	CH3	CH3	F	Cl	Cl
1144	CH3	CH3	F	Br	Cl
1145	CH3	CH3	F	F	Cl
1146	CH3	CH3	F	H	Br
1147	CH3	CH3	F	CH3	Br
1148	CH3	CH3	F	OCH3	Br
1149	CH3	CH3	F	Cl	Br
1150	CH3	CH3	F	Br	Br
1151	CH3	CH3	F	F	Br
1152	CH3	CH3	F	H	F
1153	CH3	CH3	F	F	F
1154	CH3	OCH3	CH3	H	H
1155	CH3	OCH3	CH3	H	CH3
1156	CH3	OCH3	CH3	H	OCH3
1157	CH3	OCH3	CH3	H	Cl
1158	CH3	OCH3	CH3	H	Br
1159	CH3	OCH3	CH3	H	F
1160	CH3	OCH3	CH3	CH3	H
1161	CH3	OCH3	CH3	CH3	CH3
1162	CH3	OCH3	CH3	CH3	OCH3
1163	CH3	OCH3	CH3	CH3	Cl
1164	CH3	OCH3	CH3	CH3	Br
1165	CH3	OCH3	CH3	CH3	F
1166	CH3	OCH3	CH3	OCH3	H
1167	CH3	OCH3	CH3	OCH3	OCH3
1168	CH3	OCH3	CH3	OCH3	Cl
1169	CH3	OCH3	CH3	OCH3	Br
1170	CH3	OCH3	CH3	OCH3	F
1171	CH3	OCH3	CH3	Cl	H
1172	CH3	OCH3	CH3	Cl	OCH3
1173	CH3	OCH3	CH3	Cl	Cl
1174	CH3	OCH3	CH3	Cl	Br
1175	CH3	OCH3	CH3	Cl	F
1176	CH3	OCH3	CH3	Br	H
1177	CH3	OCH3	CH3	Br	OCH3
1178	CH3	OCH3	CH3	Br	Cl
1179	CH3	OCH3	CH3	Br	Br
1180	CH3	OCH3	CH3	Br	F
1181	CH3	OCH3	CH3	F	H
1182	CH3	OCH3	CH3	F	OCH3
1183	CH3	OCH3	CH3	F	Cl
1184	CH3	OCH3	CH3	F	Br
1185	CH3	OCH3	CH3	F	F
1186	CH3	OCH3	OCH3	H	H
1187	CH3	OCH3	OCH3	H	CH3
1188	CH3	OCH3	OCH3	H	OCH3
1189	CH3	OCH3	OCH3	H	Cl
1190	CH3	OCH3	OCH3	H	Br
1191	CH3	OCH3	OCH3	H	F
1192	CH3	OCH3	OCH3	CH3	H
1193	CH3	OCH3	OCH3	CH3	CH3
1194	CH3	OCH3	OCH3	CH3	Cl
1195	CH3	OCH3	OCH3	CH3	Br
1196	CH3	OCH3	OCH3	CH3	F
1197	CH3	OCH3	OCH3	OCH3	H
1198	CH3	OCH3	OCH3	OCH3	CH3
1199	CH3	OCH3	OCH3	OCH3	OCH3
1200	CH3	OCH3	OCH3	OCH3	Cl
1201	CH3	OCH3	OCH3	OCH3	Br
1202	CH3	OCH3	OCH3	OCH3	F
1203	CH3	OCH3	OCH3	Cl	H
1204	CH3	OCH3	OCH3	Cl	CH3
1205	CH3	OCH3	OCH3	Cl	Cl
1206	CH3	OCH3	OCH3	Cl	Br
1207	CH3	OCH3	OCH3	Cl	F
1208	CH3	OCH3	OCH3	Br	H
1209	CH3	OCH3	OCH3	Br	CH3
1210	CH3	OCH3	OCH3	Br	Cl
1211	CH3	OCH3	OCH3	Br	Br
1212	CH3	OCH3	OCH3	Br	F
1213	CH3	OCH3	OCH3	F	H
1214	CH3	OCH3	OCH3	F	CH3
1215	CH3	OCH3	OCH3	F	Cl
1216	CH3	OCH3	OCH3	F	Br
1217	CH3	OCH3	OCH3	F	F
1218	CH3	OCH3	Cl	H	H
1219	CH3	OCH3	Cl	H	CH3
1220	CH3	OCH3	Cl	H	OCH3
1221	CH3	OCH3	Cl	H	Cl
1222	CH3	OCH3	Cl	H	Br
1223	CH3	OCH3	Cl	H	F
1224	CH3	OCH3	Cl	CH3	H
1225	CH3	OCH3	Cl	CH3	CH3
1226	CH3	OCH3	Cl	CH3	OCH3
1227	CH3	OCH3	Cl	CH3	Br
1228	CH3	OCH3	Cl	CH3	F
1229	CH3	OCH3	Cl	OCH3	H
1230	CH3	OCH3	Cl	OCH3	CH3
1231	CH3	OCH3	Cl	OCH3	OCH3
1232	CH3	OCH3	Cl	OCH3	Br
1233	CH3	OCH3	Cl	OCH3	F
1234	CH3	OCH3	Cl	Cl	H
1235	CH3	OCH3	Cl	Cl	CH3
1236	CH3	OCH3	Cl	Cl	OCH3
1237	CH3	OCH3	Cl	Cl	Cl
1238	CH3	OCH3	Cl	Cl	Br
1239	CH3	OCH3	Cl	Cl	F
1240	CH3	OCH3	Cl	Br	H
1241	CH3	OCH3	Cl	Br	CH3
1242	CH3	OCH3	Cl	Br	OCH3
1243	CH3	OCH3	Cl	Br	Br
1244	CH3	OCH3	Cl	F	H
1245	CH3	OCH3	Cl	F	CH3
1246	CH3	OCH3	Cl	F	OCH3
1247	CH3	OCH3	Cl	F	Br
1248	CH3	OCH3	Cl	F	F
1249	CH3	OCH3	Br	H	H
1250	CH3	OCH3	Br	H	CH3
1251	CH3	OCH3	Br	H	OCH3
1252	CH3	OCH3	Br	H	Cl
1253	CH3	OCH3	Br	H	Br
1254	CH3	OCH3	Br	H	F
1255	CH3	OCH3	Br	CH3	H
1256	CH3	OCH3	Br	CH3	CH3
1257	CH3	OCH3	Br	CH3	OCH3
1258	CH3	OCH3	Br	CH3	Cl
1259	CH3	OCH3	Br	CH3	F
1260	CH3	OCH3	Br	OCH3	H
1261	CH3	OCH3	Br	OCH3	CH3
1262	CH3	OCH3	Br	OCH3	OCH3
1263	CH3	OCH3	Br	OCH3	Cl
1264	CH3	OCH3	Br	OCH3	F
1265	CH3	OCH3	Br	Cl	H
1266	CH3	OCH3	Br	Cl	CH3
1267	CH3	OCH3	Br	Cl	OCH3
1268	CH3	OCH3	Br	Cl	Cl
1269	CH3	OCH3	Br	Cl	F
1270	CH3	OCH3	Br	Br	H
1271	CH3	OCH3	Br	Br	CH3
1272	CH3	OCH3	Br	Br	OCH3
1273	CH3	OCH3	Br	Br	Cl
1274	CH3	OCH3	Br	Br	Br
1275	CH3	OCH3	Br	Br	F
1276	CH3	OCH3	Br	F	H
1277	CH3	OCH3	Br	F	CH3
1278	CH3	OCH3	Br	F	OCH3
1279	CH3	OCH3	Br	F	Cl
1280	CH3	OCH3	Br	F	F
1281	CH3	OCH3	F	H	H
1282	CH3	OCH3	F	H	CH3
1283	CH3	OCH3	F	H	OCH3
1284	CH3	OCH3	F	H	Cl
1285	CH3	OCH3	F	H	Br
1286	CH3	OCH3	F	H	F
1287	CH3	OCH3	F	CH3	H
1288	CH3	OCH3	F	CH3	CH3
1289	CH3	OCH3	F	CH3	OCH3
1290	CH3	OCH3	F	CH3	Cl
1291	CH3	OCH3	F	CH3	Br
1292	CH3	OCH3	F	OCH3	H
1293	CH3	OCH3	F	OCH3	CH3
1294	CH3	OCH3	F	OCH3	OCH3
1295	CH3	OCH3	F	OCH3	Cl
1296	CH3	OCH3	F	OCH3	Br
1297	CH3	OCH3	F	Cl	H
1298	CH3	OCH3	F	Cl	CH3
1299	CH3	OCH3	F	Cl	OCH3
1300	CH3	OCH3	F	Cl	Cl
1301	CH3	OCH3	F	Cl	Br
1302	CH3	OCH3	F	Br	H
1303	CH3	OCH3	F	Br	CH3
1304	CH3	OCH3	F	Br	OCH3
1305	CH3	OCH3	F	Br	Cl
1306	CH3	OCH3	F	Br	Br
1307	CH3	OCH3	F	F	H
1308	CH3	OCH3	F	F	CH3
1309	CH3	OCH3	F	F	OCH3
1310	CH3	OCH3	F	F	Cl
1311	CH3	OCH3	F	F	Br
1312	CH3	OCH3	F	F	F
1313	CH3	Cl	CH3	H	H
1314	CH3	Cl	CH3	H	CH3
1315	CH3	Cl	CH3	H	OCH3
1316	CH3	Cl	CH3	H	Cl
1317	CH3	Cl	CH3	H	Br
1318	CH3	Cl	CH3	H	F
1319	CH3	Cl	CH3	CH3	H
1320	CH3	Cl	CH3	CH3	CH3
1321	CH3	Cl	CH3	CH3	OCH3
1322	CH3	Cl	CH3	CH3	Cl
1323	CH3	Cl	CH3	CH3	Br
1324	CH3	Cl	CH3	CH3	F
1325	CH3	Cl	CH3	OCH3	H
1326	CH3	Cl	CH3	OCH3	OCH3
1327	CH3	Cl	CH3	OCH3	Cl
1328	CH3	Cl	CH3	OCH3	Br
1329	CH3	Cl	CH3	OCH3	F
1330	CH3	Cl	CH3	Cl	H
1331	CH3	Cl	CH3	Cl	OCH3
1332	CH3	Cl	CH3	Cl	Cl
1333	CH3	Cl	CH3	Cl	Br
1334	CH3	Cl	CH3	Cl	F
1335	CH3	Cl	CH3	Br	H
1336	CH3	Cl	CH3	Br	OCH3
1337	CH3	Cl	CH3	Br	Cl
1338	CH3	Cl	CH3	Br	Br
1339	CH3	Cl	CH3	Br	F
1340	CH3	Cl	CH3	F	H
1341	CH3	Cl	CH3	F	OCH3
1342	CH3	Cl	CH3	F	Cl
1343	CH3	Cl	CH3	F	Br
1344	CH3	Cl	CH3	F	F
1345	CH3	Cl	OCH3	H	H
1346	CH3	Cl	OCH3	H	CH3
1347	CH3	Cl	OCH3	H	OCH3
1348	CH3	Cl	OCH3	H	Cl
1349	CH3	Cl	OCH3	H	Br
1350	CH3	Cl	OCH3	H	F
1351	CH3	Cl	OCH3	CH3	H
1352	CH3	Cl	OCH3	CH3	CH3
1353	CH3	Cl	OCH3	CH3	Cl
1354	CH3	Cl	OCH3	CH3	Br
1355	CH3	Cl	OCH3	CH3	F
1356	CH3	Cl	OCH3	OCH3	H
1357	CH3	Cl	OCH3	OCH3	CH3
1358	CH3	Cl	OCH3	OCH3	OCH3
1359	CH3	Cl	OCH3	OCH3	Cl
1360	CH3	Cl	OCH3	OCH3	Br
1361	CH3	Cl	OCH3	OCH3	F
1362	CH3	Cl	OCH3	Cl	H
1363	CH3	Cl	OCH3	Cl	CH3
1364	CH3	Cl	OCH3	Cl	Cl
1365	CH3	Cl	OCH3	Cl	Br
1366	CH3	Cl	OCH3	Cl	F
1367	CH3	Cl	OCH3	Br	H
1368	CH3	Cl	OCH3	Br	CH3
1369	CH3	Cl	OCH3	Br	Cl
1370	CH3	Cl	OCH3	Br	Br
1371	CH3	Cl	OCH3	Br	F
1372	CH3	Cl	OCH3	F	H
1373	CH3	Cl	OCH3	F	CH3
1374	CH3	Cl	OCH3	F	Cl
1375	CH3	Cl	OCH3	F	Br
1376	CH3	Cl	OCH3	F	F
1377	CH3	Cl	Cl	H	H
1378	CH3	Cl	Cl	H	CH3
1379	CH3	Cl	Cl	H	OCH3
1380	CH3	Cl	Cl	H	Cl
1381	CH3	Cl	Cl	H	Br
1382	CH3	Cl	Cl	H	F
1383	CH3	Cl	Cl	CH3	H
1384	CH3	Cl	Cl	CH3	CH3
1385	CH3	Cl	Cl	CH3	OCH3
1386	CH3	Cl	Cl	CH3	Br
1387	CH3	Cl	Cl	CH3	F
1388	CH3	Cl	Cl	OCH3	H
1389	CH3	Cl	Cl	OCH3	CH3
1390	CH3	Cl	Cl	OCH3	OCH3
1391	CH3	Cl	Cl	OCH3	Br
1392	CH3	Cl	Cl	OCH3	F
1393	CH3	Cl	Cl	Cl	H
1394	CH3	Cl	Cl	Cl	CH3
1395	CH3	Cl	Cl	Cl	OCH3
1396	CH3	Cl	Cl	Cl	Cl
1397	CH3	Cl	Cl	Cl	Br
1398	CH3	Cl	Cl	Cl	F
1399	CH3	Cl	Cl	Br	H
1400	CH3	Cl	Cl	Br	CH3
1401	CH3	Cl	Cl	Br	OCH3
1402	CH3	Cl	Cl	Br	Br
1403	CH3	Cl	Cl	F	H
1404	CH3	Cl	Cl	F	CH3
1405	CH3	Cl	Cl	F	OCH3
1406	CH3	Cl	Cl	F	Br
1407	CH3	Cl	Cl	F	F
1408	CH3	Cl	Br	H	H
1409	CH3	Cl	Br	H	CH3
1410	CH3	Cl	Br	H	OCH3
1411	CH3	Cl	Br	H	Cl
1412	CH3	Cl	Br	H	Br
1413	CH3	Cl	Br	H	F
1414	CH3	Cl	Br	CH3	H
1415	CH3	Cl	Br	CH3	CH3
1416	CH3	Cl	Br	CH3	OCH3
1417	CH3	Cl	Br	CH3	Cl
1418	CH3	Cl	Br	CH3	F
1419	CH3	Cl	Br	OCH3	H
1420	CH3	Cl	Br	OCH3	CH3
1421	CH3	Cl	Br	OCH3	OCH3
1422	CH3	Cl	Br	OCH3	Cl
1423	CH3	Cl	Br	OCH3	F
1424	CH3	Cl	Br	Cl	H
1425	CH3	Cl	Br	Cl	CH3
1426	CH3	Cl	Br	Cl	OCH3
1427	CH3	Cl	Br	Cl	Cl
1428	CH3	Cl	Br	Cl	F
1429	CH3	Cl	Br	Br	H
1430	CH3	Cl	Br	Br	CH3
1431	CH3	Cl	Br	Br	OCH3
1432	CH3	Cl	Br	Br	Cl
1433	CH3	Cl	Br	Br	Br
1434	CH3	Cl	Br	Br	F
1435	CH3	Cl	Br	F	H
1436	CH3	Cl	Br	F	CH3
1437	CH3	Cl	Br	F	OCH3
1438	CH3	Cl	Br	F	Cl
1439	CH3	Cl	Br	F	F
1440	CH3	Cl	F	H	H
1441	CH3	Cl	F	H	CH3
1442	CH3	Cl	F	H	OCH3
1443	CH3	Cl	F	H	Cl
1444	CH3	Cl	F	H	Br
1445	CH3	Cl	F	H	F
1446	CH3	Cl	F	CH3	H
1447	CH3	Cl	F	CH3	CH3
1448	CH3	Cl	F	CH3	OCH3
1449	CH3	Cl	F	CH3	Cl
1450	CH3	Cl	F	CH3	Br
1451	CH3	Cl	F	OCH3	H
1452	CH3	Cl	F	OCH3	CH3
1453	CH3	Cl	F	OCH3	OCH3
1454	CH3	Cl	F	OCH3	Cl
1455	CH3	Cl	F	OCH3	Br
1456	CH3	Cl	F	Cl	H
1457	CH3	Cl	F	Cl	CH3
1458	CH3	Cl	F	Cl	OCH3
1459	CH3	Cl	F	Cl	Cl
1460	CH3	Cl	F	Cl	Br
1461	CH3	Cl	F	Br	H
1462	CH3	Cl	F	Br	CH3
1463	CH3	Cl	F	Br	OCH3
1464	CH3	Cl	F	Br	Cl
1465	CH3	Cl	F	Br	Br
1466	CH3	Cl	F	F	H
1467	CH3	Cl	F	F	CH3
1468	CH3	Cl	F	F	OCH3
1469	CH3	Cl	F	F	Cl
1470	CH3	Cl	F	F	Br
1471	CH3	Cl	F	F	F
1472	CH3	Br	CH3	H	H
1473	CH3	Br	CH3	H	CH3
1474	CH3	Br	CH3	H	OCH3
1475	CH3	Br	CH3	H	Cl
1476	CH3	Br	CH3	H	Br
1477	CH3	Br	CH3	H	F
1478	CH3	Br	CH3	CH3	H
1479	CH3	Br	CH3	CH3	CH3
1480	CH3	Br	CH3	CH3	OCH3
1481	CH3	Br	CH3	CH3	Cl
1482	CH3	Br	CH3	CH3	Br
1483	CH3	Br	CH3	CH3	F
1484	CH3	Br	CH3	OCH3	H
1485	CH3	Br	CH3	OCH3	OCH3
1486	CH3	Br	CH3	OCH3	Cl
1487	CH3	Br	CH3	OCH3	Br
1488	CH3	Br	CH3	OCH3	F
1489	CH3	Br	CH3	Cl	H
1490	CH3	Br	CH3	Cl	OCH3
1491	CH3	Br	CH3	Cl	Cl
1492	CH3	Br	CH3	Cl	Br
1493	CH3	Br	CH3	Cl	F
1494	CH3	Br	CH3	Br	H
1495	CH3	Br	CH3	Br	OCH3
1496	CH3	Br	CH3	Br	Cl
1497	CH3	Br	CH3	Br	Br
1498	CH3	Br	CH3	Br	F
1499	CH3	Br	CH3	F	H
1500	CH3	Br	CH3	F	OCH3
1501	CH3	Br	CH3	F	Cl
1502	CH3	Br	CH3	F	Br
1503	CH3	Br	CH3	F	F
1504	CH3	Br	OCH3	H	H
1505	CH3	Br	OCH3	H	CH3
1506	CH3	Br	OCH3	H	OCH3
1507	CH3	Br	OCH3	H	Cl
1508	CH3	Br	OCH3	H	Br
1509	CH3	Br	OCH3	H	F
1510	CH3	Br	OCH3	CH3	H
1511	CH3	Br	OCH3	CH3	CH3
1512	CH3	Br	OCH3	CH3	Cl
1513	CH3	Br	OCH3	CH3	Br
1514	CH3	Br	OCH3	CH3	F
1515	CH3	Br	OCH3	OCH3	H
1516	CH3	Br	OCH3	OCH3	CH3
1517	CH3	Br	OCH3	OCH3	OCH3
1518	CH3	Br	OCH3	OCH3	Cl
1519	CH3	Br	OCH3	OCH3	Br
1520	CH3	Br	OCH3	OCH3	F
1521	CH3	Br	OCH3	Cl	H
1522	CH3	Br	OCH3	Cl	CH3
1523	CH3	Br	OCH3	Cl	Cl
1524	CH3	Br	OCH3	Cl	Br
1525	CH3	Br	OCH3	Cl	F
1526	CH3	Br	OCH3	Br	H
1527	CH3	Br	OCH3	Br	CH3
1528	CH3	Br	OCH3	Br	Cl
1529	CH3	Br	OCH3	Br	Br
1530	CH3	Br	OCH3	Br	F
1531	CH3	Br	OCH3	F	H
1532	CH3	Br	OCH3	F	CH3
1533	CH3	Br	OCH3	F	Cl
1534	CH3	Br	OCH3	F	Br
1535	CH3	Br	OCH3	F	F
1536	CH3	Br	Cl	H	H
1537	CH3	Br	Cl	H	CH3
1538	CH3	Br	Cl	H	OCH3
1539	CH3	Br	Cl	H	Cl
1540	CH3	Br	Cl	H	Br
1541	CH3	Br	Cl	H	F
1542	CH3	Br	Cl	CH3	H
1543	CH3	Br	Cl	CH3	CH3
1544	CH3	Br	Cl	CH3	OCH3
1545	CH3	Br	Cl	CH3	Br
1546	CH3	Br	Cl	CH3	F
1547	CH3	Br	Cl	OCH3	H
1548	CH3	Br	Cl	OCH3	CH3
1549	CH3	Br	Cl	OCH3	OCH3
1550	CH3	Br	Cl	OCH3	Br
1551	CH3	Br	Cl	OCH3	F
1552	CH3	Br	Cl	Cl	H
1553	CH3	Br	Cl	Cl	CH3
1554	CH3	Br	Cl	Cl	OCH3
1555	CH3	Br	Cl	Cl	Cl
1556	CH3	Br	Cl	Cl	Br
1557	CH3	Br	Cl	Cl	F
1558	CH3	Br	Cl	Br	H
1559	CH3	Br	Cl	Br	CH3
1560	CH3	Br	Cl	Br	OCH3
1561	CH3	Br	Cl	Br	Br
1562	CH3	Br	Cl	F	H
1563	CH3	Br	Cl	F	CH3
1564	CH3	Br	Cl	F	OCH3
1565	CH3	Br	Cl	F	Br
1566	CH3	Br	Cl	F	F
1567	CH3	Br	Br	H	H
1568	CH3	Br	Br	H	CH3
1569	CH3	Br	Br	H	OCH3
1570	CH3	Br	Br	H	Cl
1571	CH3	Br	Br	H	Br
1572	CH3	Br	Br	H	F
1573	CH3	Br	Br	CH3	H
1574	CH3	Br	Br	CH3	CH3
1575	CH3	Br	Br	CH3	OCH3
1576	CH3	Br	Br	CH3	Cl
1577	CH3	Br	Br	CH3	F
1578	CH3	Br	Br	OCH3	H
1579	CH3	Br	Br	OCH3	CH3
1580	CH3	Br	Br	OCH3	OCH3
1581	CH3	Br	Br	OCH3	Cl
1582	CH3	Br	Br	OCH3	F
1583	CH3	Br	Br	Cl	H
1584	CH3	Br	Br	Cl	CH3
1585	CH3	Br	Br	Cl	OCH3
1586	CH3	Br	Br	Cl	Cl
1587	CH3	Br	Br	Cl	F
1588	CH3	Br	Br	Br	H
1589	CH3	Br	Br	Br	CH3
1590	CH3	Br	Br	Br	OCH3
1591	CH3	Br	Br	Br	Cl
1592	CH3	Br	Br	Br	Br
1593	CH3	Br	Br	Br	F
1594	CH3	Br	Br	F	H
1595	CH3	Br	Br	F	CH3
1596	CH3	Br	Br	F	OCH3
1597	CH3	Br	Br	F	Cl
1598	CH3	Br	Br	F	F
1599	CH3	Br	F	H	H
1600	CH3	Br	F	H	CH3
1601	CH3	Br	F	H	OCH3
1602	CH3	Br	F	H	Cl
1603	CH3	Br	F	H	Br
1604	CH3	Br	F	H	F
1605	CH3	Br	F	CH3	H
1606	CH3	Br	F	CH3	CH3
1607	CH3	Br	F	CH3	OCH3
1608	CH3	Br	F	CH3	Cl
1609	CH3	Br	F	CH3	Br
1610	CH3	Br	F	OCH3	H
1611	CH3	Br	F	OCH3	CH3
1612	CH3	Br	F	OCH3	OCH3
1613	CH3	Br	F	OCH3	Cl
1614	CH3	Br	F	OCH3	Br
1615	CH3	Br	F	Cl	H
1616	CH3	Br	F	Cl	CH3
1617	CH3	Br	F	Cl	OCH3
1618	CH3	Br	F	Cl	Cl
1619	CH3	Br	F	Cl	Br
1620	CH3	Br	F	Br	H
1621	CH3	Br	F	Br	CH3
1622	CH3	Br	F	Br	OCH3
1623	CH3	Br	F	Br	Cl
1624	CH3	Br	F	Br	Br
1625	CH3	Br	F	F	H
1626	CH3	Br	F	F	CH3
1627	CH3	Br	F	F	OCH3
1628	CH3	Br	F	F	Cl
1629	CH3	Br	F	F	Br
1630	CH3	Br	F	F	F
1631	CH3	F	CH3	H	H
1632	CH3	F	CH3	H	CH3
1633	CH3	F	CH3	H	OCH3
1634	CH3	F	CH3	H	Cl
1635	CH3	F	CH3	H	Br
1636	CH3	F	CH3	H	F
1637	CH3	F	CH3	CH3	H
1638	CH3	F	CH3	CH3	CH3
1639	CH3	F	CH3	CH3	OCH3
1640	CH3	F	CH3	CH3	Cl
1641	CH3	F	CH3	CH3	Br
1642	CH3	F	CH3	CH3	F
1643	CH3	F	CH3	OCH3	H
1644	CH3	F	CH3	OCH3	OCH3
1645	CH3	F	CH3	OCH3	Cl
1646	CH3	F	CH3	OCH3	Br
1647	CH3	F	CH3	OCH3	F
1648	CH3	F	CH3	Cl	H
1649	CH3	F	CH3	Cl	OCH3
1650	CH3	F	CH3	Cl	Cl
1651	CH3	F	CH3	Cl	Br
1652	CH3	F	CH3	Cl	F
1653	CH3	F	CH3	Br	H
1654	CH3	F	CH3	Br	OCH3
1655	CH3	F	CH3	Br	Cl
1656	CH3	F	CH3	Br	Br
1657	CH3	F	CH3	Br	F
1658	CH3	F	CH3	F	H
1659	CH3	F	CH3	F	OCH3
1660	CH3	F	CH3	F	Cl
1661	CH3	F	CH3	F	Br
1662	CH3	F	CH3	F	F
1663	CH3	F	OCH3	H	H
1664	CH3	F	OCH3	H	CH3
1665	CH3	F	OCH3	H	OCH3
1666	CH3	F	OCH3	H	Cl
1667	CH3	F	OCH3	H	Br
1668	CH3	F	OCH3	H	F
1669	CH3	F	OCH3	CH3	H
1670	CH3	F	OCH3	CH3	CH3
1671	CH3	F	OCH3	CH3	Cl
1672	CH3	F	OCH3	CH3	Br
1673	CH3	F	OCH3	CH3	F
1674	CH3	F	OCH3	OCH3	H
1675	CH3	F	OCH3	OCH3	CH3
1676	CH3	F	OCH3	OCH3	OCH3
1677	CH3	F	OCH3	OCH3	Cl
1678	CH3	F	OCH3	OCH3	Br
1679	CH3	F	OCH3	OCH3	F
1680	CH3	F	OCH3	Cl	H
1681	CH3	F	OCH3	Cl	CH3
1682	CH3	F	OCH3	Cl	Cl
1683	CH3	F	OCH3	Cl	Br
1684	CH3	F	OCH3	Cl	F
1685	CH3	F	OCH3	Br	H
1686	CH3	F	OCH3	Br	CH3
1687	CH3	F	OCH3	Br	Cl
1688	CH3	F	OCH3	Br	Br
1689	CH3	F	OCH3	Br	F
1690	CH3	F	OCH3	F	H
1691	CH3	F	OCH3	F	CH3
1692	CH3	F	OCH3	F	Cl
1693	CH3	F	OCH3	F	Br
1694	CH3	F	OCH3	F	F
1695	CH3	F	Cl	H	H
1696	CH3	F	Cl	H	CH3
1697	CH3	F	Cl	H	OCH3
1698	CH3	F	Cl	H	Cl
1699	CH3	F	Cl	H	Br
1700	CH3	F	Cl	H	F
1701	CH3	F	Cl	CH3	H
1702	CH3	F	Cl	CH3	CH3
1703	CH3	F	Cl	CH3	OCH3
1704	CH3	F	Cl	CH3	Br
1705	CH3	F	Cl	CH3	F
1706	CH3	F	Cl	OCH3	H
1707	CH3	F	Cl	OCH3	CH3
1708	CH3	F	Cl	OCH3	OCH3
1709	CH3	F	Cl	OCH3	Br
1710	CH3	F	Cl	OCH3	F
1711	CH3	F	Cl	Cl	H
1712	CH3	F	Cl	Cl	CH3
1713	CH3	F	Cl	Cl	OCH3
1714	CH3	F	Cl	Cl	Cl
1715	CH3	F	Cl	Cl	Br
1716	CH3	F	Cl	Cl	F
1717	CH3	F	Cl	Br	H
1718	CH3	F	Cl	Br	CH3
1719	CH3	F	Cl	Br	OCH3
1720	CH3	F	Cl	Br	Br
1721	CH3	F	Cl	F	H
1722	CH3	F	Cl	F	CH3
1723	CH3	F	Cl	F	OCH3
1724	CH3	F	Cl	F	Br
1725	CH3	F	Cl	F	F
1726	CH3	F	Br	H	H
1727	CH3	F	Br	H	CH3
1728	CH3	F	Br	H	OCH3
1729	CH3	F	Br	H	Cl
1730	CH3	F	Br	H	Br
1731	CH3	F	Br	H	F
1732	CH3	F	Br	CH3	H
1733	CH3	F	Br	CH3	CH3
1734	CH3	F	Br	CH3	OCH3
1735	CH3	F	Br	CH3	Cl
1736	CH3	F	Br	CH3	F
1737	CH3	F	Br	OCH3	H
1738	CH3	F	Br	OCH3	CH3
1739	CH3	F	Br	OCH3	OCH3
1740	CH3	F	Br	OCH3	Cl
1741	CH3	F	Br	OCH3	F
1742	CH3	F	Br	Cl	H
1743	CH3	F	Br	Cl	CH3
1744	CH3	F	Br	Cl	OCH3
1745	CH3	F	Br	Cl	Cl
1746	CH3	F	Br	Cl	F
1747	CH3	F	Br	Br	H
1748	CH3	F	Br	Br	CH3
1749	CH3	F	Br	Br	OCH3
1750	CH3	F	Br	Br	Cl
1751	CH3	F	Br	Br	Br
1752	CH3	F	Br	Br	F
1753	CH3	F	Br	F	H
1754	CH3	F	Br	F	CH3
1755	CH3	F	Br	F	OCH3
1756	CH3	F	Br	F	Cl
1757	CH3	F	Br	F	F
1758	CH3	F	F	H	H
1759	CH3	F	F	H	CH3
1760	CH3	F	F	H	OCH3
1761	CH3	F	F	H	Cl
1762	CH3	F	F	H	Br
1763	CH3	F	F	H	F
1764	CH3	F	F	CH3	H
1765	CH3	F	F	CH3	CH3
1766	CH3	F	F	CH3	OCH3
1767	CH3	F	F	CH3	Cl
1768	CH3	F	F	CH3	Br
1769	CH3	F	F	OCH3	H
1770	CH3	F	F	OCH3	CH3
1771	CH3	F	F	OCH3	OCH3
1772	CH3	F	F	OCH3	Cl
1773	CH3	F	F	OCH3	Br
1774	CH3	F	F	Cl	H
1775	CH3	F	F	Cl	CH3
1776	CH3	F	F	Cl	OCH3
1777	CH3	F	F	Cl	Cl
1778	CH3	F	F	Cl	Br
1779	CH3	F	F	Br	H
1780	CH3	F	F	Br	CH3
1781	CH3	F	F	Br	OCH3
1782	CH3	F	F	Br	Cl
1783	CH3	F	F	Br	Br
1784	CH3	F	F	F	H
1785	CH3	F	F	F	CH3
1786	CH3	F	F	F	OCH3
1787	CH3	F	F	F	Cl
1788	CH3	F	F	F	Br
1789	CH3	F	F	F	F
1790	OCH3	CH3	CH3	H	H
1791	OCH3	CH3	CH3	CH3	H
1792	OCH3	CH3	CH3	OCH3	H
1793	OCH3	CH3	CH3	Cl	H
1794	OCH3	CH3	CH3	Br	H
1795	OCH3	CH3	CH3	F	H
1796	OCH3	CH3	CH3	H	CH3
1797	OCH3	CH3	CH3	CH3	CH3
1798	OCH3	CH3	CH3	H	OCH3
1799	OCH3	CH3	CH3	CH3	OCH3
1800	OCH3	CH3	CH3	OCH3	OCH3
1801	OCH3	CH3	CH3	Cl	OCH3
1802	OCH3	CH3	CH3	Br	OCH3
1803	OCH3	CH3	CH3	F	OCH3
1804	OCH3	CH3	CH3	H	Cl
1805	OCH3	CH3	CH3	CH3	Cl
1806	OCH3	CH3	CH3	OCH3	Cl
1807	OCH3	CH3	CH3	Cl	Cl
1808	OCH3	CH3	CH3	Br	Cl
1809	OCH3	CH3	CH3	F	Cl
1810	OCH3	CH3	CH3	H	Br
1811	OCH3	CH3	CH3	CH3	Br
1812	OCH3	CH3	CH3	OCH3	Br
1813	OCH3	CH3	CH3	Cl	Br
1814	OCH3	CH3	CH3	Br	Br
1815	OCH3	CH3	CH3	F	Br
1816	OCH3	CH3	CH3	H	F
1817	OCH3	CH3	CH3	CH3	F
1818	OCH3	CH3	CH3	OCH3	F
1819	OCH3	CH3	CH3	Cl	F
1820	OCH3	CH3	CH3	Br	F
1821	OCH3	CH3	CH3	F	F
1822	OCH3	CH3	OCH3	H	H
1823	OCH3	CH3	OCH3	CH3	H
1824	OCH3	CH3	OCH3	OCH3	H
1825	OCH3	CH3	OCH3	Cl	H
1826	OCH3	CH3	OCH3	Br	H
1827	OCH3	CH3	OCH3	F	H
1828	OCH3	CH3	OCH3	H	CH3
1829	OCH3	CH3	OCH3	CH3	CH3
1830	OCH3	CH3	OCH3	OCH3	CH3
1831	OCH3	CH3	OCH3	Cl	CH3
1832	OCH3	CH3	OCH3	Br	CH3
1833	OCH3	CH3	OCH3	F	CH3
1834	OCH3	CH3	OCH3	H	OCH3
1835	OCH3	CH3	OCH3	OCH3	OCH3
1836	OCH3	CH3	OCH3	H	Cl
1837	OCH3	CH3	OCH3	CH3	Cl
1838	OCH3	CH3	OCH3	OCH3	Cl
1839	OCH3	CH3	OCH3	Cl	Cl
1840	OCH3	CH3	OCH3	Br	Cl
1841	OCH3	CH3	OCH3	F	Cl
1842	OCH3	CH3	OCH3	H	Br
1843	OCH3	CH3	OCH3	CH3	Br
1844	OCH3	CH3	OCH3	OCH3	Br
1845	OCH3	CH3	OCH3	Cl	Br
1846	OCH3	CH3	OCH3	Br	Br
1847	OCH3	CH3	OCH3	F	Br
1848	OCH3	CH3	OCH3	H	F
1849	OCH3	CH3	OCH3	CH3	F
1850	OCH3	CH3	OCH3	OCH3	F
1851	OCH3	CH3	OCH3	Cl	F
1852	OCH3	CH3	OCH3	Br	F
1853	OCH3	CH3	OCH3	F	F
1854	OCH3	CH3	Cl	H	H
1855	OCH3	CH3	Cl	CH3	H
1856	OCH3	CH3	Cl	OCH3	H
1857	OCH3	CH3	Cl	Cl	H
1858	OCH3	CH3	Cl	Br	H
1859	OCH3	CH3	Cl	F	H
1860	OCH3	CH3	Cl	H	CH3
1861	OCH3	CH3	Cl	CH3	CH3
1862	OCH3	CH3	Cl	OCH3	CH3
1863	OCH3	CH3	Cl	Cl	CH3
1864	OCH3	CH3	Cl	Br	CH3
1865	OCH3	CH3	Cl	F	CH3
1866	OCH3	CH3	Cl	H	OCH3
1867	OCH3	CH3	Cl	CH3	OCH3
1868	OCH3	CH3	Cl	OCH3	OCH3
1869	OCH3	CH3	Cl	Cl	OCH3
1870	OCH3	CH3	Cl	Br	OCH3
1871	OCH3	CH3	Cl	F	OCH3
1872	OCH3	CH3	Cl	H	Cl
1873	OCH3	CH3	Cl	Cl	Cl
1874	OCH3	CH3	Cl	H	Br
1875	OCH3	CH3	Cl	CH3	Br
1876	OCH3	CH3	Cl	OCH3	Br
1877	OCH3	CH3	Cl	Cl	Br
1878	OCH3	CH3	Cl	Br	Br
1879	OCH3	CH3	Cl	F	Br
1880	OCH3	CH3	Cl	H	F
1881	OCH3	CH3	Cl	CH3	F
1882	OCH3	CH3	Cl	OCH3	F
1883	OCH3	CH3	Cl	Cl	F
1884	OCH3	CH3	Cl	F	F
1885	OCH3	CH3	Br	H	H
1886	OCH3	CH3	Br	CH3	H
1887	OCH3	CH3	Br	OCH3	H
1888	OCH3	CH3	Br	Cl	H
1889	OCH3	CH3	Br	Br	H
1890	OCH3	CH3	Br	F	H
1891	OCH3	CH3	Br	H	CH3
1892	OCH3	CH3	Br	CH3	CH3
1893	OCH3	CH3	Br	OCH3	CH3
1894	OCH3	CH3	Br	Cl	CH3
1895	OCH3	CH3	Br	Br	CH3
1896	OCH3	CH3	Br	F	CH3
1897	OCH3	CH3	Br	H	OCH3
1898	OCH3	CH3	Br	CH3	OCH3
1899	OCH3	CH3	Br	OCH3	OCH3
1900	OCH3	CH3	Br	Cl	OCH3
1901	OCH3	CH3	Br	Br	OCH3
1902	OCH3	CH3	Br	F	OCH3
1903	OCH3	CH3	Br	H	Cl
1904	OCH3	CH3	Br	CH3	Cl
1905	OCH3	CH3	Br	OCH3	Cl
1906	OCH3	CH3	Br	Cl	Cl
1907	OCH3	CH3	Br	Br	Cl
1908	OCH3	CH3	Br	F	Cl
1909	OCH3	CH3	Br	H	Br
1910	OCH3	CH3	Br	Br	Br
1911	OCH3	CH3	Br	H	F
1912	OCH3	CH3	Br	CH3	F
1913	OCH3	CH3	Br	OCH3	F
1914	OCH3	CH3	Br	Cl	F
1915	OCH3	CH3	Br	Br	F
1916	OCH3	CH3	Br	F	F
1917	OCH3	CH3	F	H	H
1918	OCH3	CH3	F	CH3	H
1919	OCH3	CH3	F	OCH3	H
1920	OCH3	CH3	F	Cl	H
1921	OCH3	CH3	F	Br	H
1922	OCH3	CH3	F	F	H
1923	OCH3	CH3	F	H	CH3
1924	OCH3	CH3	F	CH3	CH3
1925	OCH3	CH3	F	OCH3	CH3
1926	OCH3	CH3	F	Cl	CH3
1927	OCH3	CH3	F	Br	CH3
1928	OCH3	CH3	F	F	CH3
1929	OCH3	CH3	F	H	OCH3
1930	OCH3	CH3	F	CH3	OCH3
1931	OCH3	CH3	F	OCH3	OCH3
1932	OCH3	CH3	F	Cl	OCH3
1933	OCH3	CH3	F	Br	OCH3
1934	OCH3	CH3	F	F	OCH3
1935	OCH3	CH3	F	H	Cl
1936	OCH3	CH3	F	CH3	Cl
1937	OCH3	CH3	F	OCH3	Cl
1938	OCH3	CH3	F	Cl	Cl
1939	OCH3	CH3	F	Br	Cl
1940	OCH3	CH3	F	F	Cl
1941	OCH3	CH3	F	H	Br
1942	OCH3	CH3	F	CH3	Br
1943	OCH3	CH3	F	OCH3	Br
1944	OCH3	CH3	F	Cl	Br
1945	OCH3	CH3	F	Br	Br
1946	OCH3	CH3	F	F	Br
1947	OCH3	CH3	F	H	F
1948	OCH3	CH3	F	F	F
1949	OCH3	OCH3	CH3	H	H
1950	OCH3	OCH3	CH3	H	CH3
1951	OCH3	OCH3	CH3	H	OCH3
1952	OCH3	OCH3	CH3	H	Cl
1953	OCH3	OCH3	CH3	H	Br
1954	OCH3	OCH3	CH3	H	F
1955	OCH3	OCH3	CH3	CH3	H
1956	OCH3	OCH3	CH3	CH3	CH3
1957	OCH3	OCH3	CH3	CH3	OCH3
1958	OCH3	OCH3	CH3	CH3	Cl
1959	OCH3	OCH3	CH3	CH3	Br
1960	OCH3	OCH3	CH3	CH3	F
1961	OCH3	OCH3	CH3	OCH3	H
1962	OCH3	OCH3	CH3	OCH3	OCH3
1963	OCH3	OCH3	CH3	OCH3	Cl
1964	OCH3	OCH3	CH3	OCH3	Br
1965	OCH3	OCH3	CH3	OCH3	F
1966	OCH3	OCH3	CH3	Cl	H
1967	OCH3	OCH3	CH3	Cl	OCH3
1968	OCH3	OCH3	CH3	Cl	Cl
1969	OCH3	OCH3	CH3	Cl	Br
1970	OCH3	OCH3	CH3	Cl	F
1971	OCH3	OCH3	CH3	Br	H
1972	OCH3	OCH3	CH3	Br	OCH3
1973	OCH3	OCH3	CH3	Br	Cl
1974	OCH3	OCH3	CH3	Br	Br
1975	OCH3	OCH3	CH3	Br	F
1976	OCH3	OCH3	CH3	F	H
1977	OCH3	OCH3	CH3	F	OCH3
1978	OCH3	OCH3	CH3	F	Cl
1979	OCH3	OCH3	CH3	F	Br
1980	OCH3	OCH3	CH3	F	F
1981	OCH3	OCH3	OCH3	H	H
1982	OCH3	OCH3	OCH3	H	CH3
1983	OCH3	OCH3	OCH3	H	OCH3
1984	OCH3	OCH3	OCH3	H	Cl
1985	OCH3	OCH3	OCH3	H	Br
1986	OCH3	OCH3	OCH3	H	F
1987	OCH3	OCH3	OCH3	CH3	H
1988	OCH3	OCH3	OCH3	CH3	CH3
1989	OCH3	OCH3	OCH3	CH3	Cl
1990	OCH3	OCH3	OCH3	CH3	Br
1991	OCH3	OCH3	OCH3	CH3	F
1992	OCH3	OCH3	OCH3	OCH3	H
1993	OCH3	OCH3	OCH3	OCH3	CH3
1994	OCH3	OCH3	OCH3	OCH3	OCH3
1995	OCH3	OCH3	OCH3	OCH3	Cl
1996	OCH3	OCH3	OCH3	OCH3	Br
1997	OCH3	OCH3	OCH3	OCH3	F
1998	OCH3	OCH3	OCH3	Cl	H
1999	OCH3	OCH3	OCH3	Cl	CH3
2000	OCH3	OCH3	OCH3	Cl	Cl
2001	OCH3	OCH3	OCH3	Cl	Br
2002	OCH3	OCH3	OCH3	Cl	F
2003	OCH3	OCH3	OCH3	Br	H
2004	OCH3	OCH3	OCH3	Br	CH3
2005	OCH3	OCH3	OCH3	Br	Cl
2006	OCH3	OCH3	OCH3	Br	Br
2007	OCH3	OCH3	OCH3	Br	F
2008	OCH3	OCH3	OCH3	F	H
2009	OCH3	OCH3	OCH3	F	CH3
2010	OCH3	OCH3	OCH3	F	Cl
2011	OCH3	OCH3	OCH3	F	Br
2012	OCH3	OCH3	OCH3	F	F
2013	OCH3	OCH3	Cl	H	H
2014	OCH3	OCH3	Cl	H	CH3
2015	OCH3	OCH3	Cl	H	OCH3
2016	OCH3	OCH3	Cl	H	Cl
2017	OCH3	OCH3	Cl	H	Br
2018	OCH3	OCH3	Cl	H	F
2019	OCH3	OCH3	Cl	CH3	H
2020	OCH3	OCH3	Cl	CH3	CH3
2021	OCH3	OCH3	Cl	CH3	OCH3
2022	OCH3	OCH3	Cl	CH3	Br
2023	OCH3	OCH3	Cl	CH3	F
2024	OCH3	OCH3	Cl	OCH3	H
2025	OCH3	OCH3	Cl	OCH3	CH3
2026	OCH3	OCH3	Cl	OCH3	OCH3
2027	OCH3	OCH3	Cl	OCH3	Br
2028	OCH3	OCH3	Cl	OCH3	F
2029	OCH3	OCH3	Cl	Cl	H
2030	OCH3	OCH3	Cl	Cl	CH3
2031	OCH3	OCH3	Cl	Cl	OCH3
2032	OCH3	OCH3	Cl	Cl	Cl
2033	OCH3	OCH3	Cl	Cl	Br
2034	OCH3	OCH3	Cl	Cl	F
2035	OCH3	OCH3	Cl	Br	H
2036	OCH3	OCH3	Cl	Br	CH3
2037	OCH3	OCH3	Cl	Br	OCH3
2038	OCH3	OCH3	Cl	Br	Br
2039	OCH3	OCH3	Cl	F	H
2040	OCH3	OCH3	Cl	F	CH3
2041	OCH3	OCH3	Cl	F	OCH3
2042	OCH3	OCH3	Cl	F	Br
2043	OCH3	OCH3	Cl	F	F
2044	OCH3	OCH3	Br	H	H
2045	OCH3	OCH3	Br	H	CH3
2046	OCH3	OCH3	Br	H	OCH3
2047	OCH3	OCH3	Br	H	Cl
2048	OCH3	OCH3	Br	H	Br
2049	OCH3	OCH3	Br	H	F
2050	OCH3	OCH3	Br	CH3	H
2051	OCH3	OCH3	Br	CH3	CH3
2052	OCH3	OCH3	Br	CH3	OCH3
2053	OCH3	OCH3	Br	CH3	Cl
2054	OCH3	OCH3	Br	CH3	F
2055	OCH3	OCH3	Br	OCH3	H
2056	OCH3	OCH3	Br	OCH3	CH3
2057	OCH3	OCH3	Br	OCH3	OCH3
2058	OCH3	OCH3	Br	OCH3	Cl
2059	OCH3	OCH3	Br	OCH3	F
2060	OCH3	OCH3	Br	Cl	H
2061	OCH3	OCH3	Br	Cl	CH3
2062	OCH3	OCH3	Br	Cl	OCH3
2063	OCH3	OCH3	Br	Cl	Cl
2064	OCH3	OCH3	Br	Cl	F
2065	OCH3	OCH3	Br	Br	H
2066	OCH3	OCH3	Br	Br	CH3
2067	OCH3	OCH3	Br	Br	OCH3
2068	OCH3	OCH3	Br	Br	Cl
2069	OCH3	OCH3	Br	Br	Br
2070	OCH3	OCH3	Br	Br	F
2071	OCH3	OCH3	Br	F	H
2072	OCH3	OCH3	Br	F	CH3
2073	OCH3	OCH3	Br	F	OCH3
2074	OCH3	OCH3	Br	F	Cl
2075	OCH3	OCH3	Br	F	F
2076	OCH3	OCH3	F	H	H
2077	OCH3	OCH3	F	H	CH3
2078	OCH3	OCH3	F	H	OCH3
2079	OCH3	OCH3	F	H	Cl
2080	OCH3	OCH3	F	H	Br
2081	OCH3	OCH3	F	H	F
2082	OCH3	OCH3	F	CH3	H
2083	OCH3	OCH3	F	CH3	CH3
2084	OCH3	OCH3	F	CH3	OCH3
2085	OCH3	OCH3	F	CH3	Cl
2086	OCH3	OCH3	F	CH3	Br
2087	OCH3	OCH3	F	OCH3	H
2088	OCH3	OCH3	F	OCH3	CH3
2089	OCH3	OCH3	F	OCH3	OCH3
2090	OCH3	OCH3	F	OCH3	Cl
2091	OCH3	OCH3	F	OCH3	Br
2092	OCH3	OCH3	F	Cl	H
2093	OCH3	OCH3	F	Cl	CH3
2094	OCH3	OCH3	F	Cl	OCH3
2095	OCH3	OCH3	F	Cl	Cl
2096	OCH3	OCH3	F	Cl	Br
2097	OCH3	OCH3	F	Br	H
2098	OCH3	OCH3	F	Br	CH3
2099	OCH3	OCH3	F	Br	OCH3
2100	OCH3	OCH3	F	Br	Cl
2101	OCH3	OCH3	F	Br	Br
2102	OCH3	OCH3	F	F	H
2103	OCH3	OCH3	F	F	CH3
2104	OCH3	OCH3	F	F	OCH3
2105	OCH3	OCH3	F	F	Cl
2106	OCH3	OCH3	F	F	Br
2107	OCH3	OCH3	F	F	F
2108	OCH3	Cl	CH3	H	H
2109	OCH3	Cl	CH3	H	CH3
2110	OCH3	Cl	CH3	H	OCH3
2111	OCH3	Cl	CH3	H	Cl
2112	OCH3	Cl	CH3	H	Br
2113	OCH3	Cl	CH3	H	F
2114	OCH3	Cl	CH3	CH3	H
2115	OCH3	Cl	CH3	CH3	CH3
2116	OCH3	Cl	CH3	CH3	OCH3
2117	OCH3	Cl	CH3	CH3	Cl
2118	OCH3	Cl	CH3	CH3	Br
2119	OCH3	Cl	CH3	CH3	F
2120	OCH3	Cl	CH3	OCH3	H
2121	OCH3	Cl	CH3	OCH3	OCH3
2122	OCH3	Cl	CH3	OCH3	Cl
2123	OCH3	Cl	CH3	OCH3	Br
2124	OCH3	Cl	CH3	OCH3	F
2125	OCH3	Cl	CH3	Cl	H
2126	OCH3	Cl	CH3	Cl	OCH3
2127	OCH3	Cl	CH3	Cl	Cl
2128	OCH3	Cl	CH3	Cl	Br
2129	OCH3	Cl	CH3	Cl	F
2130	OCH3	Cl	CH3	Br	H
2131	OCH3	Cl	CH3	Br	OCH3
2132	OCH3	Cl	CH3	Br	Cl
2133	OCH3	Cl	CH3	Br	Br
2134	OCH3	Cl	CH3	Br	F
2135	OCH3	Cl	CH3	F	H
2136	OCH3	Cl	CH3	F	OCH3
2137	OCH3	Cl	CH3	F	Cl
2138	OCH3	Cl	CH3	F	Br
2139	OCH3	Cl	CH3	F	F
2140	OCH3	Cl	OCH3	H	H
2141	OCH3	Cl	OCH3	H	CH3
2142	OCH3	Cl	OCH3	H	OCH3
2143	OCH3	Cl	OCH3	H	Cl
2144	OCH3	Cl	OCH3	H	Br
2145	OCH3	Cl	OCH3	H	F
2146	OCH3	Cl	OCH3	CH3	H
2147	OCH3	Cl	OCH3	CH3	CH3
2148	OCH3	Cl	OCH3	CH3	Cl
2149	OCH3	Cl	OCH3	CH3	Br
2150	OCH3	Cl	OCH3	CH3	F
2151	OCH3	Cl	OCH3	OCH3	H
2152	OCH3	Cl	OCH3	OCH3	CH3
2153	OCH3	Cl	OCH3	OCH3	OCH3
2154	OCH3	Cl	OCH3	OCH3	Cl
2155	OCH3	Cl	OCH3	OCH3	Br
2156	OCH3	Cl	OCH3	OCH3	F
2157	OCH3	Cl	OCH3	Cl	H
2158	OCH3	Cl	OCH3	Cl	CH3
2159	OCH3	Cl	OCH3	Cl	Cl
2160	OCH3	Cl	OCH3	Cl	Br
2161	OCH3	Cl	OCH3	Cl	F
2162	OCH3	Cl	OCH3	Br	H
2163	OCH3	Cl	OCH3	Br	CH3
2164	OCH3	Cl	OCH3	Br	Cl
2165	OCH3	Cl	OCH3	Br	Br
2166	OCH3	Cl	OCH3	Br	F
2167	OCH3	Cl	OCH3	F	H
2168	OCH3	Cl	OCH3	F	CH3
2169	OCH3	Cl	OCH3	F	Cl
2170	OCH3	Cl	OCH3	F	Br
2171	OCH3	Cl	OCH3	F	F
2172	OCH3	Cl	Cl	H	H
2173	OCH3	Cl	Cl	H	CH3
2174	OCH3	Cl	Cl	H	OCH3
2175	OCH3	Cl	Cl	H	Cl
2176	OCH3	Cl	Cl	H	Br
2177	OCH3	Cl	Cl	H	F
2178	OCH3	Cl	Cl	CH3	H
2179	OCH3	Cl	Cl	CH3	CH3
2180	OCH3	Cl	Cl	CH3	OCH3
2181	OCH3	Cl	Cl	CH3	Br
2182	OCH3	Cl	Cl	CH3	F
2183	OCH3	Cl	Cl	OCH3	H
2184	OCH3	Cl	Cl	OCH3	CH3
2185	OCH3	Cl	Cl	OCH3	OCH3
2186	OCH3	Cl	Cl	OCH3	Br
2187	OCH3	Cl	Cl	OCH3	F
2188	OCH3	Cl	Cl	Cl	H
2189	OCH3	Cl	Cl	Cl	CH3
2190	OCH3	Cl	Cl	Cl	OCH3
2191	OCH3	Cl	Cl	Cl	Cl
2192	OCH3	Cl	Cl	Cl	Br
2193	OCH3	Cl	Cl	Cl	F
2194	OCH3	Cl	Cl	Br	H
2195	OCH3	Cl	Cl	Br	CH3
2196	OCH3	Cl	Cl	Br	OCH3
2197	OCH3	Cl	Cl	Br	Br
2198	OCH3	Cl	Cl	F	H
2199	OCH3	Cl	Cl	F	CH3
2200	OCH3	Cl	Cl	F	OCH3
2201	OCH3	Cl	Cl	F	Br
2202	OCH3	Cl	Cl	F	F
2203	OCH3	Cl	Br	H	H
2204	OCH3	Cl	Br	H	CH3
2205	OCH3	Cl	Br	H	OCH3
2206	OCH3	Cl	Br	H	Cl
2207	OCH3	Cl	Br	H	Br
2208	OCH3	Cl	Br	H	F
2209	OCH3	Cl	Br	CH3	H
2210	OCH3	Cl	Br	CH3	CH3
2211	OCH3	Cl	Br	CH3	OCH3
2212	OCH3	Cl	Br	CH3	Cl
2213	OCH3	Cl	Br	CH3	F
2214	OCH3	Cl	Br	OCH3	H
2215	OCH3	Cl	Br	OCH3	CH3
2216	OCH3	Cl	Br	OCH3	OCH3
2217	OCH3	Cl	Br	OCH3	Cl
2218	OCH3	Cl	Br	OCH3	F
2219	OCH3	Cl	Br	Cl	H
2220	OCH3	Cl	Br	Cl	CH3
2221	OCH3	Cl	Br	Cl	OCH3
2222	OCH3	Cl	Br	Cl	Cl
2223	OCH3	Cl	Br	Cl	F
2224	OCH3	Cl	Br	Br	H
2225	OCH3	Cl	Br	Br	CH3
2226	OCH3	Cl	Br	Br	OCH3
2227	OCH3	Cl	Br	Br	Cl
2228	OCH3	Cl	Br	Br	Br
2229	OCH3	Cl	Br	Br	F
2230	OCH3	Cl	Br	F	H
2231	OCH3	Cl	Br	F	CH3
2232	OCH3	Cl	Br	F	OCH3
2233	OCH3	Cl	Br	F	Cl
2234	OCH3	Cl	Br	F	F
2235	OCH3	Cl	F	H	H
2236	OCH3	Cl	F	H	CH3
2237	OCH3	Cl	F	H	OCH3
2238	OCH3	Cl	F	H	Cl
2239	OCH3	Cl	F	H	Br
2240	OCH3	Cl	F	H	F
2241	OCH3	Cl	F	CH3	H
2242	OCH3	Cl	F	CH3	CH3
2243	OCH3	Cl	F	CH3	OCH3
2244	OCH3	Cl	F	CH3	Cl
2245	OCH3	Cl	F	CH3	Br
2246	OCH3	Cl	F	OCH3	H
2247	OCH3	Cl	F	OCH3	CH3
2248	OCH3	Cl	F	OCH3	OCH3
2249	OCH3	Cl	F	OCH3	Cl
2250	OCH3	Cl	F	OCH3	Br
2251	OCH3	Cl	F	Cl	H
2252	OCH3	Cl	F	Cl	CH3
2253	OCH3	Cl	F	Cl	OCH3
2254	OCH3	Cl	F	Cl	Cl
2255	OCH3	Cl	F	Cl	Br
2256	OCH3	Cl	F	Br	H
2257	OCH3	Cl	F	Br	CH3
2258	OCH3	Cl	F	Br	OCH3
2259	OCH3	Cl	F	Br	Cl
2260	OCH3	Cl	F	Br	Br
2261	OCH3	Cl	F	F	H
2262	OCH3	Cl	F	F	CH3
2263	OCH3	Cl	F	F	OCH3
2264	OCH3	Cl	F	F	Cl
2265	OCH3	Cl	F	F	Br
2266	OCH3	Cl	F	F	F
2267	OCH3	Br	CH3	H	H
2268	OCH3	Br	CH3	H	CH3
2269	OCH3	Br	CH3	H	OCH3
2270	OCH3	Br	CH3	H	Cl
2271	OCH3	Br	CH3	H	Br
2272	OCH3	Br	CH3	H	F
2273	OCH3	Br	CH3	CH3	H
2274	OCH3	Br	CH3	CH3	CH3
2275	OCH3	Br	CH3	CH3	OCH3
2276	OCH3	Br	CH3	CH3	Cl
2277	OCH3	Br	CH3	CH3	Br
2278	OCH3	Br	CH3	CH3	F
2279	OCH3	Br	CH3	OCH3	H
2280	OCH3	Br	CH3	OCH3	OCH3
2281	OCH3	Br	CH3	OCH3	Cl
2282	OCH3	Br	CH3	OCH3	Br
2283	OCH3	Br	CH3	OCH3	F
2284	OCH3	Br	CH3	Cl	H
2285	OCH3	Br	CH3	Cl	OCH3
2286	OCH3	Br	CH3	Cl	Cl
2287	OCH3	Br	CH3	Cl	Br
2288	OCH3	Br	CH3	Cl	F
2289	OCH3	Br	CH3	Br	H
2290	OCH3	Br	CH3	Br	OCH3
2291	OCH3	Br	CH3	Br	Cl
2292	OCH3	Br	CH3	Br	Br
2293	OCH3	Br	CH3	Br	F
2294	OCH3	Br	CH3	F	H
2295	OCH3	Br	CH3	F	OCH3
2296	OCH3	Br	CH3	F	Cl
2297	OCH3	Br	CH3	F	Br
2298	OCH3	Br	CH3	F	F
2299	OCH3	Br	OCH3	H	H
2300	OCH3	Br	OCH3	H	CH3
2301	OCH3	Br	OCH3	H	OCH3
2302	OCH3	Br	OCH3	H	Cl
2303	OCH3	Br	OCH3	H	Br
2304	OCH3	Br	OCH3	H	F
2305	OCH3	Br	OCH3	CH3	H
2306	OCH3	Br	OCH3	CH3	CH3
2307	OCH3	Br	OCH3	CH3	Cl
2308	OCH3	Br	OCH3	CH3	Br
2309	OCH3	Br	OCH3	CH3	F
2310	OCH3	Br	OCH3	OCH3	H
2311	OCH3	Br	OCH3	OCH3	CH3
2312	OCH3	Br	OCH3	OCH3	OCH3
2313	OCH3	Br	OCH3	OCH3	Cl
2314	OCH3	Br	OCH3	OCH3	Br
2315	OCH3	Br	OCH3	OCH3	F
2316	OCH3	Br	OCH3	Cl	H
2317	OCH3	Br	OCH3	Cl	CH3
2318	OCH3	Br	OCH3	Cl	Cl
2319	OCH3	Br	OCH3	Cl	Br
2320	OCH3	Br	OCH3	Cl	F
2321	OCH3	Br	OCH3	Br	H
2322	OCH3	Br	OCH3	Br	CH3
2323	OCH3	Br	OCH3	Br	Cl
2324	OCH3	Br	OCH3	Br	Br
2325	OCH3	Br	OCH3	Br	F
2326	OCH3	Br	OCH3	F	H
2327	OCH3	Br	OCH3	F	CH3
2328	OCH3	Br	OCH3	F	Cl
2329	OCH3	Br	OCH3	F	Br
2330	OCH3	Br	OCH3	F	F
2331	OCH3	Br	Cl	H	H
2332	OCH3	Br	Cl	H	CH3
2333	OCH3	Br	Cl	H	OCH3
2334	OCH3	Br	Cl	H	Cl
2335	OCH3	Br	Cl	H	Br
2336	OCH3	Br	Cl	H	F
2337	OCH3	Br	Cl	CH3	H
2338	OCH3	Br	Cl	CH3	CH3
2339	OCH3	Br	Cl	CH3	OCH3
2340	OCH3	Br	Cl	CH3	Br
2341	OCH3	Br	Cl	CH3	F
2342	OCH3	Br	Cl	OCH3	H
2343	OCH3	Br	Cl	OCH3	CH3
2344	OCH3	Br	Cl	OCH3	OCH3
2345	OCH3	Br	Cl	OCH3	Br
2346	OCH3	Br	Cl	OCH3	F
2347	OCH3	Br	Cl	Cl	H
2348	OCH3	Br	Cl	Cl	CH3
2349	OCH3	Br	Cl	Cl	OCH3
2350	OCH3	Br	Cl	Cl	Cl
2351	OCH3	Br	Cl	Cl	Br
2352	OCH3	Br	Cl	Cl	F
2353	OCH3	Br	Cl	Br	H
2354	OCH3	Br	Cl	Br	CH3
2355	OCH3	Br	Cl	Br	OCH3
2356	OCH3	Br	Cl	Br	Br
2357	OCH3	Br	Cl	F	H
2358	OCH3	Br	Cl	F	CH3
2359	OCH3	Br	Cl	F	OCH3
2360	OCH3	Br	Cl	F	Br
2361	OCH3	Br	Cl	F	F
2362	OCH3	Br	Br	H	H
2363	OCH3	Br	Br	H	CH3
2364	OCH3	Br	Br	H	OCH3
2365	OCH3	Br	Br	H	Cl
2366	OCH3	Br	Br	H	Br
2367	OCH3	Br	Br	H	F
2368	OCH3	Br	Br	CH3	H
2369	OCH3	Br	Br	CH3	CH3
2370	OCH3	Br	Br	CH3	OCH3
2371	OCH3	Br	Br	CH3	Cl
2372	OCH3	Br	Br	CH3	F
2373	OCH3	Br	Br	OCH3	H
2374	OCH3	Br	Br	OCH3	CH3
2375	OCH3	Br	Br	OCH3	OCH3
2376	OCH3	Br	Br	OCH3	Cl
2377	OCH3	Br	Br	OCH3	F
2378	OCH3	Br	Br	Cl	H
2379	OCH3	Br	Br	Cl	CH3
2380	OCH3	Br	Br	Cl	OCH3
2381	OCH3	Br	Br	Cl	Cl
2382	OCH3	Br	Br	Cl	F
2383	OCH3	Br	Br	Br	H
2384	OCH3	Br	Br	Br	CH3
2385	OCH3	Br	Br	Br	OCH3
2386	OCH3	Br	Br	Br	Cl
2387	OCH3	Br	Br	Br	Br
2388	OCH3	Br	Br	Br	F
2389	OCH3	Br	Br	F	H
2390	OCH3	Br	Br	F	CH3
2391	OCH3	Br	Br	F	OCH3
2392	OCH3	Br	Br	F	Cl
2393	OCH3	Br	Br	F	F
2394	OCH3	Br	F	H	H
2395	OCH3	Br	F	H	CH3
2396	OCH3	Br	F	H	OCH3
2397	OCH3	Br	F	H	Cl
2398	OCH3	Br	F	H	Br
2399	OCH3	Br	F	H	F
2400	OCH3	Br	F	CH3	H
2401	OCH3	Br	F	CH3	CH3
2402	OCH3	Br	F	CH3	OCH3
2403	OCH3	Br	F	CH3	Cl
2404	OCH3	Br	F	CH3	Br
2405	OCH3	Br	F	OCH3	H
2406	OCH3	Br	F	OCH3	CH3
2407	OCH3	Br	F	OCH3	OCH3
2408	OCH3	Br	F	OCH3	Cl
2409	OCH3	Br	F	OCH3	Br
2410	OCH3	Br	F	Cl	H
2411	OCH3	Br	F	Cl	CH3
2412	OCH3	Br	F	Cl	OCH3
2413	OCH3	Br	F	Cl	Cl
2414	OCH3	Br	F	Cl	Br
2415	OCH3	Br	F	Br	H
2416	OCH3	Br	F	Br	CH3
2417	OCH3	Br	F	Br	OCH3
2418	OCH3	Br	F	Br	Cl
2419	OCH3	Br	F	Br	Br
2420	OCH3	Br	F	F	H
2421	OCH3	Br	F	F	CH3
2422	OCH3	Br	F	F	OCH3
2423	OCH3	Br	F	F	Cl
2424	OCH3	Br	F	F	Br
2425	OCH3	Br	F	F	F
2426	OCH3	F	CH3	H	H
2427	OCH3	F	CH3	H	CH3
2428	OCH3	F	CH3	H	OCH3
2429	OCH3	F	CH3	H	Cl
2430	OCH3	F	CH3	H	Br
2431	OCH3	F	CH3	H	F
2432	OCH3	F	CH3	CH3	H
2433	OCH3	F	CH3	CH3	CH3
2434	OCH3	F	CH3	CH3	OCH3
2435	OCH3	F	CH3	CH3	Cl
2436	OCH3	F	CH3	CH3	Br
2437	OCH3	F	CH3	CH3	F
2438	OCH3	F	CH3	OCH3	H
2439	OCH3	F	CH3	OCH3	OCH3
2440	OCH3	F	CH3	OCH3	Cl
2441	OCH3	F	CH3	OCH3	Br
2442	OCH3	F	CH3	OCH3	F
2443	OCH3	F	CH3	Cl	H
2444	OCH3	F	CH3	Cl	OCH3
2445	OCH3	F	CH3	Cl	Cl
2446	OCH3	F	CH3	Cl	Br
2447	OCH3	F	CH3	Cl	F
2448	OCH3	F	CH3	Br	H
2449	OCH3	F	CH3	Br	OCH3
2450	OCH3	F	CH3	Br	Cl
2451	OCH3	F	CH3	Br	Br
2452	OCH3	F	CH3	Br	F
2453	OCH3	F	CH3	F	H
2454	OCH3	F	CH3	F	OCH3
2455	OCH3	F	CH3	F	Cl
2456	OCH3	F	CH3	F	Br
2457	OCH3	F	CH3	F	F
2458	OCH3	F	OCH3	H	H
2459	OCH3	F	OCH3	H	CH3
2460	OCH3	F	OCH3	H	OCH3
2461	OCH3	F	OCH3	H	Cl
2462	OCH3	F	OCH3	H	Br
2463	OCH3	F	OCH3	H	F
2464	OCH3	F	OCH3	CH3	H
2465	OCH3	F	OCH3	CH3	CH3
2466	OCH3	F	OCH3	CH3	Cl
2467	OCH3	F	OCH3	CH3	Br
2468	OCH3	F	OCH3	CH3	F
2469	OCH3	F	OCH3	OCH3	H
2470	OCH3	F	OCH3	OCH3	CH3
2471	OCH3	F	OCH3	OCH3	OCH3
2472	OCH3	F	OCH3	OCH3	Cl
2473	OCH3	F	OCH3	OCH3	Br
2474	OCH3	F	OCH3	OCH3	F
2475	OCH3	F	OCH3	Cl	H
2476	OCH3	F	OCH3	Cl	CH3
2477	OCH3	F	OCH3	Cl	Cl
2478	OCH3	F	OCH3	Cl	Br
2479	OCH3	F	OCH3	Cl	F
2480	OCH3	F	OCH3	Br	H
2481	OCH3	F	OCH3	Br	CH3
2482	OCH3	F	OCH3	Br	Cl
2483	OCH3	F	OCH3	Br	Br
2484	OCH3	F	OCH3	Br	F
2485	OCH3	F	OCH3	F	H
2486	OCH3	F	OCH3	F	CH3
2487	OCH3	F	OCH3	F	Cl
2488	OCH3	F	OCH3	F	Br
2489	OCH3	F	OCH3	F	F
2490	OCH3	F	Cl	H	H
2491	OCH3	F	Cl	H	CH3
2492	OCH3	F	Cl	H	OCH3
2493	OCH3	F	Cl	H	Cl
2494	OCH3	F	Cl	H	Br
2495	OCH3	F	Cl	H	F
2496	OCH3	F	Cl	CH3	H
2497	OCH3	F	Cl	CH3	CH3
2498	OCH3	F	Cl	CH3	OCH3
2499	OCH3	F	Cl	CH3	Br
2500	OCH3	F	Cl	CH3	F
2501	OCH3	F	Cl	OCH3	H
2502	OCH3	F	Cl	OCH3	CH3
2503	OCH3	F	Cl	OCH3	OCH3
2504	OCH3	F	Cl	OCH3	Br
2505	OCH3	F	Cl	OCH3	F
2506	OCH3	F	Cl	Cl	H
2507	OCH3	F	Cl	Cl	CH3
2508	OCH3	F	Cl	Cl	OCH3
2509	OCH3	F	Cl	Cl	Cl
2510	OCH3	F	Cl	Cl	Br
2511	OCH3	F	Cl	Cl	F
2512	OCH3	F	Cl	Br	H
2513	OCH3	F	Cl	Br	CH3
2514	OCH3	F	Cl	Br	OCH3
2515	OCH3	F	Cl	Br	Br
2516	OCH3	F	Cl	F	H
2517	OCH3	F	Cl	F	CH3
2518	OCH3	F	Cl	F	OCH3
2519	OCH3	F	Cl	F	Br
2520	OCH3	F	Cl	F	F
2521	OCH3	F	Br	H	H
2522	OCH3	F	Br	H	CH3
2523	OCH3	F	Br	H	OCH3
2524	OCH3	F	Br	H	Cl
2525	OCH3	F	Br	H	Br
2526	OCH3	F	Br	H	F
2527	OCH3	F	Br	CH3	H
2528	OCH3	F	Br	CH3	CH3
2529	OCH3	F	Br	CH3	OCH3
2530	OCH3	F	Br	CH3	Cl
2531	OCH3	F	Br	CH3	F
2532	OCH3	F	Br	OCH3	H
2533	OCH3	F	Br	OCH3	CH3
2534	OCH3	F	Br	OCH3	OCH3
2535	OCH3	F	Br	OCH3	Cl
2536	OCH3	F	Br	OCH3	F
2537	OCH3	F	Br	Cl	H
2538	OCH3	F	Br	Cl	CH3
2539	OCH3	F	Br	Cl	OCH3
2540	OCH3	F	Br	Cl	Cl
2541	OCH3	F	Br	Cl	F
2542	OCH3	F	Br	Br	H
2543	OCH3	F	Br	Br	CH3
2544	OCH3	F	Br	Br	OCH3
2545	OCH3	F	Br	Br	Cl
2546	OCH3	F	Br	Br	Br
2547	OCH3	F	Br	Br	F
2548	OCH3	F	Br	F	H
2549	OCH3	F	Br	F	CH3
2550	OCH3	F	Br	F	OCH3
2551	OCH3	F	Br	F	Cl
2552	OCH3	F	Br	F	F
2553	OCH3	F	F	H	H
2554	OCH3	F	F	H	CH3
2555	OCH3	F	F	H	OCH3
2556	OCH3	F	F	H	Cl
2557	OCH3	F	F	H	Br
2558	OCH3	F	F	H	F
2559	OCH3	F	F	CH3	H
2560	OCH3	F	F	CH3	CH3
2561	OCH3	F	F	CH3	OCH3
2562	OCH3	F	F	CH3	Cl
2563	OCH3	F	F	CH3	Br
2564	OCH3	F	F	OCH3	H
2565	OCH3	F	F	OCH3	CH3
2566	OCH3	F	F	OCH3	OCH3
2567	OCH3	F	F	OCH3	Cl
2568	OCH3	F	F	OCH3	Br
2569	OCH3	F	F	Cl	H
2570	OCH3	F	F	Cl	CH3
2571	OCH3	F	F	Cl	OCH3
2572	OCH3	F	F	Cl	Cl
2573	OCH3	F	F	Cl	Br
2574	OCH3	F	F	Br	H
2575	OCH3	F	F	Br	CH3
2576	OCH3	F	F	Br	OCH3
2577	OCH3	F	F	Br	Cl
2578	OCH3	F	F	Br	Br
2579	OCH3	F	F	F	H
2580	OCH3	F	F	F	CH3
2581	OCH3	F	F	F	OCH3
2582	OCH3	F	F	F	Cl
2583	OCH3	F	F	F	Br
2584	OCH3	F	F	F	F
2585	Cl	CH3	CH3	H	H
2586	Cl	CH3	CH3	CH3	H
2587	Cl	CH3	CH3	OCH3	H
2588	Cl	CH3	CH3	Cl	H
2589	Cl	CH3	CH3	Br	H
2590	Cl	CH3	CH3	F	H
2591	Cl	CH3	CH3	H	CH3
2592	Cl	CH3	CH3	CH3	CH3
2593	Cl	CH3	CH3	H	OCH3
2594	Cl	CH3	CH3	CH3	OCH3
2595	Cl	CH3	CH3	OCH3	OCH3
2596	Cl	CH3	CH3	Cl	OCH3
2597	Cl	CH3	CH3	Br	OCH3
2598	Cl	CH3	CH3	F	OCH3
2599	Cl	CH3	CH3	H	Cl
2600	Cl	CH3	CH3	CH3	Cl
2601	Cl	CH3	CH3	OCH3	Cl
2602	Cl	CH3	CH3	Cl	Cl
2603	Cl	CH3	CH3	Br	Cl
2604	Cl	CH3	CH3	F	Cl
2605	Cl	CH3	CH3	H	Br
2606	Cl	CH3	CH3	CH3	Br
2607	Cl	CH3	CH3	OCH3	Br
2608	Cl	CH3	CH3	Cl	Br
2609	Cl	CH3	CH3	Br	Br
2610	Cl	CH3	CH3	F	Br
2611	Cl	CH3	CH3	H	F
2612	Cl	CH3	CH3	CH3	F
2613	Cl	CH3	CH3	OCH3	F
2614	Cl	CH3	CH3	Cl	F
2615	Cl	CH3	CH3	Br	F
2616	Cl	CH3	CH3	F	F
2617	Cl	CH3	OCH3	H	H
2618	Cl	CH3	OCH3	CH3	H
2619	Cl	CH3	OCH3	OCH3	H
2620	Cl	CH3	OCH3	Cl	H
2621	Cl	CH3	OCH3	Br	H
2622	Cl	CH3	OCH3	F	H
2623	Cl	CH3	OCH3	H	CH3
2624	Cl	CH3	OCH3	CH3	CH3
2625	Cl	CH3	OCH3	OCH3	CH3
2626	Cl	CH3	OCH3	Cl	CH3
2627	Cl	CH3	OCH3	Br	CH3
2628	Cl	CH3	OCH3	F	CH3
2629	Cl	CH3	OCH3	H	OCH3
2630	Cl	CH3	OCH3	OCH3	OCH3
2631	Cl	CH3	OCH3	H	Cl
2632	Cl	CH3	OCH3	CH3	Cl
2633	Cl	CH3	OCH3	OCH3	Cl
2634	Cl	CH3	OCH3	Cl	Cl
2635	Cl	CH3	OCH3	Br	Cl
2636	Cl	CH3	OCH3	F	Cl
2637	Cl	CH3	OCH3	H	Br
2638	Cl	CH3	OCH3	CH3	Br
2639	Cl	CH3	OCH3	OCH3	Br
2640	Cl	CH3	OCH3	Cl	Br
2641	Cl	CH3	OCH3	Br	Br
2642	Cl	CH3	OCH3	F	Br
2643	Cl	CH3	OCH3	H	F
2644	Cl	CH3	OCH3	CH3	F
2645	Cl	CH3	OCH3	OCH3	F
2646	Cl	CH3	OCH3	Cl	F
2647	Cl	CH3	OCH3	Br	F
2648	Cl	CH3	OCH3	F	F
2649	Cl	CH3	Cl	H	H
2650	Cl	CH3	Cl	CH3	H
2651	Cl	CH3	Cl	OCH3	H
2652	Cl	CH3	Cl	Cl	H
2653	Cl	CH3	Cl	Br	H
2654	Cl	CH3	Cl	F	H
2655	Cl	CH3	Cl	H	CH3
2656	Cl	CH3	Cl	CH3	CH3
2657	Cl	CH3	Cl	OCH3	CH3
2658	Cl	CH3	Cl	Cl	CH3
2659	Cl	CH3	Cl	Br	CH3
2660	Cl	CH3	Cl	F	CH3
2661	Cl	CH3	Cl	H	OCH3
2662	Cl	CH3	Cl	CH3	OCH3
2663	Cl	CH3	Cl	OCH3	OCH3
2664	Cl	CH3	Cl	Cl	OCH3
2665	Cl	CH3	Cl	Br	OCH3
2666	Cl	CH3	Cl	F	OCH3
2667	Cl	CH3	Cl	H	Cl
2668	Cl	CH3	Cl	Cl	Cl
2669	Cl	CH3	Cl	H	Br
2670	Cl	CH3	Cl	CH3	Br
2671	Cl	CH3	Cl	OCH3	Br
2672	Cl	CH3	Cl	Cl	Br
2673	Cl	CH3	Cl	Br	Br
2674	Cl	CH3	Cl	F	Br
2675	Cl	CH3	Cl	H	F
2676	Cl	CH3	Cl	CH3	F
2677	Cl	CH3	Cl	OCH3	F
2678	Cl	CH3	Cl	Cl	F
2679	Cl	CH3	Cl	F	F
2680	Cl	CH3	Br	H	H
2681	Cl	CH3	Br	CH3	H
2682	Cl	CH3	Br	OCH3	H
2683	Cl	CH3	Br	Cl	H
2684	Cl	CH3	Br	Br	H
2685	Cl	CH3	Br	F	H
2686	Cl	CH3	Br	H	CH3
2687	Cl	CH3	Br	CH3	CH3
2688	Cl	CH3	Br	OCH3	CH3
2689	Cl	CH3	Br	Cl	CH3
2690	Cl	CH3	Br	Br	CH3
2691	Cl	CH3	Br	F	CH3
2692	Cl	CH3	Br	H	OCH3
2693	Cl	CH3	Br	CH3	OCH3
2694	Cl	CH3	Br	OCH3	OCH3
2695	Cl	CH3	Br	Cl	OCH3
2696	Cl	CH3	Br	Br	OCH3
2697	Cl	CH3	Br	F	OCH3
2698	Cl	CH3	Br	H	Cl
2699	Cl	CH3	Br	CH3	Cl
2700	Cl	CH3	Br	OCH3	Cl
2701	Cl	CH3	Br	Cl	Cl
2702	Cl	CH3	Br	Br	Cl
2703	Cl	CH3	Br	F	Cl
2704	Cl	CH3	Br	H	Br
2705	Cl	CH3	Br	Br	Br
2706	Cl	CH3	Br	H	F
2707	Cl	CH3	Br	CH3	F
2708	Cl	CH3	Br	OCH3	F
2709	Cl	CH3	Br	Cl	F
2710	Cl	CH3	Br	Br	F
2711	Cl	CH3	Br	F	F
2712	Cl	CH3	F	H	H
2713	Cl	CH3	F	CH3	H
2714	Cl	CH3	F	OCH3	H
2715	Cl	CH3	F	Cl	H
2716	Cl	CH3	F	Br	H
2717	Cl	CH3	F	F	H
2718	Cl	CH3	F	H	CH3
2719	Cl	CH3	F	CH3	CH3
2720	Cl	CH3	F	OCH3	CH3
2721	Cl	CH3	F	Cl	CH3
2722	Cl	CH3	F	Br	CH3
2723	Cl	CH3	F	F	CH3
2724	Cl	CH3	F	H	OCH3
2725	Cl	CH3	F	CH3	OCH3
2726	Cl	CH3	F	OCH3	OCH3
2727	Cl	CH3	F	Cl	OCH3
2728	Cl	CH3	F	Br	OCH3
2729	Cl	CH3	F	F	OCH3
2730	Cl	CH3	F	H	Cl
2731	Cl	CH3	F	CH3	Cl
2732	Cl	CH3	F	OCH3	Cl
2733	Cl	CH3	F	Cl	Cl
2734	Cl	CH3	F	Br	Cl
2735	Cl	CH3	F	F	Cl
2736	Cl	CH3	F	H	Br
2737	Cl	CH3	F	CH3	Br
2738	Cl	CH3	F	OCH3	Br
2739	Cl	CH3	F	Cl	Br
2740	Cl	CH3	F	Br	Br
2741	Cl	CH3	F	F	Br
2742	Cl	CH3	F	H	F
2743	Cl	CH3	F	F	F
2744	Cl	OCH3	CH3	H	H
2745	Cl	OCH3	CH3	H	CH3
2746	Cl	OCH3	CH3	H	OCH3
2747	Cl	OCH3	CH3	H	Cl
2748	Cl	OCH3	CH3	H	Br
2749	Cl	OCH3	CH3	H	F
2750	Cl	OCH3	CH3	CH3	H
2751	Cl	OCH3	CH3	CH3	CH3
2752	Cl	OCH3	CH3	CH3	OCH3
2753	Cl	OCH3	CH3	CH3	Cl
2754	Cl	OCH3	CH3	CH3	Br
2755	Cl	OCH3	CH3	CH3	F
2756	Cl	OCH3	CH3	OCH3	H
2757	Cl	OCH3	CH3	OCH3	OCH3
2758	Cl	OCH3	CH3	OCH3	Cl
2759	Cl	OCH3	CH3	OCH3	Br
2760	Cl	OCH3	CH3	OCH3	F
2761	Cl	OCH3	CH3	Cl	H
2762	Cl	OCH3	CH3	Cl	OCH3
2763	Cl	OCH3	CH3	Cl	Cl
2764	Cl	OCH3	CH3	Cl	Br
2765	Cl	OCH3	CH3	Cl	F
2766	Cl	OCH3	CH3	Br	H
2767	Cl	OCH3	CH3	Br	OCH3
2768	Cl	OCH3	CH3	Br	Cl
2769	Cl	OCH3	CH3	Br	Br
2770	Cl	OCH3	CH3	Br	F
2771	Cl	OCH3	CH3	F	H
2772	Cl	OCH3	CH3	F	OCH3
2773	Cl	OCH3	CH3	F	Cl
2774	Cl	OCH3	CH3	F	Br
2775	Cl	OCH3	CH3	F	F
2776	Cl	OCH3	OCH3	H	H
2777	Cl	OCH3	OCH3	H	CH3
2778	Cl	OCH3	OCH3	H	OCH3
2779	Cl	OCH3	OCH3	H	Cl
2780	Cl	OCH3	OCH3	H	Br
2781	Cl	OCH3	OCH3	H	F
2782	Cl	OCH3	OCH3	CH3	H
2783	Cl	OCH3	OCH3	CH3	CH3
2784	Cl	OCH3	OCH3	CH3	Cl
2785	Cl	OCH3	OCH3	CH3	Br
2786	Cl	OCH3	OCH3	CH3	F
2787	Cl	OCH3	OCH3	OCH3	H
2788	Cl	OCH3	OCH3	OCH3	CH3
2789	Cl	OCH3	OCH3	OCH3	OCH3
2790	Cl	OCH3	OCH3	OCH3	Cl
2791	Cl	OCH3	OCH3	OCH3	Br
2792	Cl	OCH3	OCH3	OCH3	F
2793	Cl	OCH3	OCH3	Cl	H
2794	Cl	OCH3	OCH3	Cl	CH3
2795	Cl	OCH3	OCH3	Cl	Cl
2796	Cl	OCH3	OCH3	Cl	Br
2797	Cl	OCH3	OCH3	Cl	F
2798	Cl	OCH3	OCH3	Br	H
2799	Cl	OCH3	OCH3	Br	CH3
2800	Cl	OCH3	OCH3	Br	Cl
2801	Cl	OCH3	OCH3	Br	Br
2802	Cl	OCH3	OCH3	Br	F
2803	Cl	OCH3	OCH3	F	H
2804	Cl	OCH3	OCH3	F	CH3
2805	Cl	OCH3	OCH3	F	Cl
2806	Cl	OCH3	OCH3	F	Br
2807	Cl	OCH3	OCH3	F	F
2808	Cl	OCH3	Cl	H	H
2809	Cl	OCH3	Cl	H	CH3
2810	Cl	OCH3	Cl	H	OCH3
2811	Cl	OCH3	Cl	H	Cl
2812	Cl	OCH3	Cl	H	Br
2813	Cl	OCH3	Cl	H	F
2814	Cl	OCH3	Cl	CH3	H
2815	Cl	OCH3	Cl	CH3	CH3
2816	Cl	OCH3	Cl	CH3	OCH3
2817	Cl	OCH3	Cl	CH3	Br
2818	Cl	OCH3	Cl	CH3	F
2819	Cl	OCH3	Cl	OCH3	H
2820	Cl	OCH3	Cl	OCH3	CH3
2821	Cl	OCH3	Cl	OCH3	OCH3
2822	Cl	OCH3	Cl	OCH3	Br
2823	Cl	OCH3	Cl	OCH3	F
2824	Cl	OCH3	Cl	Cl	H
2825	Cl	OCH3	Cl	Cl	CH3
2826	Cl	OCH3	Cl	Cl	OCH3
2827	Cl	OCH3	Cl	Cl	Cl
2828	Cl	OCH3	Cl	Cl	Br
2829	Cl	OCH3	Cl	Cl	F
2830	Cl	OCH3	Cl	Br	H
2831	Cl	OCH3	Cl	Br	CH3
2832	Cl	OCH3	Cl	Br	OCH3
2833	Cl	OCH3	Cl	Br	Br
2834	Cl	OCH3	Cl	F	H
2835	Cl	OCH3	Cl	F	CH3
2836	Cl	OCH3	Cl	F	OCH3
2837	Cl	OCH3	Cl	F	Br
2838	Cl	OCH3	Cl	F	F
2839	Cl	OCH3	Br	H	H
2840	Cl	OCH3	Br	H	CH3
2841	Cl	OCH3	Br	H	OCH3
2842	Cl	OCH3	Br	H	Cl
2843	Cl	OCH3	Br	H	Br
2844	Cl	OCH3	Br	H	F
2845	Cl	OCH3	Br	CH3	H
2846	Cl	OCH3	Br	CH3	CH3
2847	Cl	OCH3	Br	CH3	OCH3
2848	Cl	OCH3	Br	CH3	Cl
2849	Cl	OCH3	Br	CH3	F
2850	Cl	OCH3	Br	OCH3	H
2851	Cl	OCH3	Br	OCH3	CH3
2852	Cl	OCH3	Br	OCH3	OCH3
2853	Cl	OCH3	Br	OCH3	Cl
2854	Cl	OCH3	Br	OCH3	F
2855	Cl	OCH3	Br	Cl	H
2856	Cl	OCH3	Br	Cl	CH3
2857	Cl	OCH3	Br	Cl	OCH3
2858	Cl	OCH3	Br	Cl	Cl
2859	Cl	OCH3	Br	Cl	F
2860	Cl	OCH3	Br	Br	H
2861	Cl	OCH3	Br	Br	CH3
2862	Cl	OCH3	Br	Br	OCH3
2863	Cl	OCH3	Br	Br	Cl
2864	Cl	OCH3	Br	Br	Br
2865	Cl	OCH3	Br	Br	F
2866	Cl	OCH3	Br	F	H
2867	Cl	OCH3	Br	F	CH3
2868	Cl	OCH3	Br	F	OCH3
2869	Cl	OCH3	Br	F	Cl
2870	Cl	OCH3	Br	F	F
2871	Cl	OCH3	F	H	H
2872	Cl	OCH3	F	H	CH3
2873	Cl	OCH3	F	H	OCH3
2874	Cl	OCH3	F	H	Cl
2875	Cl	OCH3	F	H	Br
2876	Cl	OCH3	F	H	F
2877	Cl	OCH3	F	CH3	H
2878	Cl	OCH3	F	CH3	CH3
2879	Cl	OCH3	F	CH3	OCH3
2880	Cl	OCH3	F	CH3	Cl
2881	Cl	OCH3	F	CH3	Br
2882	Cl	OCH3	F	OCH3	H
2883	Cl	OCH3	F	OCH3	CH3
2884	Cl	OCH3	F	OCH3	OCH3
2885	Cl	OCH3	F	OCH3	Cl
2886	Cl	OCH3	F	OCH3	Br
2887	Cl	OCH3	F	Cl	H
2888	Cl	OCH3	F	Cl	CH3
2889	Cl	OCH3	F	Cl	OCH3
2890	Cl	OCH3	F	Cl	Cl
2891	Cl	OCH3	F	Cl	Br
2892	Cl	OCH3	F	Br	H
2893	Cl	OCH3	F	Br	CH3
2894	Cl	OCH3	F	Br	OCH3
2895	Cl	OCH3	F	Br	Cl
2896	Cl	OCH3	F	Br	Br
2897	Cl	OCH3	F	F	H
2898	Cl	OCH3	F	F	CH3
2899	Cl	OCH3	F	F	OCH3
2900	Cl	OCH3	F	F	Cl
2901	Cl	OCH3	F	F	Br
2902	Cl	OCH3	F	F	F
2903	Cl	Cl	CH3	H	H
2904	Cl	Cl	CH3	H	CH3
2905	Cl	Cl	CH3	H	OCH3
2906	Cl	Cl	CH3	H	Cl
2907	Cl	Cl	CH3	H	Br
2908	Cl	Cl	CH3	H	F
2909	Cl	Cl	CH3	CH3	H
2910	Cl	Cl	CH3	CH3	CH3
2911	Cl	Cl	CH3	CH3	OCH3
2912	Cl	Cl	CH3	CH3	Cl
2913	Cl	Cl	CH3	CH3	Br
2914	Cl	Cl	CH3	CH3	F
2915	Cl	Cl	CH3	OCH3	H
2916	Cl	Cl	CH3	OCH3	OCH3
2917	Cl	Cl	CH3	OCH3	Cl
2918	Cl	Cl	CH3	OCH3	Br
2919	Cl	Cl	CH3	OCH3	F
2920	Cl	Cl	CH3	Cl	H
2921	Cl	Cl	CH3	Cl	OCH3
2922	Cl	Cl	CH3	Cl	Cl
2923	Cl	Cl	CH3	Cl	Br
2924	Cl	Cl	CH3	Cl	F
2925	Cl	Cl	CH3	Br	H
2926	Cl	Cl	CH3	Br	OCH3
2927	Cl	Cl	CH3	Br	Cl
2928	Cl	Cl	CH3	Br	Br
2929	Cl	Cl	CH3	Br	F
2930	Cl	Cl	CH3	F	H
2931	Cl	Cl	CH3	F	OCH3
2932	Cl	Cl	CH3	F	Cl
2933	Cl	Cl	CH3	F	Br
2934	Cl	Cl	CH3	F	F
2935	Cl	Cl	OCH3	H	H
2936	Cl	Cl	OCH3	H	CH3
2937	Cl	Cl	OCH3	H	OCH3
2938	Cl	Cl	OCH3	H	Cl
2939	Cl	Cl	OCH3	H	Br
2940	Cl	Cl	OCH3	H	F
2941	Cl	Cl	OCH3	CH3	H
2942	Cl	Cl	OCH3	CH3	CH3
2943	Cl	Cl	OCH3	CH3	Cl
2944	Cl	Cl	OCH3	CH3	Br
2945	Cl	Cl	OCH3	CH3	F
2946	Cl	Cl	OCH3	OCH3	H
2947	Cl	Cl	OCH3	OCH3	CH3
2948	Cl	Cl	OCH3	OCH3	OCH3
2949	Cl	Cl	OCH3	OCH3	Cl
2950	Cl	Cl	OCH3	OCH3	Br
2951	Cl	Cl	OCH3	OCH3	F
2952	Cl	Cl	OCH3	Cl	H
2953	Cl	Cl	OCH3	Cl	CH3
2954	Cl	Cl	OCH3	Cl	Cl
2955	Cl	Cl	OCH3	Cl	Br
2956	Cl	Cl	OCH3	Cl	F
2957	Cl	Cl	OCH3	Br	H
2958	Cl	Cl	OCH3	Br	CH3
2959	Cl	Cl	OCH3	Br	Cl
2960	Cl	Cl	OCH3	Br	Br
2961	Cl	Cl	OCH3	Br	F
2962	Cl	Cl	OCH3	F	H
2963	Cl	Cl	OCH3	F	CH3
2964	Cl	Cl	OCH3	F	Cl
2965	Cl	Cl	OCH3	F	Br
2966	Cl	Cl	OCH3	F	F
2967	Cl	Cl	Cl	H	H
2968	Cl	Cl	Cl	H	CH3
2969	Cl	Cl	Cl	H	OCH3
2970	Cl	Cl	Cl	H	Cl
2971	Cl	Cl	Cl	H	Br
2972	Cl	Cl	Cl	H	F
2973	Cl	Cl	Cl	CH3	H
2974	Cl	Cl	Cl	CH3	CH3
2975	Cl	Cl	Cl	CH3	OCH3
2976	Cl	Cl	Cl	CH3	Br
2977	Cl	Cl	Cl	CH3	F
2978	Cl	Cl	Cl	OCH3	H
2979	Cl	Cl	Cl	OCH3	CH3
2980	Cl	Cl	Cl	OCH3	OCH3
2981	Cl	Cl	Cl	OCH3	Br
2982	Cl	Cl	Cl	OCH3	F
2983	Cl	Cl	Cl	Cl	H
2984	Cl	Cl	Cl	Cl	CH3
2985	Cl	Cl	Cl	Cl	OCH3
2986	Cl	Cl	Cl	Cl	Cl
2987	Cl	Cl	Cl	Cl	Br
2988	Cl	Cl	Cl	Cl	F
2989	Cl	Cl	Cl	Br	H
2990	Cl	Cl	Cl	Br	CH3
2991	Cl	Cl	Cl	Br	OCH3
2992	Cl	Cl	Cl	Br	Br
2993	Cl	Cl	Cl	F	H
2994	Cl	Cl	Cl	F	CH3
2995	Cl	Cl	Cl	F	OCH3
2996	Cl	Cl	Cl	F	Br
2997	Cl	Cl	Cl	F	F
2998	Cl	Cl	Br	H	H
2999	Cl	Cl	Br	H	CH3
3000	Cl	Cl	Br	H	OCH3
3001	Cl	Cl	Br	H	Cl
3002	Cl	Cl	Br	H	Br
3003	Cl	Cl	Br	H	F
3004	Cl	Cl	Br	CH3	H
3005	Cl	Cl	Br	CH3	CH3
3006	Cl	Cl	Br	CH3	OCH3
3007	Cl	Cl	Br	CH3	Cl
3008	Cl	Cl	Br	CH3	F
3009	Cl	Cl	Br	OCH3	H
3010	Cl	Cl	Br	OCH3	CH3
3011	Cl	Cl	Br	OCH3	OCH3
3012	Cl	Cl	Br	OCH3	Cl
3013	Cl	Cl	Br	OCH3	F
3014	Cl	Cl	Br	Cl	H
3015	Cl	Cl	Br	Cl	CH3
3016	Cl	Cl	Br	Cl	OCH3
3017	Cl	Cl	Br	Cl	Cl
3018	Cl	Cl	Br	Cl	F
3019	Cl	Cl	Br	Br	H
3020	Cl	Cl	Br	Br	CH3
3021	Cl	Cl	Br	Br	OCH3
3022	Cl	Cl	Br	Br	Cl
3023	Cl	Cl	Br	Br	Br
3024	Cl	Cl	Br	Br	F
3025	Cl	Cl	Br	F	H
3026	Cl	Cl	Br	F	CH3
3027	Cl	Cl	Br	F	OCH3
3028	Cl	Cl	Br	F	Cl
3029	Cl	Cl	Br	F	F
3030	Cl	Cl	F	H	H
3031	Cl	Cl	F	H	CH3
3032	Cl	Cl	F	H	OCH3
3033	Cl	Cl	F	H	Cl
3034	Cl	Cl	F	H	Br
3035	Cl	Cl	F	H	F
3036	Cl	Cl	F	CH3	H
3037	Cl	Cl	F	CH3	CH3
3038	Cl	Cl	F	CH3	OCH3
3039	Cl	Cl	F	CH3	Cl
3040	Cl	Cl	F	CH3	Br
3041	Cl	Cl	F	OCH3	H
3042	Cl	Cl	F	OCH3	CH3
3043	Cl	Cl	F	OCH3	OCH3
3044	Cl	Cl	F	OCH3	Cl
3045	Cl	Cl	F	OCH3	Br
3046	Cl	Cl	F	Cl	H
3047	Cl	Cl	F	Cl	CH3
3048	Cl	Cl	F	Cl	OCH3
3049	Cl	Cl	F	Cl	Cl
3050	Cl	Cl	F	Cl	Br
3051	Cl	Cl	F	Br	H
3052	Cl	Cl	F	Br	CH3
3053	Cl	Cl	F	Br	OCH3
3054	Cl	Cl	F	Br	Cl
3055	Cl	Cl	F	Br	Br
3056	Cl	Cl	F	F	H
3057	Cl	Cl	F	F	CH3
3058	Cl	Cl	F	F	OCH3
3059	Cl	Cl	F	F	Cl
3060	Cl	Cl	F	F	Br
3061	Cl	Cl	F	F	F
3062	Cl	Br	CH3	H	H
3063	Cl	Br	CH3	H	CH3
3064	Cl	Br	CH3	H	OCH3
3065	Cl	Br	CH3	H	Cl
3066	Cl	Br	CH3	H	Br
3067	Cl	Br	CH3	H	F
3068	Cl	Br	CH3	CH3	H
3069	Cl	Br	CH3	CH3	CH3
3070	Cl	Br	CH3	CH3	OCH3
3071	Cl	Br	CH3	CH3	Cl
3072	Cl	Br	CH3	CH3	Br
3073	Cl	Br	CH3	CH3	F
3074	Cl	Br	CH3	OCH3	H
3075	Cl	Br	CH3	OCH3	OCH3
3076	Cl	Br	CH3	OCH3	Cl
3077	Cl	Br	CH3	OCH3	Br
3078	Cl	Br	CH3	OCH3	F
3079	Cl	Br	CH3	Cl	H
3080	Cl	Br	CH3	Cl	OCH3
3081	Cl	Br	CH3	Cl	Cl
3082	Cl	Br	CH3	Cl	Br
3083	Cl	Br	CH3	Cl	F
3084	Cl	Br	CH3	Br	H
3085	Cl	Br	CH3	Br	OCH3
3086	Cl	Br	CH3	Br	Cl
3087	Cl	Br	CH3	Br	Br
3088	Cl	Br	CH3	Br	F
3089	Cl	Br	CH3	F	H
3090	Cl	Br	CH3	F	OCH3
3091	Cl	Br	CH3	F	Cl
3092	Cl	Br	CH3	F	Br
3093	Cl	Br	CH3	F	F
3094	Cl	Br	OCH3	H	H
3095	Cl	Br	OCH3	H	CH3
3096	Cl	Br	OCH3	H	OCH3
3097	Cl	Br	OCH3	H	Cl
3098	Cl	Br	OCH3	H	Br
3099	Cl	Br	OCH3	H	F
3100	Cl	Br	OCH3	CH3	H
3101	Cl	Br	OCH3	CH3	CH3
3102	Cl	Br	OCH3	CH3	Cl
3103	Cl	Br	OCH3	CH3	Br
3104	Cl	Br	OCH3	CH3	F
3105	Cl	Br	OCH3	OCH3	H
3106	Cl	Br	OCH3	OCH3	CH3
3107	Cl	Br	OCH3	OCH3	OCH3
3108	Cl	Br	OCH3	OCH3	Cl
3109	Cl	Br	OCH3	OCH3	Br
3110	Cl	Br	OCH3	OCH3	F
3111	Cl	Br	OCH3	Cl	H
3112	Cl	Br	OCH3	Cl	CH3
3113	Cl	Br	OCH3	Cl	Cl
3114	Cl	Br	OCH3	Cl	Br
3115	Cl	Br	OCH3	Cl	F
3116	Cl	Br	OCH3	Br	H
3117	Cl	Br	OCH3	Br	CH3
3118	Cl	Br	OCH3	Br	Cl
3119	Cl	Br	OCH3	Br	Br
3120	Cl	Br	OCH3	Br	F
3121	Cl	Br	OCH3	F	H
3122	Cl	Br	OCH3	F	CH3
3123	Cl	Br	OCH3	F	Cl
3124	Cl	Br	OCH3	F	Br
3125	Cl	Br	OCH3	F	F
3126	Cl	Br	Cl	H	H
3127	Cl	Br	Cl	H	CH3
3128	Cl	Br	Cl	H	OCH3
3129	Cl	Br	Cl	H	Cl
3130	Cl	Br	Cl	H	Br
3131	Cl	Br	Cl	H	F
3132	Cl	Br	Cl	CH3	H
3133	Cl	Br	Cl	CH3	CH3
3134	Cl	Br	Cl	CH3	OCH3
3135	Cl	Br	Cl	CH3	Br
3136	Cl	Br	Cl	CH3	F
3137	Cl	Br	Cl	OCH3	H
3138	Cl	Br	Cl	OCH3	CH3
3139	Cl	Br	Cl	OCH3	OCH3
3140	Cl	Br	Cl	OCH3	Br
3141	Cl	Br	Cl	OCH3	F
3142	Cl	Br	Cl	Cl	H
3143	Cl	Br	Cl	Cl	CH3
3144	Cl	Br	Cl	Cl	OCH3
3145	Cl	Br	Cl	Cl	Cl
3146	Cl	Br	Cl	Cl	Br
3147	Cl	Br	Cl	Cl	F
3148	Cl	Br	Cl	Br	H
3149	Cl	Br	Cl	Br	CH3
3150	Cl	Br	Cl	Br	OCH3
3151	Cl	Br	Cl	Br	Br
3152	Cl	Br	Cl	F	H
3153	Cl	Br	Cl	F	CH3
3154	Cl	Br	Cl	F	OCH3
3155	Cl	Br	Cl	F	Br
3156	Cl	Br	Cl	F	F
3157	Cl	Br	Br	H	H
3158	Cl	Br	Br	H	CH3
3159	Cl	Br	Br	H	OCH3
3160	Cl	Br	Br	H	Cl
3161	Cl	Br	Br	H	Br
3162	Cl	Br	Br	H	F
3163	Cl	Br	Br	CH3	H
3164	Cl	Br	Br	CH3	CH3
3165	Cl	Br	Br	CH3	OCH3
3166	Cl	Br	Br	CH3	Cl
3167	Cl	Br	Br	CH3	F
3168	Cl	Br	Br	OCH3	H
3169	Cl	Br	Br	OCH3	CH3
3170	Cl	Br	Br	OCH3	OCH3
3171	Cl	Br	Br	OCH3	Cl
3172	Cl	Br	Br	OCH3	F
3173	Cl	Br	Br	Cl	H
3174	Cl	Br	Br	Cl	CH3
3175	Cl	Br	Br	Cl	OCH3
3176	Cl	Br	Br	Cl	Cl
3177	Cl	Br	Br	Cl	F
3178	Cl	Br	Br	Br	H
3179	Cl	Br	Br	Br	CH3
3180	Cl	Br	Br	Br	OCH3
3181	Cl	Br	Br	Br	Cl
3182	Cl	Br	Br	Br	Br
3183	Cl	Br	Br	Br	F
3184	Cl	Br	Br	F	H
3185	Cl	Br	Br	F	CH3
3186	Cl	Br	Br	F	OCH3
3187	Cl	Br	Br	F	Cl
3188	Cl	Br	Br	F	F
3189	Cl	Br	F	H	H
3190	Cl	Br	F	H	CH3
3191	Cl	Br	F	H	OCH3
3192	Cl	Br	F	H	Cl
3193	Cl	Br	F	H	Br
3194	Cl	Br	F	H	F
3195	Cl	Br	F	CH3	H
3196	Cl	Br	F	CH3	CH3
3197	Cl	Br	F	CH3	OCH3
3198	Cl	Br	F	CH3	Cl
3199	Cl	Br	F	CH3	Br
3200	Cl	Br	F	OCH3	H
3201	Cl	Br	F	OCH3	CH3
3202	Cl	Br	F	OCH3	OCH3
3203	Cl	Br	F	OCH3	Cl
3204	Cl	Br	F	OCH3	Br
3205	Cl	Br	F	Cl	H
3206	Cl	Br	F	Cl	CH3
3207	Cl	Br	F	Cl	OCH3
3208	Cl	Br	F	Cl	Cl
3209	Cl	Br	F	Cl	Br
3210	Cl	Br	F	Br	H
3211	Cl	Br	F	Br	CH3
3212	Cl	Br	F	Br	OCH3
3213	Cl	Br	F	Br	Cl
3214	Cl	Br	F	Br	Br
3215	Cl	Br	F	F	H
3216	Cl	Br	F	F	CH3
3217	Cl	Br	F	F	OCH3
3218	Cl	Br	F	F	Cl
3219	Cl	Br	F	F	Br
3220	Cl	Br	F	F	F
3221	Cl	F	CH3	H	H
3222	Cl	F	CH3	H	CH3
3223	Cl	F	CH3	H	OCH3
3224	Cl	F	CH3	H	Cl
3225	Cl	F	CH3	H	Br
3226	Cl	F	CH3	H	F
3227	Cl	F	CH3	CH3	H
3228	Cl	F	CH3	CH3	CH3
3229	Cl	F	CH3	CH3	OCH3
3230	Cl	F	CH3	CH3	Cl
3231	Cl	F	CH3	CH3	Br
3232	Cl	F	CH3	CH3	F
3233	Cl	F	CH3	OCH3	H
3234	Cl	F	CH3	OCH3	OCH3
3235	Cl	F	CH3	OCH3	Cl
3236	Cl	F	CH3	OCH3	Br
3237	Cl	F	CH3	OCH3	F
3238	Cl	F	CH3	Cl	H
3239	Cl	F	CH3	Cl	OCH3
3240	Cl	F	CH3	Cl	Cl
3241	Cl	F	CH3	Cl	Br
3242	Cl	F	CH3	Cl	F
3243	Cl	F	CH3	Br	H
3244	Cl	F	CH3	Br	OCH3
3245	Cl	F	CH3	Br	Cl
3246	Cl	F	CH3	Br	Br
3247	Cl	F	CH3	Br	F
3248	Cl	F	CH3	F	H
3249	Cl	F	CH3	F	OCH3
3250	Cl	F	CH3	F	Cl
3251	Cl	F	CH3	F	Br
3252	Cl	F	CH3	F	F
3253	Cl	F	OCH3	H	H
3254	Cl	F	OCH3	H	CH3
3255	Cl	F	OCH3	H	OCH3
3256	Cl	F	OCH3	H	Cl
3257	Cl	F	OCH3	H	Br
3258	Cl	F	OCH3	H	F
3259	Cl	F	OCH3	CH3	H
3260	Cl	F	OCH3	CH3	CH3
3261	Cl	F	OCH3	CH3	Cl
3262	Cl	F	OCH3	CH3	Br
3263	Cl	F	OCH3	CH3	F
3264	Cl	F	OCH3	OCH3	H
3265	Cl	F	OCH3	OCH3	CH3
3266	Cl	F	OCH3	OCH3	OCH3
3267	Cl	F	OCH3	OCH3	Cl
3268	Cl	F	OCH3	OCH3	Br
3269	Cl	F	OCH3	OCH3	F
3270	Cl	F	OCH3	Cl	H
3271	Cl	F	OCH3	Cl	CH3
3272	Cl	F	OCH3	Cl	Cl
3273	Cl	F	OCH3	Cl	Br
3274	Cl	F	OCH3	Cl	F
3275	Cl	F	OCH3	Br	H
3276	Cl	F	OCH3	Br	CH3
3277	Cl	F	OCH3	Br	Cl
3278	Cl	F	OCH3	Br	Br
3279	Cl	F	OCH3	Br	F
3280	Cl	F	OCH3	F	H
3281	Cl	F	OCH3	F	CH3
3282	Cl	F	OCH3	F	Cl
3283	Cl	F	OCH3	F	Br
3284	Cl	F	OCH3	F	F
3285	Cl	F	Cl	H	H
3286	Cl	F	Cl	H	CH3
3287	Cl	F	Cl	H	OCH3
3288	Cl	F	Cl	H	Cl
3289	Cl	F	Cl	H	Br
3290	Cl	F	Cl	H	F
3291	Cl	F	Cl	CH3	H
3292	Cl	F	Cl	CH3	CH3
3293	Cl	F	Cl	CH3	OCH3
3294	Cl	F	Cl	CH3	Br
3295	Cl	F	Cl	CH3	F
3296	Cl	F	Cl	OCH3	H
3297	Cl	F	Cl	OCH3	CH3
3298	Cl	F	Cl	OCH3	OCH3
3299	Cl	F	Cl	OCH3	Br
3300	Cl	F	Cl	OCH3	F
3301	Cl	F	Cl	Cl	H
3302	Cl	F	Cl	Cl	CH3
3303	Cl	F	Cl	Cl	OCH3
3304	Cl	F	Cl	Cl	Cl
3305	Cl	F	Cl	Cl	Br
3306	Cl	F	Cl	Cl	F
3307	Cl	F	Cl	Br	H
3308	Cl	F	Cl	Br	CH3
3309	Cl	F	Cl	Br	OCH3
3310	Cl	F	Cl	Br	Br
3311	Cl	F	Cl	F	H
3312	Cl	F	Cl	F	CH3
3313	Cl	F	Cl	F	OCH3
3314	Cl	F	Cl	F	Br
3315	Cl	F	Cl	F	F
3316	Cl	F	Br	H	H
3317	Cl	F	Br	H	CH3
3318	Cl	F	Br	H	OCH3
3319	Cl	F	Br	H	Cl
3320	Cl	F	Br	H	Br
3321	Cl	F	Br	H	F
3322	Cl	F	Br	CH3	H
3323	Cl	F	Br	CH3	CH3
3324	Cl	F	Br	CH3	OCH3
3325	Cl	F	Br	CH3	Cl
3326	Cl	F	Br	CH3	F
3327	Cl	F	Br	OCH3	H
3328	Cl	F	Br	OCH3	CH3
3329	Cl	F	Br	OCH3	OCH3
3330	Cl	F	Br	OCH3	Cl
3331	Cl	F	Br	OCH3	F
3332	Cl	F	Br	Cl	H
3333	Cl	F	Br	Cl	CH3
3334	Cl	F	Br	Cl	OCH3
3335	Cl	F	Br	Cl	Cl
3336	Cl	F	Br	Cl	F
3337	Cl	F	Br	Br	H
3338	Cl	F	Br	Br	CH3
3339	Cl	F	Br	Br	OCH3
3340	Cl	F	Br	Br	Cl
3341	Cl	F	Br	Br	Br
3342	Cl	F	Br	Br	F
3343	Cl	F	Br	F	H
3344	Cl	F	Br	F	CH3
3345	Cl	F	Br	F	OCH3
3346	Cl	F	Br	F	Cl
3347	Cl	F	Br	F	F
3348	Cl	F	F	H	H
3349	Cl	F	F	H	CH3
3350	Cl	F	F	H	OCH3
3351	Cl	F	F	H	Cl
3352	Cl	F	F	H	Br
3353	Cl	F	F	H	F
3354	Cl	F	F	CH3	H
3355	Cl	F	F	CH3	CH3
3356	Cl	F	F	CH3	OCH3
3357	Cl	F	F	CH3	Cl
3358	Cl	F	F	CH3	Br
3359	Cl	F	F	OCH3	H
3360	Cl	F	F	OCH3	CH3
3361	Cl	F	F	OCH3	OCH3
3362	Cl	F	F	OCH3	Cl
3363	Cl	F	F	OCH3	Br
3364	Cl	F	F	Cl	H
3365	Cl	F	F	Cl	CH3
3366	Cl	F	F	Cl	OCH3
3367	Cl	F	F	Cl	Cl
3368	Cl	F	F	Cl	Br
3369	Cl	F	F	Br	H
3370	Cl	F	F	Br	CH3
3371	Cl	F	F	Br	OCH3
3372	Cl	F	F	Br	Cl
3373	Cl	F	F	Br	Br
3374	Cl	F	F	F	H
3375	Cl	F	F	F	CH3
3376	Cl	F	F	F	OCH3
3377	Cl	F	F	F	Cl
3378	Cl	F	F	F	Br
3379	Cl	F	F	F	F
3380	Br	CH3	CH3	H	H
3381	Br	CH3	CH3	CH3	H
3382	Br	CH3	CH3	OCH3	H
3383	Br	CH3	CH3	Cl	H
3384	Br	CH3	CH3	Br	H
3385	Br	CH3	CH3	F	H
3386	Br	CH3	CH3	H	CH3
3387	Br	CH3	CH3	CH3	CH3
3388	Br	CH3	CH3	H	OCH3
3389	Br	CH3	CH3	CH3	OCH3
3390	Br	CH3	CH3	OCH3	OCH3
3391	Br	CH3	CH3	Cl	OCH3
3392	Br	CH3	CH3	Br	OCH3
3393	Br	CH3	CH3	F	OCH3
3394	Br	CH3	CH3	H	Cl
3395	Br	CH3	CH3	CH3	Cl
3396	Br	CH3	CH3	OCH3	Cl
3397	Br	CH3	CH3	Cl	Cl
3398	Br	CH3	CH3	Br	Cl
3399	Br	CH3	CH3	F	Cl
3400	Br	CH3	CH3	H	Br
3401	Br	CH3	CH3	CH3	Br
3402	Br	CH3	CH3	OCH3	Br
3403	Br	CH3	CH3	Cl	Br
3404	Br	CH3	CH3	Br	Br
3405	Br	CH3	CH3	F	Br
3406	Br	CH3	CH3	H	F
3407	Br	CH3	CH3	CH3	F
3408	Br	CH3	CH3	OCH3	F
3409	Br	CH3	CH3	Cl	F
3410	Br	CH3	CH3	Br	F
3411	Br	CH3	CH3	F	F
3412	Br	CH3	OCH3	H	H
3413	Br	CH3	OCH3	CH3	H
3414	Br	CH3	OCH3	OCH3	H
3415	Br	CH3	OCH3	Cl	H
3416	Br	CH3	OCH3	Br	H
3417	Br	CH3	OCH3	F	H
3418	Br	CH3	OCH3	H	CH3
3419	Br	CH3	OCH3	CH3	CH3
3420	Br	CH3	OCH3	OCH3	CH3
3421	Br	CH3	OCH3	Cl	CH3
3422	Br	CH3	OCH3	Br	CH3
3423	Br	CH3	OCH3	F	CH3
3424	Br	CH3	OCH3	H	OCH3
3425	Br	CH3	OCH3	OCH3	OCH3
3426	Br	CH3	OCH3	H	Cl
3427	Br	CH3	OCH3	CH3	Cl
3428	Br	CH3	OCH3	OCH3	Cl
3429	Br	CH3	OCH3	Cl	Cl
3430	Br	CH3	OCH3	Br	Cl
3431	Br	CH3	OCH3	F	Cl
3432	Br	CH3	OCH3	H	Br
3433	Br	CH3	OCH3	CH3	Br
3434	Br	CH3	OCH3	OCH3	Br
3435	Br	CH3	OCH3	Cl	Br
3436	Br	CH3	OCH3	Br	Br
3437	Br	CH3	OCH3	F	Br
3438	Br	CH3	OCH3	H	F
3439	Br	CH3	OCH3	CH3	F
3440	Br	CH3	OCH3	OCH3	F
3441	Br	CH3	OCH3	Cl	F
3442	Br	CH3	OCH3	Br	F
3443	Br	CH3	OCH3	F	F
3444	Br	CH3	Cl	H	H
3445	Br	CH3	Cl	CH3	H
3446	Br	CH3	Cl	OCH3	H
3447	Br	CH3	Cl	Cl	H
3448	Br	CH3	Cl	Br	H
3449	Br	CH3	Cl	F	H
3450	Br	CH3	Cl	H	CH3
3451	Br	CH3	Cl	CH3	CH3
3452	Br	CH3	Cl	OCH3	CH3
3453	Br	CH3	Cl	Cl	CH3
3454	Br	CH3	Cl	Br	CH3
3455	Br	CH3	Cl	F	CH3
3456	Br	CH3	Cl	H	OCH3
3457	Br	CH3	Cl	CH3	OCH3
3458	Br	CH3	Cl	OCH3	OCH3
3459	Br	CH3	Cl	Cl	OCH3
3460	Br	CH3	Cl	Br	OCH3
3461	Br	CH3	Cl	F	OCH3
3462	Br	CH3	Cl	H	Cl
3463	Br	CH3	Cl	Cl	Cl
3464	Br	CH3	Cl	H	Br
3465	Br	CH3	Cl	CH3	Br
3466	Br	CH3	Cl	OCH3	Br
3467	Br	CH3	Cl	Cl	Br
3468	Br	CH3	Cl	Br	Br
3469	Br	CH3	Cl	F	Br
3470	Br	CH3	Cl	H	F
3471	Br	CH3	Cl	CH3	F
3472	Br	CH3	Cl	OCH3	F
3473	Br	CH3	Cl	Cl	F
3474	Br	CH3	Cl	F	F
3475	Br	CH3	Br	H	H
3476	Br	CH3	Br	CH3	H
3477	Br	CH3	Br	OCH3	H
3478	Br	CH3	Br	Cl	H
3479	Br	CH3	Br	Br	H
3480	Br	CH3	Br	F	H
3481	Br	CH3	Br	H	CH3
3482	Br	CH3	Br	CH3	CH3
3483	Br	CH3	Br	OCH3	CH3
3484	Br	CH3	Br	Cl	CH3
3485	Br	CH3	Br	Br	CH3
3486	Br	CH3	Br	F	CH3
3487	Br	CH3	Br	H	OCH3
3488	Br	CH3	Br	CH3	OCH3
3489	Br	CH3	Br	OCH3	OCH3
3490	Br	CH3	Br	Cl	OCH3
3491	Br	CH3	Br	Br	OCH3
3492	Br	CH3	Br	F	OCH3
3493	Br	CH3	Br	H	Cl
3494	Br	CH3	Br	CH3	Cl
3495	Br	CH3	Br	OCH3	Cl
3496	Br	CH3	Br	Cl	Cl
3497	Br	CH3	Br	Br	Cl
3498	Br	CH3	Br	F	Cl
3499	Br	CH3	Br	H	Br
3500	Br	CH3	Br	Br	Br
3501	Br	CH3	Br	H	F
3502	Br	CH3	Br	CH3	F
3503	Br	CH3	Br	OCH3	F
3504	Br	CH3	Br	Cl	F
3505	Br	CH3	Br	Br	F
3506	Br	CH3	Br	F	F
3507	Br	CH3	F	H	H
3508	Br	CH3	F	CH3	H
3509	Br	CH3	F	OCH3	H
3510	Br	CH3	F	Cl	H
3511	Br	CH3	F	Br	H
3512	Br	CH3	F	F	H
3513	Br	CH3	F	H	CH3
3514	Br	CH3	F	CH3	CH3
3515	Br	CH3	F	OCH3	CH3
3516	Br	CH3	F	Cl	CH3
3517	Br	CH3	F	Br	CH3
3518	Br	CH3	F	F	CH3
3519	Br	CH3	F	H	OCH3
3520	Br	CH3	F	CH3	OCH3
3521	Br	CH3	F	OCH3	OCH3
3522	Br	CH3	F	Cl	OCH3
3523	Br	CH3	F	Br	OCH3
3524	Br	CH3	F	F	OCH3
3525	Br	CH3	F	H	Cl
3526	Br	CH3	F	CH3	Cl
3527	Br	CH3	F	OCH3	Cl
3528	Br	CH3	F	Cl	Cl
3529	Br	CH3	F	Br	Cl
3530	Br	CH3	F	F	Cl
3531	Br	CH3	F	H	Br
3532	Br	CH3	F	CH3	Br
3533	Br	CH3	F	OCH3	Br
3534	Br	CH3	F	Cl	Br
3535	Br	CH3	F	Br	Br
3536	Br	CH3	F	F	Br
3537	Br	CH3	F	H	F
3538	Br	CH3	F	F	F
3539	Br	OCH3	CH3	H	H
3540	Br	OCH3	CH3	H	CH3
3541	Br	OCH3	CH3	H	OCH3
3542	Br	OCH3	CH3	H	Cl
3543	Br	OCH3	CH3	H	Br
3544	Br	OCH3	CH3	H	F
3545	Br	OCH3	CH3	CH3	H
3546	Br	OCH3	CH3	CH3	CH3
3547	Br	OCH3	CH3	CH3	OCH3
3548	Br	OCH3	CH3	CH3	Cl
3549	Br	OCH3	CH3	CH3	Br
3550	Br	OCH3	CH3	CH3	F
3551	Br	OCH3	CH3	OCH3	H
3552	Br	OCH3	CH3	OCH3	OCH3
3553	Br	OCH3	CH3	OCH3	Cl
3554	Br	OCH3	CH3	OCH3	Br
3555	Br	OCH3	CH3	OCH3	F
3556	Br	OCH3	CH3	Cl	H
3557	Br	OCH3	CH3	Cl	OCH3
3558	Br	OCH3	CH3	Cl	Cl
3559	Br	OCH3	CH3	Cl	Br
3560	Br	OCH3	CH3	Cl	F
3561	Br	OCH3	CH3	Br	H
3562	Br	OCH3	CH3	Br	OCH3
3563	Br	OCH3	CH3	Br	Cl
3564	Br	OCH3	CH3	Br	Br
3565	Br	OCH3	CH3	Br	F
3566	Br	OCH3	CH3	F	H
3567	Br	OCH3	CH3	F	OCH3
3568	Br	OCH3	CH3	F	Cl
3569	Br	OCH3	CH3	F	Br
3570	Br	OCH3	CH3	F	F
3571	Br	OCH3	OCH3	H	H
3572	Br	OCH3	OCH3	H	CH3
3573	Br	OCH3	OCH3	H	OCH3
3574	Br	OCH3	OCH3	H	Cl
3575	Br	OCH3	OCH3	H	Br
3576	Br	OCH3	OCH3	H	F
3577	Br	OCH3	OCH3	CH3	H
3578	Br	OCH3	OCH3	CH3	CH3
3579	Br	OCH3	OCH3	CH3	Cl
3580	Br	OCH3	OCH3	CH3	Br
3581	Br	OCH3	OCH3	CH3	F
3582	Br	OCH3	OCH3	OCH3	H
3583	Br	OCH3	OCH3	OCH3	CH3
3584	Br	OCH3	OCH3	OCH3	OCH3
3585	Br	OCH3	OCH3	OCH3	Cl
3586	Br	OCH3	OCH3	OCH3	Br
3587	Br	OCH3	OCH3	OCH3	F
3588	Br	OCH3	OCH3	Cl	H
3589	Br	OCH3	OCH3	Cl	CH3
3590	Br	OCH3	OCH3	Cl	Cl
3591	Br	OCH3	OCH3	Cl	Br
3592	Br	OCH3	OCH3	Cl	F
3593	Br	OCH3	OCH3	Br	H
3594	Br	OCH3	OCH3	Br	CH3
3595	Br	OCH3	OCH3	Br	Cl
3596	Br	OCH3	OCH3	Br	Br
3597	Br	OCH3	OCH3	Br	F
3598	Br	OCH3	OCH3	F	H
3599	Br	OCH3	OCH3	F	CH3
3600	Br	OCH3	OCH3	F	Cl
3601	Br	OCH3	OCH3	F	Br
3602	Br	OCH3	OCH3	F	F
3603	Br	OCH3	Cl	H	H
3604	Br	OCH3	Cl	H	CH3
3605	Br	OCH3	Cl	H	OCH3
3606	Br	OCH3	Cl	H	Cl
3607	Br	OCH3	Cl	H	Br
3608	Br	OCH3	Cl	H	F
3609	Br	OCH3	Cl	CH3	H
3610	Br	OCH3	Cl	CH3	CH3
3611	Br	OCH3	Cl	CH3	OCH3
3612	Br	OCH3	Cl	CH3	Br
3613	Br	OCH3	Cl	CH3	F
3614	Br	OCH3	Cl	OCH3	H
3615	Br	OCH3	Cl	OCH3	CH3
3616	Br	OCH3	Cl	OCH3	OCH3
3617	Br	OCH3	Cl	OCH3	Br
3618	Br	OCH3	Cl	OCH3	F
3619	Br	OCH3	Cl	Cl	H
3620	Br	OCH3	Cl	Cl	CH3
3621	Br	OCH3	Cl	Cl	OCH3
3622	Br	OCH3	Cl	Cl	Cl
3623	Br	OCH3	Cl	Cl	Br
3624	Br	OCH3	Cl	Cl	F
3625	Br	OCH3	Cl	Br	H
3626	Br	OCH3	Cl	Br	CH3
3627	Br	OCH3	Cl	Br	OCH3
3628	Br	OCH3	Cl	Br	Br
3629	Br	OCH3	Cl	F	H
3630	Br	OCH3	Cl	F	CH3
3631	Br	OCH3	Cl	F	OCH3
3632	Br	OCH3	Cl	F	Br
3633	Br	OCH3	Cl	F	F
3634	Br	OCH3	Br	H	H
3635	Br	OCH3	Br	H	CH3
3636	Br	OCH3	Br	H	OCH3
3637	Br	OCH3	Br	H	Cl
3638	Br	OCH3	Br	H	Br
3639	Br	OCH3	Br	H	F
3640	Br	OCH3	Br	CH3	H
3641	Br	OCH3	Br	CH3	CH3
3642	Br	OCH3	Br	CH3	OCH3
3643	Br	OCH3	Br	CH3	Cl
3644	Br	OCH3	Br	CH3	F
3645	Br	OCH3	Br	OCH3	H
3646	Br	OCH3	Br	OCH3	CH3
3647	Br	OCH3	Br	OCH3	OCH3
3648	Br	OCH3	Br	OCH3	Cl
3649	Br	OCH3	Br	OCH3	F
3650	Br	OCH3	Br	Cl	H
3651	Br	OCH3	Br	Cl	CH3
3652	Br	OCH3	Br	Cl	OCH3
3653	Br	OCH3	Br	Cl	Cl
3654	Br	OCH3	Br	Cl	F
3655	Br	OCH3	Br	Br	H
3656	Br	OCH3	Br	Br	CH3
3657	Br	OCH3	Br	Br	OCH3
3658	Br	OCH3	Br	Br	Cl
3659	Br	OCH3	Br	Br	Br
3660	Br	OCH3	Br	Br	F
3661	Br	OCH3	Br	F	H
3662	Br	OCH3	Br	F	CH3
3663	Br	OCH3	Br	F	OCH3
3664	Br	OCH3	Br	F	Cl
3665	Br	OCH3	Br	F	F
3666	Br	OCH3	F	H	H
3667	Br	OCH3	F	H	CH3
3668	Br	OCH3	F	H	OCH3
3669	Br	OCH3	F	H	Cl
3670	Br	OCH3	F	H	Br
3671	Br	OCH3	F	H	F
3672	Br	OCH3	F	CH3	H
3673	Br	OCH3	F	CH3	CH3
3674	Br	OCH3	F	CH3	OCH3
3675	Br	OCH3	F	CH3	Cl
3676	Br	OCH3	F	CH3	Br
3677	Br	OCH3	F	OCH3	H
3678	Br	OCH3	F	OCH3	CH3
3679	Br	OCH3	F	OCH3	OCH3
3680	Br	OCH3	F	OCH3	Cl
3681	Br	OCH3	F	OCH3	Br
3682	Br	OCH3	F	Cl	H
3683	Br	OCH3	F	Cl	CH3
3684	Br	OCH3	F	Cl	OCH3
3685	Br	OCH3	F	Cl	Cl
3686	Br	OCH3	F	Cl	Br
3687	Br	OCH3	F	Br	H
3688	Br	OCH3	F	Br	CH3
3689	Br	OCH3	F	Br	OCH3
3690	Br	OCH3	F	Br	Cl
3691	Br	OCH3	F	Br	Br
3692	Br	OCH3	F	F	H
3693	Br	OCH3	F	F	CH3
3694	Br	OCH3	F	F	OCH3
3695	Br	OCH3	F	F	Cl
3696	Br	OCH3	F	F	Br
3697	Br	OCH3	F	F	F
3698	Br	Cl	CH3	H	H
3699	Br	Cl	CH3	H	CH3
3700	Br	Cl	CH3	H	OCH3
3701	Br	Cl	CH3	H	Cl
3702	Br	Cl	CH3	H	Br
3703	Br	Cl	CH3	H	F
3704	Br	Cl	CH3	CH3	H
3705	Br	Cl	CH3	CH3	CH3
3706	Br	Cl	CH3	CH3	OCH3
3707	Br	Cl	CH3	CH3	Cl
3708	Br	Cl	CH3	CH3	Br
3709	Br	Cl	CH3	CH3	F
3710	Br	Cl	CH3	OCH3	H
3711	Br	Cl	CH3	OCH3	OCH3
3712	Br	Cl	CH3	OCH3	Cl
3713	Br	Cl	CH3	OCH3	Br
3714	Br	Cl	CH3	OCH3	F
3715	Br	Cl	CH3	Cl	H
3716	Br	Cl	CH3	Cl	OCH3
3717	Br	Cl	CH3	Cl	Cl
3718	Br	Cl	CH3	Cl	Br
3719	Br	Cl	CH3	Cl	F
3720	Br	Cl	CH3	Br	H
3721	Br	Cl	CH3	Br	OCH3
3722	Br	Cl	CH3	Br	Cl
3723	Br	Cl	CH3	Br	Br
3724	Br	Cl	CH3	Br	F
3725	Br	Cl	CH3	F	H
3726	Br	Cl	CH3	F	OCH3
3727	Br	Cl	CH3	F	Cl
3728	Br	Cl	CH3	F	Br
3729	Br	Cl	CH3	F	F
3730	Br	Cl	OCH3	H	H
3731	Br	Cl	OCH3	H	CH3
3732	Br	Cl	OCH3	H	OCH3
3733	Br	Cl	OCH3	H	Cl
3734	Br	Cl	OCH3	H	Br
3735	Br	Cl	OCH3	H	F
3736	Br	Cl	OCH3	CH3	H
3737	Br	Cl	OCH3	CH3	CH3
3738	Br	Cl	OCH3	CH3	Cl
3739	Br	Cl	OCH3	CH3	Br
3740	Br	Cl	OCH3	CH3	F
3741	Br	Cl	OCH3	OCH3	H
3742	Br	Cl	OCH3	OCH3	CH3
3743	Br	Cl	OCH3	OCH3	OCH3
3744	Br	Cl	OCH3	OCH3	Cl
3745	Br	Cl	OCH3	OCH3	Br
3746	Br	Cl	OCH3	OCH3	F
3747	Br	Cl	OCH3	Cl	H
3748	Br	Cl	OCH3	Cl	CH3
3749	Br	Cl	OCH3	Cl	Cl
3750	Br	Cl	OCH3	Cl	Br
3751	Br	Cl	OCH3	Cl	F
3752	Br	Cl	OCH3	Br	H
3753	Br	Cl	OCH3	Br	CH3
3754	Br	Cl	OCH3	Br	Cl
3755	Br	Cl	OCH3	Br	Br
3756	Br	Cl	OCH3	Br	F
3757	Br	Cl	OCH3	F	H
3758	Br	Cl	OCH3	F	CH3
3759	Br	Cl	OCH3	F	Cl
3760	Br	Cl	OCH3	F	Br
3761	Br	Cl	OCH3	F	F
3762	Br	Cl	Cl	H	H
3763	Br	Cl	Cl	H	CH3
3764	Br	Cl	Cl	H	OCH3
3765	Br	Cl	Cl	H	Cl
3766	Br	Cl	Cl	H	Br
3767	Br	Cl	Cl	H	F
3768	Br	Cl	Cl	CH3	H
3769	Br	Cl	Cl	CH3	CH3
3770	Br	Cl	Cl	CH3	OCH3
3771	Br	Cl	Cl	CH3	Br
3772	Br	Cl	Cl	CH3	F
3773	Br	Cl	Cl	OCH3	H
3774	Br	Cl	Cl	OCH3	CH3
3775	Br	Cl	Cl	OCH3	OCH3
3776	Br	Cl	Cl	OCH3	Br
3777	Br	Cl	Cl	OCH3	F
3778	Br	Cl	Cl	Cl	H
3779	Br	Cl	Cl	Cl	CH3
3780	Br	Cl	Cl	Cl	OCH3
3781	Br	Cl	Cl	Cl	Cl
3782	Br	Cl	Cl	Cl	Br
3783	Br	Cl	Cl	Cl	F
3784	Br	Cl	Cl	Br	H
3785	Br	Cl	Cl	Br	CH3
3786	Br	Cl	Cl	Br	OCH3
3787	Br	Cl	Cl	Br	Br
3788	Br	Cl	Cl	F	H
3789	Br	Cl	Cl	F	CH3
3790	Br	Cl	Cl	F	OCH3
3791	Br	Cl	Cl	F	Br
3792	Br	Cl	Cl	F	F
3793	Br	Cl	Br	H	H
3794	Br	Cl	Br	H	CH3
3795	Br	Cl	Br	H	OCH3
3796	Br	Cl	Br	H	Cl
3797	Br	Cl	Br	H	Br
3798	Br	Cl	Br	H	F
3799	Br	Cl	Br	CH3	H
3800	Br	Cl	Br	CH3	CH3
3801	Br	Cl	Br	CH3	OCH3
3802	Br	Cl	Br	CH3	Cl
3803	Br	Cl	Br	CH3	F
3804	Br	Cl	Br	OCH3	H
3805	Br	Cl	Br	OCH3	CH3
3806	Br	Cl	Br	OCH3	OCH3
3807	Br	Cl	Br	OCH3	Cl
3808	Br	Cl	Br	OCH3	F
3809	Br	Cl	Br	Cl	H
3810	Br	Cl	Br	Cl	CH3
3811	Br	Cl	Br	Cl	OCH3
3812	Br	Cl	Br	Cl	Cl
3813	Br	Cl	Br	Cl	F
3814	Br	Cl	Br	Br	H
3815	Br	Cl	Br	Br	CH3
3816	Br	Cl	Br	Br	OCH3
3817	Br	Cl	Br	Br	Cl
3818	Br	Cl	Br	Br	Br
3819	Br	Cl	Br	Br	F
3820	Br	Cl	Br	F	H
3821	Br	Cl	Br	F	CH3
3822	Br	Cl	Br	F	OCH3
3823	Br	Cl	Br	F	Cl
3824	Br	Cl	Br	F	F
3825	Br	Cl	F	H	H
3826	Br	Cl	F	H	CH3
3827	Br	Cl	F	H	OCH3
3828	Br	Cl	F	H	Cl
3829	Br	Cl	F	H	Br
3830	Br	Cl	F	H	F
3831	Br	Cl	F	CH3	H
3832	Br	Cl	F	CH3	CH3
3833	Br	Cl	F	CH3	OCH3
3834	Br	Cl	F	CH3	Cl
3835	Br	Cl	F	CH3	Br
3836	Br	Cl	F	OCH3	H
3837	Br	Cl	F	OCH3	CH3
3838	Br	Cl	F	OCH3	OCH3
3839	Br	Cl	F	OCH3	Cl
3840	Br	Cl	F	OCH3	Br
3841	Br	Cl	F	Cl	H
3842	Br	Cl	F	Cl	CH3
3843	Br	Cl	F	Cl	OCH3
3844	Br	Cl	F	Cl	Cl
3845	Br	Cl	F	Cl	Br
3846	Br	Cl	F	Br	H
3847	Br	Cl	F	Br	CH3
3848	Br	Cl	F	Br	OCH3
3849	Br	Cl	F	Br	Cl
3850	Br	Cl	F	Br	Br
3851	Br	Cl	F	F	H
3852	Br	Cl	F	F	CH3
3853	Br	Cl	F	F	OCH3
3854	Br	Cl	F	F	Cl
3855	Br	Cl	F	F	Br
3856	Br	Cl	F	F	F
3857	Br	Br	CH3	H	H
3858	Br	Br	CH3	H	CH3
3859	Br	Br	CH3	H	OCH3
3860	Br	Br	CH3	H	Cl
3861	Br	Br	CH3	H	Br
3862	Br	Br	CH3	H	F
3863	Br	Br	CH3	CH3	H
3864	Br	Br	CH3	CH3	CH3
3865	Br	Br	CH3	CH3	OCH3
3866	Br	Br	CH3	CH3	Cl
3867	Br	Br	CH3	CH3	Br
3868	Br	Br	CH3	CH3	F
3869	Br	Br	CH3	OCH3	H
3870	Br	Br	CH3	OCH3	OCH3
3871	Br	Br	CH3	OCH3	Cl
3872	Br	Br	CH3	OCH3	Br
3873	Br	Br	CH3	OCH3	F
3874	Br	Br	CH3	Cl	H
3875	Br	Br	CH3	Cl	OCH3
3876	Br	Br	CH3	Cl	Cl
3877	Br	Br	CH3	Cl	Br
3878	Br	Br	CH3	Cl	F
3879	Br	Br	CH3	Br	H
3880	Br	Br	CH3	Br	OCH3
3881	Br	Br	CH3	Br	Cl
3882	Br	Br	CH3	Br	Br
3883	Br	Br	CH3	Br	F
3884	Br	Br	CH3	F	H
3885	Br	Br	CH3	F	OCH3
3886	Br	Br	CH3	F	Cl
3887	Br	Br	CH3	F	Br
3888	Br	Br	CH3	F	F
3889	Br	Br	OCH3	H	H
3890	Br	Br	OCH3	H	CH3
3891	Br	Br	OCH3	H	OCH3
3892	Br	Br	OCH3	H	Cl
3893	Br	Br	OCH3	H	Br
3894	Br	Br	OCH3	H	F
3895	Br	Br	OCH3	CH3	H
3896	Br	Br	OCH3	CH3	CH3
3897	Br	Br	OCH3	CH3	Cl
3898	Br	Br	OCH3	CH3	Br
3899	Br	Br	OCH3	CH3	F
3900	Br	Br	OCH3	OCH3	H
3901	Br	Br	OCH3	OCH3	CH3
3902	Br	Br	OCH3	OCH3	OCH3
3903	Br	Br	OCH3	OCH3	Cl
3904	Br	Br	OCH3	OCH3	Br
3905	Br	Br	OCH3	OCH3	F
3906	Br	Br	OCH3	Cl	H
3907	Br	Br	OCH3	Cl	CH3
3908	Br	Br	OCH3	Cl	Cl
3909	Br	Br	OCH3	Cl	Br
3910	Br	Br	OCH3	Cl	F
3911	Br	Br	OCH3	Br	H
3912	Br	Br	OCH3	Br	CH3
3913	Br	Br	OCH3	Br	Cl
3914	Br	Br	OCH3	Br	Br
3915	Br	Br	OCH3	Br	F
3916	Br	Br	OCH3	F	H
3917	Br	Br	OCH3	F	CH3
3918	Br	Br	OCH3	F	Cl
3919	Br	Br	OCH3	F	Br
3920	Br	Br	OCH3	F	F
3921	Br	Br	Cl	H	H
3922	Br	Br	Cl	H	CH3
3923	Br	Br	Cl	H	OCH3
3924	Br	Br	Cl	H	Cl
3925	Br	Br	Cl	H	Br
3926	Br	Br	Cl	H	F
3927	Br	Br	Cl	CH3	H
3928	Br	Br	Cl	CH3	CH3
3929	Br	Br	Cl	CH3	OCH3
3930	Br	Br	Cl	CH3	Br
3931	Br	Br	Cl	CH3	F
3932	Br	Br	Cl	OCH3	H
3933	Br	Br	Cl	OCH3	CH3
3934	Br	Br	Cl	OCH3	OCH3
3935	Br	Br	Cl	OCH3	Br
3936	Br	Br	Cl	OCH3	F
3937	Br	Br	Cl	Cl	H
3938	Br	Br	Cl	Cl	CH3
3939	Br	Br	Cl	Cl	OCH3
3940	Br	Br	Cl	Cl	Cl
3941	Br	Br	Cl	Cl	Br
3942	Br	Br	Cl	Cl	F
3943	Br	Br	Cl	Br	H
3944	Br	Br	Cl	Br	CH3
3945	Br	Br	Cl	Br	OCH3
3946	Br	Br	Cl	Br	Br
3947	Br	Br	Cl	F	H
3948	Br	Br	Cl	F	CH3
3949	Br	Br	Cl	F	OCH3
3950	Br	Br	Cl	F	Br
3951	Br	Br	Cl	F	F
3952	Br	Br	Br	H	H
3953	Br	Br	Br	H	CH3
3954	Br	Br	Br	H	OCH3
3955	Br	Br	Br	H	Cl
3956	Br	Br	Br	H	Br
3957	Br	Br	Br	H	F
3958	Br	Br	Br	CH3	H
3959	Br	Br	Br	CH3	CH3
3960	Br	Br	Br	CH3	OCH3
3961	Br	Br	Br	CH3	Cl
3962	Br	Br	Br	CH3	F
3963	Br	Br	Br	OCH3	H
3964	Br	Br	Br	OCH3	CH3
3965	Br	Br	Br	OCH3	OCH3
3966	Br	Br	Br	OCH3	Cl
3967	Br	Br	Br	OCH3	F
3968	Br	Br	Br	Cl	H
3969	Br	Br	Br	Cl	CH3
3970	Br	Br	Br	Cl	OCH3
3971	Br	Br	Br	Cl	Cl
3972	Br	Br	Br	Cl	F
3973	Br	Br	Br	Br	H
3974	Br	Br	Br	Br	CH3
3975	Br	Br	Br	Br	OCH3
3976	Br	Br	Br	Br	Cl
3977	Br	Br	Br	Br	Br
3978	Br	Br	Br	Br	F
3979	Br	Br	Br	F	H
3980	Br	Br	Br	F	CH3
3981	Br	Br	Br	F	OCH3
3982	Br	Br	Br	F	Cl
3983	Br	Br	Br	F	F
3984	Br	Br	F	H	H
3985	Br	Br	F	H	CH3
3986	Br	Br	F	H	OCH3
3987	Br	Br	F	H	Cl
3988	Br	Br	F	H	Br
3989	Br	Br	F	H	F
3990	Br	Br	F	CH3	H
3991	Br	Br	F	CH3	CH3
3992	Br	Br	F	CH3	OCH3
3993	Br	Br	F	CH3	Cl
3994	Br	Br	F	CH3	Br
3995	Br	Br	F	OCH3	H
3996	Br	Br	F	OCH3	CH3
3997	Br	Br	F	OCH3	OCH3
3998	Br	Br	F	OCH3	Cl
3999	Br	Br	F	OCH3	Br
4000	Br	Br	F	Cl	H
4001	Br	Br	F	Cl	CH3
4002	Br	Br	F	Cl	OCH3
4003	Br	Br	F	Cl	Cl
4004	Br	Br	F	Cl	Br
4005	Br	Br	F	Br	H
4006	Br	Br	F	Br	CH3
4007	Br	Br	F	Br	OCH3
4008	Br	Br	F	Br	Cl
4009	Br	Br	F	Br	Br
4010	Br	Br	F	F	H
4011	Br	Br	F	F	CH3
4012	Br	Br	F	F	OCH3
4013	Br	Br	F	F	Cl
4014	Br	Br	F	F	Br
4015	Br	Br	F	F	F
4016	Br	F	CH3	H	H
4017	Br	F	CH3	H	CH3
4018	Br	F	CH3	H	OCH3
4019	Br	F	CH3	H	Cl
4020	Br	F	CH3	H	Br
4021	Br	F	CH3	H	F
4022	Br	F	CH3	CH3	H
4023	Br	F	CH3	CH3	CH3
4024	Br	F	CH3	CH3	OCH3
4025	Br	F	CH3	CH3	Cl
4026	Br	F	CH3	CH3	Br
4027	Br	F	CH3	CH3	F
4028	Br	F	CH3	OCH3	H
4029	Br	F	CH3	OCH3	OCH3
4030	Br	F	CH3	OCH3	Cl
4031	Br	F	CH3	OCH3	Br
4032	Br	F	CH3	OCH3	F
4033	Br	F	CH3	Cl	H
4034	Br	F	CH3	Cl	OCH3
4035	Br	F	CH3	Cl	Cl
4036	Br	F	CH3	Cl	Br
4037	Br	F	CH3	Cl	F
4038	Br	F	CH3	Br	H
4039	Br	F	CH3	Br	OCH3
4040	Br	F	CH3	Br	Cl
4041	Br	F	CH3	Br	Br
4042	Br	F	CH3	Br	F
4043	Br	F	CH3	F	H
4044	Br	F	CH3	F	OCH3
4045	Br	F	CH3	F	Cl
4046	Br	F	CH3	F	Br
4047	Br	F	CH3	F	F
4048	Br	F	OCH3	H	H
4049	Br	F	OCH3	H	CH3
4050	Br	F	OCH3	H	OCH3
4051	Br	F	OCH3	H	Cl
4052	Br	F	OCH3	H	Br
4053	Br	F	OCH3	H	F
4054	Br	F	OCH3	CH3	H
4055	Br	F	OCH3	CH3	CH3
4056	Br	F	OCH3	CH3	Cl
4057	Br	F	OCH3	CH3	Br
4058	Br	F	OCH3	CH3	F
4059	Br	F	OCH3	OCH3	H
4060	Br	F	OCH3	OCH3	CH3
4061	Br	F	OCH3	OCH3	OCH3
4062	Br	F	OCH3	OCH3	Cl
4063	Br	F	OCH3	OCH3	Br
4064	Br	F	OCH3	OCH3	F
4065	Br	F	OCH3	Cl	H
4066	Br	F	OCH3	Cl	CH3
4067	Br	F	OCH3	Cl	Cl
4068	Br	F	OCH3	Cl	Br
4069	Br	F	OCH3	Cl	F
4070	Br	F	OCH3	Br	H
4071	Br	F	OCH3	Br	CH3
4072	Br	F	OCH3	Br	Cl
4073	Br	F	OCH3	Br	Br
4074	Br	F	OCH3	Br	F
4075	Br	F	OCH3	F	H
4076	Br	F	OCH3	F	CH3
4077	Br	F	OCH3	F	Cl
4078	Br	F	OCH3	F	Br
4079	Br	F	OCH3	F	F
4080	Br	F	Cl	H	H
4081	Br	F	Cl	H	CH3
4082	Br	F	Cl	H	OCH3
4083	Br	F	Cl	H	Cl
4084	Br	F	Cl	H	Br
4085	Br	F	Cl	H	F
4086	Br	F	Cl	CH3	H
4087	Br	F	Cl	CH3	CH3
4088	Br	F	Cl	CH3	OCH3
4089	Br	F	Cl	CH3	Br
4090	Br	F	Cl	CH3	F
4091	Br	F	Cl	OCH3	H
4092	Br	F	Cl	OCH3	CH3
4093	Br	F	Cl	OCH3	OCH3
4094	Br	F	Cl	OCH3	Br
4095	Br	F	Cl	OCH3	F
4096	Br	F	Cl	Cl	H
4097	Br	F	Cl	Cl	CH3
4098	Br	F	Cl	Cl	OCH3
4099	Br	F	Cl	Cl	Cl
4100	Br	F	Cl	Cl	Br
4101	Br	F	Cl	Cl	F
4102	Br	F	Cl	Br	H
4103	Br	F	Cl	Br	CH3
4104	Br	F	Cl	Br	OCH3
4105	Br	F	Cl	Br	Br
4106	Br	F	Cl	F	H
4107	Br	F	Cl	F	CH3
4108	Br	F	Cl	F	OCH3
4109	Br	F	Cl	F	Br
4110	Br	F	Cl	F	F
4111	Br	F	Br	H	H
4112	Br	F	Br	H	CH3
4113	Br	F	Br	H	OCH3
4114	Br	F	Br	H	Cl
4115	Br	F	Br	H	Br
4116	Br	F	Br	H	F
4117	Br	F	Br	CH3	H
4118	Br	F	Br	CH3	CH3
4119	Br	F	Br	CH3	OCH3
4120	Br	F	Br	CH3	Cl
4121	Br	F	Br	CH3	F
4122	Br	F	Br	OCH3	H
4123	Br	F	Br	OCH3	CH3
4124	Br	F	Br	OCH3	OCH3
4125	Br	F	Br	OCH3	Cl
4126	Br	F	Br	OCH3	F
4127	Br	F	Br	Cl	H
4128	Br	F	Br	Cl	CH3
4129	Br	F	Br	Cl	OCH3
4130	Br	F	Br	Cl	Cl
4131	Br	F	Br	Cl	F
4132	Br	F	Br	Br	H
4133	Br	F	Br	Br	CH3
4134	Br	F	Br	Br	OCH3
4135	Br	F	Br	Br	Cl
4136	Br	F	Br	Br	Br
4137	Br	F	Br	Br	F
4138	Br	F	Br	F	H
4139	Br	F	Br	F	CH3
4140	Br	F	Br	F	OCH3
4141	Br	F	Br	F	Cl
4142	Br	F	Br	F	F
4143	Br	F	F	H	H
4144	Br	F	F	H	CH3
4145	Br	F	F	H	OCH3
4146	Br	F	F	H	Cl
4147	Br	F	F	H	Br
4148	Br	F	F	H	F
4149	Br	F	F	CH3	H
4150	Br	F	F	CH3	CH3
4151	Br	F	F	CH3	OCH3
4152	Br	F	F	CH3	Cl
4153	Br	F	F	CH3	Br
4154	Br	F	F	OCH3	H
4155	Br	F	F	OCH3	CH3
4156	Br	F	F	OCH3	OCH3
4157	Br	F	F	OCH3	Cl
4158	Br	F	F	OCH3	Br
4159	Br	F	F	Cl	H
4160	Br	F	F	Cl	CH3
4161	Br	F	F	Cl	OCH3
4162	Br	F	F	Cl	Cl
4163	Br	F	F	Cl	Br
4164	Br	F	F	Br	H
4165	Br	F	F	Br	CH3
4166	Br	F	F	Br	OCH3
4167	Br	F	F	Br	Cl
4168	Br	F	F	Br	Br
4169	Br	F	F	F	H
4170	Br	F	F	F	CH3
4171	Br	F	F	F	OCH3
4172	Br	F	F	F	Cl
4173	Br	F	F	F	Br
4174	Br	F	F	F	F
4175	F	CH3	CH3	H	H
4176	F	CH3	CH3	CH3	H
4177	F	CH3	CH3	OCH3	H
4178	F	CH3	CH3	Cl	H
4179	F	CH3	CH3	Br	H
4180	F	CH3	CH3	F	H
4181	F	CH3	CH3	H	CH3
4182	F	CH3	CH3	CH3	CH3
4183	F	CH3	CH3	H	OCH3
4184	F	CH3	CH3	CH3	OCH3
4185	F	CH3	CH3	OCH3	OCH3
4186	F	CH3	CH3	Cl	OCH3
4187	F	CH3	CH3	Br	OCH3
4188	F	CH3	CH3	F	OCH3
4189	F	CH3	CH3	H	Cl
4190	F	CH3	CH3	CH3	Cl
4191	F	CH3	CH3	OCH3	Cl
4192	F	CH3	CH3	Cl	Cl
4193	F	CH3	CH3	Br	Cl
4194	F	CH3	CH3	F	Cl
4195	F	CH3	CH3	H	Br
4196	F	CH3	CH3	CH3	Br
4197	F	CH3	CH3	OCH3	Br
4198	F	CH3	CH3	Cl	Br
4199	F	CH3	CH3	Br	Br
4200	F	CH3	CH3	F	Br
4201	F	CH3	CH3	H	F
4202	F	CH3	CH3	CH3	F
4203	F	CH3	CH3	OCH3	F
4204	F	CH3	CH3	Cl	F
4205	F	CH3	CH3	Br	F
4206	F	CH3	CH3	F	F
4207	F	CH3	OCH3	H	H
4208	F	CH3	OCH3	CH3	H
4209	F	CH3	OCH3	OCH3	H
4210	F	CH3	OCH3	Cl	H
4211	F	CH3	OCH3	Br	H
4212	F	CH3	OCH3	F	H
4213	F	CH3	OCH3	H	CH3
4214	F	CH3	OCH3	CH3	CH3
4215	F	CH3	OCH3	OCH3	CH3
4216	F	CH3	OCH3	Cl	CH3
4217	F	CH3	OCH3	Br	CH3
4218	F	CH3	OCH3	F	CH3
4219	F	CH3	OCH3	H	OCH3
4220	F	CH3	OCH3	OCH3	OCH3
4221	F	CH3	OCH3	H	Cl
4222	F	CH3	OCH3	CH3	Cl
4223	F	CH3	OCH3	OCH3	Cl
4224	F	CH3	OCH3	Cl	Cl
4225	F	CH3	OCH3	Br	Cl
4226	F	CH3	OCH3	F	Cl
4227	F	CH3	OCH3	H	Br
4228	F	CH3	OCH3	CH3	Br
4229	F	CH3	OCH3	OCH3	Br
4230	F	CH3	OCH3	Cl	Br
4232	F	CH3	OCH3	Br	Br
4232	F	CH3	OCH3	F	Br
4233	F	CH3	OCH3	H	F
4234	F	CH3	OCH3	CH3	F
4235	F	CH3	OCH3	OCH3	F
4236	F	CH3	OCH3	Cl	F
4237	F	CH3	OCH3	Br	F
4238	F	CH3	OCH3	F	F
4239	F	CH3	Cl	H	H
4240	F	CH3	Cl	CH3	H
4241	F	CH3	Cl	OCH3	H
4242	F	CH3	Cl	Cl	H
4243	F	CH3	Cl	Br	H
4244	F	CH3	Cl	F	H
4245	F	CH3	Cl	H	CH3
4246	F	CH3	Cl	CH3	CH3
4247	F	CH3	Cl	OCH3	CH3
4248	F	CH3	Cl	Cl	CH3
4249	F	CH3	Cl	Br	CH3
4250	F	CH3	Cl	F	CH3
4251	F	CH3	Cl	H	OCH3
4252	F	CH3	Cl	CH3	OCH3
4253	F	CH3	Cl	OCH3	OCH3
4254	F	CH3	Cl	Cl	OCH3
4255	F	CH3	Cl	Br	OCH3
4256	F	CH3	Cl	F	OCH3
4257	F	CH3	Cl	H	Cl
4258	F	CH3	Cl	Cl	Cl
4259	F	CH3	Cl	H	Br
4260	F	CH3	Cl	CH3	Br
4261	F	CH3	Cl	OCH3	Br
4262	F	CH3	Cl	Cl	Br
4263	F	CH3	Cl	Br	Br
4264	F	CH3	Cl	F	Br
4265	F	CH3	Cl	H	F
4266	F	CH3	Cl	CH3	F
4267	F	CH3	Cl	OCH3	F
4268	F	CH3	Cl	Cl	F
4269	F	CH3	Cl	F	F
4270	F	CH3	Br	H	H
4271	F	CH3	Br	CH3	H
4272	F	CH3	Br	OCH3	H
4273	F	CH3	Br	Cl	H
4274	F	CH3	Br	Br	H
4275	F	CH3	Br	F	H
4276	F	CH3	Br	H	CH3
4277	F	CH3	Br	CH3	CH3
4278	F	CH3	Br	OCH3	CH3
4279	F	CH3	Br	Cl	CH3
4280	F	CH3	Br	Br	CH3
4281	F	CH3	Br	F	CH3
4282	F	CH3	Br	H	OCH3
4283	F	CH3	Br	CH3	OCH3
4284	F	CH3	Br	OCH3	OCH3
4285	F	CH3	Br	Cl	OCH3
4286	F	CH3	Br	Br	OCH3
4287	F	CH3	Br	F	OCH3
4288	F	CH3	Br	H	Cl
4289	F	CH3	Br	CH3	Cl
4290	F	CH3	Br	OCH3	Cl
4291	F	CH3	Br	Cl	Cl
4292	F	CH3	Br	Br	Cl
4293	F	CH3	Br	F	Cl
4294	F	CH3	Br	H	Br
4295	F	CH3	Br	Br	Br
4296	F	CH3	Br	H	F
4297	F	CH3	Br	CH3	F
4298	F	CH3	Br	OCH3	F
4299	F	CH3	Br	Cl	F
4300	F	CH3	Br	Br	F
4301	F	CH3	Br	F	F
4302	F	CH3	F	H	H
4303	F	CH3	F	CH3	H
4304	F	CH3	F	OCH3	H
4305	F	CH3	F	Cl	H
4306	F	CH3	F	Br	H
4307	F	CH3	F	F	H
4308	F	CH3	F	H	CH3
4309	F	CH3	F	CH3	CH3
4310	F	CH3	F	OCH3	CH3
4311	F	CH3	F	Cl	CH3
4312	F	CH3	F	Br	CH3
4313	F	CH3	F	F	CH3
4314	F	CH3	F	H	OCH3
4315	F	CH3	F	CH3	OCH3
4316	F	CH3	F	OCH3	OCH3
4317	F	CH3	F	Cl	OCH3
4318	F	CH3	F	Br	OCH3
4319	F	CH3	F	F	OCH3
4320	F	CH3	F	H	Cl
4321	F	CH3	F	CH3	Cl
4322	F	CH3	F	OCH3	Cl
4323	F	CH3	F	Cl	Cl
4324	F	CH3	F	Br	Cl
4325	F	CH3	F	F	Cl
4326	F	CH3	F	H	Br
4327	F	CH3	F	CH3	Br
4328	F	CH3	F	OCH3	Br
4329	F	CH3	F	Cl	Br
4330	F	CH3	F	Br	Br
4331	F	CH3	F	F	Br
4332	F	CH3	F	H	F
4333	F	CH3	F	F	F
4334	F	OCH3	CH3	H	H
4335	F	OCH3	CH3	H	CH3
4336	F	OCH3	CH3	H	OCH3
4337	F	OCH3	CH3	H	Cl
4338	F	OCH3	CH3	H	Br
4339	F	OCH3	CH3	H	F
4340	F	OCH3	CH3	CH3	H
4341	F	OCH3	CH3	CH3	CH3
4342	F	OCH3	CH3	CH3	OCH3
4343	F	OCH3	CH3	CH3	Cl
4344	F	OCH3	CH3	CH3	Br
4345	F	OCH3	CH3	CH3	F
4346	F	OCH3	CH3	OCH3	H
4347	F	OCH3	CH3	OCH3	OCH3
4348	F	OCH3	CH3	OCH3	Cl
4349	F	OCH3	CH3	OCH3	Br
4350	F	OCH3	CH3	OCH3	F
4351	F	OCH3	CH3	Cl	H
4352	F	OCH3	CH3	Cl	OCH3
4353	F	OCH3	CH3	Cl	Cl
4354	F	OCH3	CH3	Cl	Br
4355	F	OCH3	CH3	Cl	F
4356	F	OCH3	CH3	Br	H
4357	F	OCH3	CH3	Br	OCH3
4358	F	OCH3	CH3	Br	Cl
4359	F	OCH3	CH3	Br	Br
4360	F	OCH3	CH3	Br	F
4361	F	OCH3	CH3	F	H
4362	F	OCH3	CH3	F	OCH3
4363	F	OCH3	CH3	F	Cl
4364	F	OCH3	CH3	F	Br
4365	F	OCH3	CH3	F	F
4366	F	OCH3	OCH3	H	H
4367	F	OCH3	OCH3	H	CH3
4368	F	OCH3	OCH3	H	OCH3
4369	F	OCH3	OCH3	H	Cl
4370	F	OCH3	OCH3	H	Br
4371	F	OCH3	OCH3	H	F
4372	F	OCH3	OCH3	CH3	H
4373	F	OCH3	OCH3	CH3	CH3
4374	F	OCH3	OCH3	CH3	Cl
4375	F	OCH3	OCH3	CH3	Br
4376	F	OCH3	OCH3	CH3	F
4377	F	OCH3	OCH3	OCH3	H
4378	F	OCH3	OCH3	OCH3	CH3
4379	F	OCH3	OCH3	OCH3	OCH3
4380	F	OCH3	OCH3	OCH3	Cl
4381	F	OCH3	OCH3	OCH3	Br
4382	F	OCH3	OCH3	OCH3	F
4383	F	OCH3	OCH3	Cl	H
4384	F	OCH3	OCH3	Cl	CH3
4385	F	OCH3	OCH3	Cl	Cl
4386	F	OCH3	OCH3	Cl	Br
4387	F	OCH3	OCH3	Cl	F
4388	F	OCH3	OCH3	Br	H
4389	F	OCH3	OCH3	Br	CH3
4390	F	OCH3	OCH3	Br	Cl
4391	F	OCH3	OCH3	Br	Br
4392	F	OCH3	OCH3	Br	F
4393	F	OCH3	OCH3	F	H
4394	F	OCH3	OCH3	F	CH3
4395	F	OCH3	OCH3	F	Cl
4396	F	OCH3	OCH3	F	Br
4397	F	OCH3	OCH3	F	F
4398	F	OCH3	Cl	H	H
4399	F	OCH3	Cl	H	CH3
4400	F	OCH3	Cl	H	OCH3
4401	F	OCH3	Cl	H	Cl
4402	F	OCH3	Cl	H	Br
4403	F	OCH3	Cl	H	F
4404	F	OCH3	Cl	CH3	H
4405	F	OCH3	Cl	CH3	CH3
4406	F	OCH3	Cl	CH3	OCH3
4407	F	OCH3	Cl	CH3	Br
4408	F	OCH3	Cl	CH3	F
4409	F	OCH3	Cl	OCH3	H
4410	F	OCH3	Cl	OCH3	CH3
4411	F	OCH3	Cl	OCH3	OCH3
4412	F	OCH3	Cl	OCH3	Br
4413	F	OCH3	Cl	OCH3	F
4414	F	OCH3	Cl	Cl	H
4415	F	OCH3	Cl	Cl	CH3
4416	F	OCH3	Cl	Cl	OCH3
4417	F	OCH3	Cl	Cl	Cl
4418	F	OCH3	Cl	Cl	Br
4419	F	OCH3	Cl	Cl	F
4420	F	OCH3	Cl	Br	H
4421	F	OCH3	Cl	Br	CH3
4422	F	OCH3	Cl	Br	OCH3
4423	F	OCH3	Cl	Br	Br
4424	F	OCH3	Cl	F	H
4425	F	OCH3	Cl	F	CH3
4426	F	OCH3	Cl	F	OCH3
4427	F	OCH3	Cl	F	Br
4428	F	OCH3	Cl	F	F
4429	F	OCH3	Br	H	H
4430	F	OCH3	Br	H	CH3
4431	F	OCH3	Br	H	OCH3
4432	F	OCH3	Br	H	Cl
4433	F	OCH3	Br	H	Br
4434	F	OCH3	Br	H	F
4435	F	OCH3	Br	CH3	H
4436	F	OCH3	Br	CH3	CH3
4437	F	OCH3	Br	CH3	OCH3
4438	F	OCH3	Br	CH3	Cl
4439	F	OCH3	Br	CH3	F
4440	F	OCH3	Br	OCH3	H
4441	F	OCH3	Br	OCH3	CH3
4442	F	OCH3	Br	OCH3	OCH3
4443	F	OCH3	Br	OCH3	Cl
4444	F	OCH3	Br	OCH3	F
4445	F	OCH3	Br	Cl	H
4446	F	OCH3	Br	Cl	CH3
4447	F	OCH3	Br	Cl	OCH3
4448	F	OCH3	Br	Cl	Cl
4449	F	OCH3	Br	Cl	F
4450	F	OCH3	Br	Br	H
4451	F	OCH3	Br	Br	CH3
4452	F	OCH3	Br	Br	OCH3
4453	F	OCH3	Br	Br	Cl
4454	F	OCH3	Br	Br	Br
4455	F	OCH3	Br	Br	F
4456	F	OCH3	Br	F	H
4457	F	OCH3	Br	F	CH3
4458	F	OCH3	Br	F	OCH3
4459	F	OCH3	Br	F	Cl
4460	F	OCH3	Br	F	F
4461	F	OCH3	F	H	H
4462	F	OCH3	F	H	CH3
4463	F	OCH3	F	H	OCH3
4464	F	OCH3	F	H	Cl
4465	F	OCH3	F	H	Br
4466	F	OCH3	F	H	F
4467	F	OCH3	F	CH3	H
4468	F	OCH3	F	CH3	CH3
4469	F	OCH3	F	CH3	OCH3
4470	F	OCH3	F	CH3	Cl
4471	F	OCH3	F	CH3	Br
4472	F	OCH3	F	OCH3	H
4473	F	OCH3	F	OCH3	CH3
4474	F	OCH3	F	OCH3	OCH3
4475	F	OCH3	F	OCH3	Cl
4476	F	OCH3	F	OCH3	Br
4477	F	OCH3	F	Cl	H
4478	F	OCH3	F	Cl	CH3
4479	F	OCH3	F	Cl	OCH3
4480	F	OCH3	F	Cl	Cl
4481	F	OCH3	F	Cl	Br
4482	F	OCH3	F	Br	H
4483	F	OCH3	F	Br	CH3
4484	F	OCH3	F	Br	OCH3
4485	F	OCH3	F	Br	Cl
4486	F	OCH3	F	Br	Br
4487	F	OCH3	F	F	H
4488	F	OCH3	F	F	CH3
4489	F	OCH3	F	F	OCH3
4490	F	OCH3	F	F	Cl
4491	F	OCH3	F	F	Br
4492	F	OCH3	F	F	F
4493	F	Cl	CH3	H	H
4494	F	Cl	CH3	H	CH3
4495	F	Cl	CH3	H	OCH3
4496	F	Cl	CH3	H	Cl
4497	F	Cl	CH3	H	Br
4498	F	Cl	CH3	H	F
4499	F	Cl	CH3	CH3	H
4500	F	Cl	CH3	CH3	CH3
4501	F	Cl	CH3	CH3	OCH3
4502	F	Cl	CH3	CH3	Cl
4503	F	Cl	CH3	CH3	Br
4504	F	Cl	CH3	CH3	F
4505	F	Cl	CH3	OCH3	H
4506	F	Cl	CH3	OCH3	OCH3
4507	F	Cl	CH3	OCH3	Cl
4508	F	Cl	CH3	OCH3	Br
4509	F	Cl	CH3	OCH3	F
4510	F	Cl	CH3	Cl	H
4511	F	Cl	CH3	Cl	OCH3
4512	F	Cl	CH3	Cl	Cl
4513	F	Cl	CH3	Cl	Br
4514	F	Cl	CH3	Cl	F
4515	F	Cl	CH3	Br	H
4516	F	Cl	CH3	Br	OCH3
4517	F	Cl	CH3	Br	Cl
4518	F	Cl	CH3	Br	Br
4519	F	Cl	CH3	Br	F
4520	F	Cl	CH3	F	H
4521	F	Cl	CH3	F	OCH3
4522	F	Cl	CH3	F	Cl
4523	F	Cl	CH3	F	Br
4524	F	Cl	CH3	F	F
4525	F	Cl	OCH3	H	H
4526	F	Cl	OCH3	H	CH3
4527	F	Cl	OCH3	H	OCH3
4528	F	Cl	OCH3	H	Cl
4529	F	Cl	OCH3	H	Br
4530	F	Cl	OCH3	H	F
4531	F	Cl	OCH3	CH3	H
4532	F	Cl	OCH3	CH3	CH3
4533	F	Cl	OCH3	CH3	Cl
4534	F	Cl	OCH3	CH3	Br
4535	F	Cl	OCH3	CH3	F
4536	F	Cl	OCH3	OCH3	H
4537	F	Cl	OCH3	OCH3	CH3
4538	F	Cl	OCH3	OCH3	OCH3
4539	F	Cl	OCH3	OCH3	Cl
4540	F	Cl	OCH3	OCH3	Br
4541	F	Cl	OCH3	OCH3	F
4542	F	Cl	OCH3	Cl	H
4543	F	Cl	OCH3	Cl	CH3
4544	F	Cl	OCH3	Cl	Cl
4545	F	Cl	OCH3	Cl	Br
4546	F	Cl	OCH3	Cl	F
4547	F	Cl	OCH3	Br	H
4548	F	Cl	OCH3	Br	CH3
4549	F	Cl	OCH3	Br	Cl
4550	F	Cl	OCH3	Br	Br
4551	F	Cl	OCH3	Br	F
4552	F	Cl	OCH3	F	H
4553	F	Cl	OCH3	F	CH3
4554	F	Cl	OCH3	F	Cl
4555	F	Cl	OCH3	F	Br
4556	F	Cl	OCH3	F	F
4557	F	Cl	Cl	H	H
4558	F	Cl	Cl	H	CH3
4559	F	Cl	Cl	H	OCH3
4560	F	Cl	Cl	H	Cl
4561	F	Cl	Cl	H	Br
4562	F	Cl	Cl	H	F
4563	F	Cl	Cl	CH3	H
4564	F	Cl	Cl	CH3	CH3
4565	F	Cl	Cl	CH3	OCH3
4566	F	Cl	Cl	CH3	Br
4567	F	Cl	Cl	CH3	F
4568	F	Cl	Cl	OCH3	H
4569	F	Cl	Cl	OCH3	CH3
4570	F	Cl	Cl	OCH3	OCH3
4571	F	Cl	Cl	OCH3	Br
4572	F	Cl	Cl	OCH3	F
4573	F	Cl	Cl	Cl	H
4574	F	Cl	Cl	Cl	CH3
4575	F	Cl	Cl	Cl	OCH3
4576	F	Cl	Cl	Cl	Cl
4577	F	Cl	Cl	Cl	Br
4578	F	Cl	Cl	Cl	F
4579	F	Cl	Cl	Br	H
4580	F	Cl	Cl	Br	CH3
4581	F	Cl	Cl	Br	OCH3
4582	F	Cl	Cl	Br	Br
4583	F	Cl	Cl	F	H
4584	F	Cl	Cl	F	CH3
4585	F	Cl	Cl	F	OCH3
4586	F	Cl	Cl	F	Br
4587	F	Cl	Cl	F	F
4588	F	Cl	Br	H	H
4589	F	Cl	Br	H	CH3
4590	F	Cl	Br	H	OCH3
4591	F	Cl	Br	H	Cl
4592	F	Cl	Br	H	Br
4593	F	Cl	Br	H	F
4594	F	Cl	Br	CH3	H
4595	F	Cl	Br	CH3	CH3
4596	F	Cl	Br	CH3	OCH3
4597	F	Cl	Br	CH3	Cl
4598	F	Cl	Br	CH3	F
4599	F	Cl	Br	OCH3	H
4600	F	Cl	Br	OCH3	CH3
4601	F	Cl	Br	OCH3	OCH3
4602	F	Cl	Br	OCH3	Cl
4603	F	Cl	Br	OCH3	F
4604	F	Cl	Br	Cl	H
4605	F	Cl	Br	Cl	CH3
4606	F	Cl	Br	Cl	OCH3
4607	F	Cl	Br	Cl	Cl
4608	F	Cl	Br	Cl	F
4609	F	Cl	Br	Br	H
4610	F	Cl	Br	Br	CH3
4611	F	Cl	Br	Br	OCH3
4612	F	Cl	Br	Br	Cl
4613	F	Cl	Br	Br	Br
4614	F	Cl	Br	Br	F
4615	F	Cl	Br	F	H
4616	F	Cl	Br	F	CH3
4617	F	Cl	Br	F	OCH3
4618	F	Cl	Br	F	Cl
4619	F	Cl	Br	F	F
4620	F	Cl	F	H	H
4621	F	Cl	F	H	CH3
4622	F	Cl	F	H	OCH3
4623	F	Cl	F	H	Cl
4624	F	Cl	F	H	Br
4625	F	Cl	F	H	F
4626	F	Cl	F	CH3	H
4627	F	Cl	F	CH3	CH3
4628	F	Cl	F	CH3	OCH3
4629	F	Cl	F	CH3	Cl
4630	F	Cl	F	CH3	Br
4631	F	Cl	F	OCH3	H
4632	F	Cl	F	OCH3	CH3
4633	F	Cl	F	OCH3	OCH3
4634	F	Cl	F	OCH3	Cl
4635	F	Cl	F	OCH3	Br
4636	F	Cl	F	Cl	H
4637	F	Cl	F	Cl	CH3
4638	F	Cl	F	Cl	OCH3
4639	F	Cl	F	Cl	Cl
4640	F	Cl	F	Cl	Br
4641	F	Cl	F	Br	H
4642	F	Cl	F	Br	CH3
4643	F	Cl	F	Br	OCH3
4644	F	Cl	F	Br	Cl
4645	F	Cl	F	Br	Br
4646	F	Cl	F	F	H
4647	F	Cl	F	F	CH3
4648	F	Cl	F	F	OCH3
4649	F	Cl	F	F	Cl
4650	F	Cl	F	F	Br
4651	F	Cl	F	F	F
4652	F	Br	CH3	H	H
4653	F	Br	CH3	H	CH3
4654	F	Br	CH3	H	OCH3
4655	F	Br	CH3	H	Cl
4656	F	Br	CH3	H	Br
4657	F	Br	CH3	H	F
4658	F	Br	CH3	CH3	H
4659	F	Br	CH3	CH3	CH3
4660	F	Br	CH3	CH3	OCH3
4661	F	Br	CH3	CH3	Cl
4662	F	Br	CH3	CH3	Br
4663	F	Br	CH3	CH3	F
4664	F	Br	CH3	OCH3	H
4665	F	Br	CH3	OCH3	OCH3
4666	F	Br	CH3	OCH3	Cl
4667	F	Br	CH3	OCH3	Br
4668	F	Br	CH3	OCH3	F
4669	F	Br	CH3	Cl	H
4670	F	Br	CH3	Cl	OCH3
4671	F	Br	CH3	Cl	Cl
4672	F	Br	CH3	Cl	Br
4673	F	Br	CH3	Cl	F
4674	F	Br	CH3	Br	H
4675	F	Br	CH3	Br	OCH3
4676	F	Br	CH3	Br	Cl
4677	F	Br	CH3	Br	Br
4678	F	Br	CH3	Br	F
4679	F	Br	CH3	F	H
4680	F	Br	CH3	F	OCH3
4681	F	Br	CH3	F	Cl
4682	F	Br	CH3	F	Br
4683	F	Br	CH3	F	F
4684	F	Br	OCH3	H	H
4685	F	Br	OCH3	H	CH3
4686	F	Br	OCH3	H	OCH3
4687	F	Br	OCH3	H	Cl
4688	F	Br	OCH3	H	Br
4689	F	Br	OCH3	H	F
4690	F	Br	OCH3	CH3	H
4691	F	Br	OCH3	CH3	CH3
4692	F	Br	OCH3	CH3	Cl
4693	F	Br	OCH3	CH3	Br
4694	F	Br	OCH3	CH3	F
4695	F	Br	OCH3	OCH3	H
4696	F	Br	OCH3	OCH3	CH3
4697	F	Br	OCH3	OCH3	OCH3
4698	F	Br	OCH3	OCH3	Cl
4699	F	Br	OCH3	OCH3	Br
4700	F	Br	OCH3	OCH3	F
4701	F	Br	OCH3	Cl	H
4702	F	Br	OCH3	Cl	CH3
4703	F	Br	OCH3	Cl	Cl
4704	F	Br	OCH3	Cl	Br
4705	F	Br	OCH3	Cl	F
4706	F	Br	OCH3	Br	H
4707	F	Br	OCH3	Br	CH3
4708	F	Br	OCH3	Br	Cl
4709	F	Br	OCH3	Br	Br
4710	F	Br	OCH3	Br	F
4711	F	Br	OCH3	F	H
4712	F	Br	OCH3	F	CH3
4713	F	Br	OCH3	F	Cl
4714	F	Br	OCH3	F	Br
4715	F	Br	OCH3	F	F
4716	F	Br	Cl	H	H
4717	F	Br	Cl	H	CH3
4718	F	Br	Cl	H	OCH3
4719	F	Br	Cl	H	Cl
4720	F	Br	Cl	H	Br
4721	F	Br	Cl	H	F
4722	F	Br	Cl	CH3	H
4723	F	Br	Cl	CH3	CH3
4724	F	Br	Cl	CH3	OCH3
4725	F	Br	Cl	CH3	Br
4726	F	Br	Cl	CH3	F
4727	F	Br	Cl	OCH3	H
4728	F	Br	Cl	OCH3	CH3
4729	F	Br	Cl	OCH3	OCH3
4730	F	Br	Cl	OCH3	Br
4731	F	Br	Cl	OCH3	F
4732	F	Br	Cl	Cl	H
4733	F	Br	Cl	Cl	CH3
4734	F	Br	Cl	Cl	OCH3
4735	F	Br	Cl	Cl	Cl
4736	F	Br	Cl	Cl	Br
4737	F	Br	Cl	Cl	F
4738	F	Br	Cl	Br	H
4739	F	Br	Cl	Br	CH3
4740	F	Br	Cl	Br	OCH3
4741	F	Br	Cl	Br	Br
4742	F	Br	Cl	F	H
4743	F	Br	Cl	F	CH3
4744	F	Br	Cl	F	OCH3
4745	F	Br	Cl	F	Br
4746	F	Br	Cl	F	F
4747	F	Br	Br	H	H
4748	F	Br	Br	H	CH3
4749	F	Br	Br	H	OCH3
4750	F	Br	Br	H	Cl
4751	F	Br	Br	H	Br
4752	F	Br	Br	H	F
4753	F	Br	Br	CH3	H
4754	F	Br	Br	CH3	CH3
4755	F	Br	Br	CH3	OCH3
4756	F	Br	Br	CH3	Cl
4757	F	Br	Br	CH3	F
4758	F	Br	Br	OCH3	H
4759	F	Br	Br	OCH3	CH3
4760	F	Br	Br	OCH3	OCH3
4761	F	Br	Br	OCH3	Cl
4762	F	Br	Br	OCH3	F
4763	F	Br	Br	Cl	H
4764	F	Br	Br	Cl	CH3
4765	F	Br	Br	Cl	OCH3
4766	F	Br	Br	Cl	Cl
4767	F	Br	Br	Cl	F
4768	F	Br	Br	Br	H
4769	F	Br	Br	Br	CH3
4770	F	Br	Br	Br	OCH3
4771	F	Br	Br	Br	Cl
4772	F	Br	Br	Br	Br
4773	F	Br	Br	Br	F
4774	F	Br	Br	F	H
4775	F	Br	Br	F	CH3
4776	F	Br	Br	F	OCH3
4777	F	Br	Br	F	Cl
4778	F	Br	Br	F	F
4779	F	Br	F	H	H
4780	F	Br	F	H	CH3
4781	F	Br	F	H	OCH3
4782	F	Br	F	H	Cl
4783	F	Br	F	H	Br
4784	F	Br	F	H	F
4785	F	Br	F	CH3	H
4786	F	Br	F	CH3	CH3
4787	F	Br	F	CH3	OCH3
4788	F	Br	F	CH3	Cl
4789	F	Br	F	CH3	Br
4790	F	Br	F	OCH3	H
4791	F	Br	F	OCH3	CH3
4792	F	Br	F	OCH3	OCH3
4793	F	Br	F	OCH3	Cl
4794	F	Br	F	OCH3	Br
4795	F	Br	F	Cl	H
4796	F	Br	F	Cl	CH3
4797	F	Br	F	Cl	OCH3
4798	F	Br	F	Cl	Cl
4799	F	Br	F	Cl	Br
4800	F	Br	F	Br	H
4801	F	Br	F	Br	CH3
4802	F	Br	F	Br	OCH3
4803	F	Br	F	Br	Cl
4804	F	Br	F	Br	Br
4805	F	Br	F	F	H
4806	F	Br	F	F	CH3
4807	F	Br	F	F	OCH3
4808	F	Br	F	F	Cl
4809	F	Br	F	F	Br
4810	F	Br	F	F	F
4811	F	F	CH3	H	H
4812	F	F	CH3	H	CH3
4813	F	F	CH3	H	OCH3
4814	F	F	CH3	H	Cl
4815	F	F	CH3	H	Br
4816	F	F	CH3	H	F
4817	F	F	CH3	CH3	H
4818	F	F	CH3	CH3	CH3
4819	F	F	CH3	CH3	OCH3
4820	F	F	CH3	CH3	Cl
4821	F	F	CH3	CH3	Br
4822	F	F	CH3	CH3	F
4823	F	F	CH3	OCH3	H
4824	F	F	CH3	OCH3	OCH3
4825	F	F	CH3	OCH3	Cl
4826	F	F	CH3	OCH3	Br
4827	F	F	CH3	OCH3	F
4828	F	F	CH3	Cl	H
4829	F	F	CH3	Cl	OCH3
4830	F	F	CH3	Cl	Cl
4831	F	F	CH3	Cl	Br
4832	F	F	CH3	Cl	F
4833	F	F	CH3	Br	H
4834	F	F	CH3	Br	OCH3
4835	F	F	CH3	Br	Cl
4836	F	F	CH3	Br	Br
4837	F	F	CH3	Br	F
4838	F	F	CH3	F	H
4839	F	F	CH3	F	OCH3
4840	F	F	CH3	F	Cl
4841	F	F	CH3	F	Br
4842	F	F	CH3	F	F
4843	F	F	OCH3	H	H
4844	F	F	OCH3	H	CH3
4845	F	F	OCH3	H	OCH3
4846	F	F	OCH3	H	Cl
4847	F	F	OCH3	H	Br
4848	F	F	OCH3	H	F
4849	F	F	OCH3	CH3	H
4850	F	F	OCH3	CH3	CH3
4851	F	F	OCH3	CH3	Cl
4852	F	F	OCH3	CH3	Br
4853	F	F	OCH3	CH3	F
4854	F	F	OCH3	OCH3	H
4855	F	F	OCH3	OCH3	CH3
4856	F	F	OCH3	OCH3	OCH3
4857	F	F	OCH3	OCH3	Cl
4858	F	F	OCH3	OCH3	Br
4859	F	F	OCH3	OCH3	F
4860	F	F	OCH3	Cl	H
4861	F	F	OCH3	Cl	CH3
4862	F	F	OCH3	Cl	Cl
4863	F	F	OCH3	Cl	Br
4864	F	F	OCH3	Cl	F
4865	F	F	OCH3	Br	H
4866	F	F	OCH3	Br	CH3
4867	F	F	OCH3	Br	Cl
4868	F	F	OCH3	Br	Br
4869	F	F	OCH3	Br	F
4870	F	F	OCH3	F	H
4871	F	F	OCH3	F	CH3
4872	F	F	OCH3	F	Cl
4873	F	F	OCH3	F	Br
4874	F	F	OCH3	F	F
4875	F	F	Cl	H	H
4876	F	F	Cl	H	CH3
4877	F	F	Cl	H	OCH3
4878	F	F	Cl	H	Cl
4879	F	F	Cl	H	Br
4880	F	F	Cl	H	F
4881	F	F	Cl	CH3	H
4882	F	F	Cl	CH3	CH3
4883	F	F	Cl	CH3	OCH3
4884	F	F	Cl	CH3	Br
4885	F	F	Cl	CH3	F
4886	F	F	Cl	OCH3	H
4887	F	F	Cl	OCH3	CH3
4888	F	F	Cl	OCH3	OCH3
4889	F	F	Cl	OCH3	Br
4890	F	F	Cl	OCH3	F
4891	F	F	Cl	Cl	H
4892	F	F	Cl	Cl	CH3
4893	F	F	Cl	Cl	OCH3
4894	F	F	Cl	Cl	Cl
4895	F	F	Cl	Cl	Br
4896	F	F	Cl	Cl	F
4897	F	F	Cl	Br	H
4898	F	F	Cl	Br	CH3
4899	F	F	Cl	Br	OCH3
4900	F	F	Cl	Br	Br
4901	F	F	Cl	F	H
4902	F	F	Cl	F	CH3
4903	F	F	Cl	F	OCH3
4904	F	F	Cl	F	Br
4905	F	F	Cl	F	F
4906	F	F	Br	H	H
4907	F	F	Br	H	CH3
4908	F	F	Br	H	OCH3
4909	F	F	Br	H	Cl
4910	F	F	Br	H	Br
4911	F	F	Br	H	F
4912	F	F	Br	CH3	H
4913	F	F	Br	CH3	CH3
4914	F	F	Br	CH3	OCH3
4915	F	F	Br	CH3	Cl
4916	F	F	Br	CH3	F
4917	F	F	Br	OCH3	H
4918	F	F	Br	OCH3	CH3
4919	F	F	Br	OCH3	OCH3
4920	F	F	Br	OCH3	Cl
4921	F	F	Br	OCH3	F
4922	F	F	Br	Cl	H
4923	F	F	Br	Cl	CH3
4924	F	F	Br	Cl	OCH3
4925	F	F	Br	Cl	Cl
4926	F	F	Br	Cl	F
4927	F	F	Br	Br	H
4928	F	F	Br	Br	CH3
4929	F	F	Br	Br	OCH3
4930	F	F	Br	Br	Cl
4931	F	F	Br	Br	Br
4932	F	F	Br	Br	F
4933	F	F	Br	F	H
4934	F	F	Br	F	CH3
4935	F	F	Br	F	OCH3
4936	F	F	Br	F	Cl
4937	F	F	Br	F	F
4938	F	F	F	H	H
4939	F	F	F	H	CH3
4940	F	F	F	H	OCH3
4941	F	F	F	H	Cl
4942	F	F	F	H	Br
4943	F	F	F	H	F
4944	F	F	F	CH3	H
4945	F	F	F	CH3	CH3
4946	F	F	F	CH3	OCH3
4947	F	F	F	CH3	Cl
4948	F	F	F	CH3	Br
4949	F	F	F	OCH3	H
4950	F	F	F	OCH3	CH3
4951	F	F	F	OCH3	OCH3
4952	F	F	F	OCH3	Cl
4953	F	F	F	OCH3	Br
4954	F	F	F	Cl	H
4955	F	F	F	Cl	CH3
4956	F	F	F	Cl	OCH3
4957	F	F	F	Cl	Cl
4958	F	F	F	Cl	Br
4959	F	F	F	Br	H
4960	F	F	F	Br	CH3
4961	F	F	F	Br	OCH3
4962	F	F	F	Br	Cl
4963	F	F	F	Br	Br
4964	F	F	F	F	H
4965	F	F	F	F	CH3
4966	F	F	F	F	OCH3
4967	F	F	F	F	Cl
4968	F	F	F	F	Br
4969	F	F	F	F	F

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:

• • wherein R^2a, R^2b, R^2c, R^2d, and R^2e are as defined in Table 2.

The compounds of Formula I are MCH receptor antagonists, as demonstrated by the ligand binding assays described hereinbelow. MCH receptor antagonist activity has been correlated with pharmaceutical activity for the treatment of eating disorders such as obesity and hyperphagia, and diabetes. Compounds of Formula I exhibit good activity in standard in vitro MCH calcium mobilization assays and/or receptor binding assays, specifically in the assays described hereinbelow, see Examples 23 and 24. Generally, compounds of Formula I have an K_i of about 10 μM or less, preferably about 1 μM or less, more preferably about 100 nM or less, or even more preferably about 10 nM or less, as determined by a standard in vitro MCH receptor mediated calcium mobilization assay as exemplified by Example 23, hereinbelow. Generally compounds of Formula I are MCH receptor antagonists and exhibit IC₅₀ values of about 10 μM or less, preferably about 1 μM or less, more preferably about 100 nM or less, or even more preferably about 10 nM or less, as determined by a standard in vitro MCH receptor binding assay such as is described hereinbelow in Example 24.

Preferably, the MCH receptor antagonists of Formula I bind specifically, and still more preferably with high affinity, to MCH receptors.

The following examples illustrate the invention.

EXAMPLE 1

To a 2 L glass bottle was added 4-formyl-3-methoxyphenoxy-polystyrene resin (100-180 mesh, 1.1 mmol/g loading, 20 g, 22 mmol), amine (5 eq, 110 mmol), and anhydrous DCE (500 mL). The resulting mixture was shaken for one hour at room temperature. Then, Na(OAc)₃BH (5 eq, 110 mmol) was added and the mixture was shaken overnight at room temperature. The mixture was degassed every half-hour for the first three hours. The resin was filtered and washed with MeOH (2×) and DCM (2×) to afford 1. Step 2

To a 2 L glass bottle was added 1, 4-fluoro-3-nitrobenzoic acid (24.4 mmol, 132 mmol), HOBt (18 g, 132 mmol), DIC (42 mL, 264 mmol), and DMF (500 mL). The resulting mixture was shaken overnight at room temperature. The resin was filtered and washed with DMF (2×), MeOH (2×), and DCM (2×) to afford 2. Step 3

To a 2 L glass bottle was added 2, phenol (27 g, 220 mmol), DBU (20 mL, 132 mmol), and DMF (400 mL). The resulting mixture was shaken overnight at room temperature. Then, the resin was filtered and washed with DMF (2×) and DCM (2×) to afford 3. Step 4

To a 2 L glass bottle was added 3, Tin(II)Cl.2H₂O (49.5 g, 220 mmol) and DMF (400 mL). The resulting mixture was then shaken overnight at room temperature. The resin was filtered and washed with DMF (2×) and DCM (2×) to afford 4.

EXAMPLE 2

Method 1

Starting material (10 mg, 0.021 mmol) was combined with 1,2-dibromoethane (2.3 μL, 0.025 mmol) and NaH (1 mg, 0.042 mmol) in 0.5 mL DMF at room temperature. The mixture was then heated to 80° C. for 1 hour. The reaction mixture was worked up with water and EtOAc.

Method 2

Starting material (20 mg, 0.04 mmol) was combined with 1,2-diiodoethane (14.3 mg, 0.05 mmol) and NaH (2 mg, 0.08 mmol) in 0.5 mL DMF, then reacted as described above.

EXAMPLE 3

To a peptide vessel was added resin (1.1 mmol/g loading, 100 mg, 0.11 mmol), 2-methoxyphenylisocyanate (1.1 mmol), and pyridine: DCM (5 mL, 1:1 ratio). The resulting mixture was shaken overnight at room temperature. The resin was washed with DCM (2×). Then, 30% TFA in DCM (10 mL) was added and the resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2×). The filtrate was concentrated to afford 30.

Examples 4-16 were prepared according to the procedure shown in Example 3.

EXAMPLE 4

EXAMPLE 5

EXAMPLE 6

EXAMPLE 7

EXAMPLE 8

EXAMPLE 9

EXAMPLE 10

EXAMPLE 11

EXAMPLE 12

EXAMPLE 13

EXAMPLE 14

EXAMPLE 15

EXAMPLE 16

EXAMPLE 17

To a round bottom flask was added resin (500 mg, 0.55 mmol) and DCM (15 mL). The resulting mixture was cooled to −78° C. Then, 20% phosgene in toluene (540 mg) was added dropwise. The resulting mixture was warmed to room temperature and shaken for 3 hours. The resin was filtered and washed with DCM (2×). The resin was transferred to a peptide vessel and excess (10-15 eq) of aminopyridine along with 15 mL of DCM were added. The resulting mixture was shaken overnight at room temperature. The resin was washed with DCM (2×). Then, 30% TFA in DCM (50 mL) was added and the resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2×). The filtrate was concentrated to afford 44.

EXAMPLE 18

To a peptide vessel was added resin (1.1 mmol/g, 200 mg, 0.22 mmol), phenylchloroformate (143 μL, 1.1 mmol), and DCM:pyridine (7 mL, 1:1 ratio). The resulting mixture was shaken overnight at room temperature. The resin was washed with DCM (2×). Then, 30% TFA in DCM (50 mL) was added and the resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2×). The filtrate was concentrated to afford 45.

EXAMPLE 19

To a peptide vessel was added resin (1.1 mmol/g, 1.1 g, 1.21 mmol), 1,1-dimethylethyl 2-oxoethyl(phenyl)carbamate (490 mg, 3.63 mmol), and DCM:DMF (10 mL, 1:1 ratio). The mixture was shaken for 30 min. at room temperature. Then, Na(OAc)₃BH (1.27 g, 6.05 mmol) was added and the mixture was shaken overnight at room temperature. The mixture was degassed every half hour for the first 3 hours. The resin was washed with MeOH (2×) and DCM (2×). Then, 30% TFA in DCM (50 mL) was added and resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2×). The filtrate was concentrated and dried. Then, phosgene (27.1 μL, 0.274 mmol) and DCM:pyridine (5 mL, 1:1 ratio) were added to the crude mixture. The resulting mixture was stirred at room temperature for 45 min. The mixture was concentrated and purified by column chromatography to afford 62.

EXAMPLE 20

To a peptide vessel was added resin (1.1 mmol/g, 500 mg, 0.55 mmol), acetaldehyde (93 μL, 1.65 mmol), and DCM:DMF (8 mL, 1:1 ratio). The mixture was shaken for 30 min. at room temperature. Then, Na(OAc)₃BH (580 mg, 2.75 mmol) was added and the mixture was shaken overnight at room temperature. The mixture was degassed every half hour for the first three hours. The resin was washed with MeOH (2×) and DCM (2×). Then, isocyanatobenzene (327 μL, 2.75 mmol) and DCM (10 mL) were added to the resin in the peptide vessel. The resulting mixture was shaken overnight at room temperature. The resin was washed with DCM (2×). Then, 30% TFA in DCM (50 mL) was added and resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2×). The filtrate was concentrated to afford 49.

EXAMPLE 21

To a round bottom flask was added resin (1.1 mmol/g, 400 mg, 0.44 mmol) and DCM (7 mL). The resulting mixture was stirred at −78° C. and phosgene (217 mg, 2.2 mmol) was added dropwise. The mixture was warmed up to room temperature and shaken for 3 hours. The resin was washed with DCM (2×) and transferred to a peptide vessel. Then, 1,2,3,4-tetrahydroquinoline (585 μL, 4.4 mmol) was added to the vessel. The resulting mixture was shaken for 2 hours. The resin was washed with DCM (2×). Then, 30% TFA in DCM (30 mL) was added and resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2×). The filtrate was concentrated to afford 46.

EXAMPLE 22

To a 20 ml vial was added 1-((4-fluoro-3-nitrophenyl)carbonyl)-2-(1-pyrrolidinylmethyl)pyrrolidine (520 mg, 1.62 mmol), 3,4-dimethylphenol (237 mg, 1.94 mmol), DBU (271 μL, 1.78 mmol), and DMF (10 mL). The resulting mixture was stirred overnight at room temperature. The mixture was extracted with H₂O and EtOAc. The organic layers were combined, dried with MgSO₄, and concentrated to give a crude intermediate. The intermediate was purified by column chromatography to give a pure intermediate. Then, EtOH:H₂O (3:1) and Na₂S₂O₄ (10 eq) were added to the intermediate. The resulting mixture was refluxed overnight. Then, the mixture was cooled to room temperature and extracted with H₂O and EtOAc. The organic layers were combined, dried with MgSO₄, and concentrated to give a crude intermediate. The crude intermediate was purified by column chromatography to give a pure intermediate. The purified intermediate was placed in a round bottom flask and DCM and phenylisocyanate (1 eq) were added. The resulting mixture was stirred at room temperature for 1 hour. The solvent was removed and the crude desired product was purified by column chromatography to afford 63.

EXAMPLE 23

Functional Assay

Human embryonic kidney cells (293 total) expressing either human, rat, or mouse MCH receptor were harvested from 150 mm culture dishes using PBS. Spinning at 1500 rpm for 2 minutes initially pelleted cells. The resulting pellet was then homogenized in 15 mL ice cold sucrose buffer (25 mM HEPES, 0.3 M sucrose, pH 7.4) with a motorized, glass fitted, Teflon® homogenizer. The homogenate was centrifuged at 48,000×g at 4° C. for 10 minutes, resuspended in 15 mL assay buffer (25 mM HEPES, 10 mM MgCl₂, 0.2% BSA, 0.1 mg/mL STI, 0.1 mg/mL Pefabloc®, 1 μM Phosphoramidon, pH 7.4) with a Tissue-Tearor® (Biospec Products) and centrifuged again at 48,000×g for 10 minutes. The pellet was homogenized for a third time in 15 mL assay buffer using the Tissue-Tearor® and again centrifuged at 48,000×g for 10 minutes. The resulting pellet was resuspended in assay buffer at a wet weight concentration of 10-20 mg/mL.

Pharmacological analyses were conducted using either a HT-PS100 device (Axiom Biotechnologies, San Diego, Calif.), which provides high-resolution dose-response fluorometric measurements of [Ca⁺⁺]_i mobilization, or using a FLIPR® device (Molecular Devices, Sunnyvale, Calif.).

HT-PS100 Protocol:

Materials: HEK 293 cells were stably transfected with the rat MCH 1 receptor and maintained under G418 antibiotic pressure. HT-PS100 assay buffer consisted of Physiological Saline Solution (145 mM NaCl, 5.4 mM KCL, 1.0 mM NaH₂PO₄, 1.8 mM CaCl₂, 0.8 mM MgSO₄, 15.0 mM HEPES, pH 7.4, 11.2 mM glucose)+50 μM Pluronic-F127. MCH peptide (Amgen, Inc.) was reconstituted in assay buffer and served as the positive agonist control for all experiments. Test compounds were prepared as 10 mM stocks in 100% DMSO and diluted to a top end working concentration of 100 μM in 96 well plates.

Methods: HEK 293 stably expressing MCH1R were maintained in Dulbeco's modified Eagle's medium (GIBCO/Life Technologies, Rockville, Md.) supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum (HyClone, Logan, Utah) at 37° C., 5% CO₂. Cells were harvested by 10′ treatment with Versene (GIBCO/Life Technologies) followed by trituration, washing twice with cold (4° C.) hybridoma medium (Serum/Protein free, with L-glutamine, sodium bicarbonate, MOPS buffer) (Sigma-Aldrich Corp, St. Louis, Mo.) and resuspended at 2×106 cells/mL in the same medium. The resuspended cells were loaded with the fluorescent calcium indicator Fura-2 by incubating with Fura-2AM (Molecular Probes, Eugene, Oreg.) at 1.6 μM for 60′ at room temperature. The loaded cells were then washed twice with hybridoma medium, adjusted to 2×105 cells/mL and kept at ambient temperature in a spinner flask under gentle stirring for up to 6 hours during the experiment.

Receptor-stimulated intracellular calcium responses were detected in the flow-through detector cuvette of the HT-PS100 by monitoring increases in the ratio of Fura-2 fluorescence intensities R340/380 measured at alternating 340/380 nm excitation and 510 nm emission.

Preliminary static experiments, conducted to determine the kinetics of MCH1R's dose response to MCH peptide, indicated the optimum time point to capture the maximum Ca⁺⁺ transients was 30 s. No interference with DMSO was seen up to 1%. Based on these observations, subsequent experiments were conducted on the HT-PS100 to generate high resolution dose response curves, characterize agonist/antagonist properties, and evaluate antagonist potencies via Schild experiments. During HT-PS100 validation, reproducible EC₅₀s for MCH of 10 nM were generated within a broad range of cell passage and harvest density. HT-PS100 gradient generation was calibrated with a standardized stock of fluorescein.

Test compounds were screened for MCH1R activity in the HT-PS100 for both agonist and antagonist action. Agonist mode challenges were conducted at a maximum gradient concentration of 100 μM. Antagonist activity was tested by 30 s pre-incubation of cells at a compound concentration of 100 μM, with subsequent introduction of MCH at a concentration 5-fold of EC₅₀ as determined in preliminary experiments. Compounds that showed inhibition of the MCH-induced Ca⁺⁺ response were automatically tagged for re-interrogation, IC₅₀ generation, and Schild analysis.

Schild experiments were conducted on the HT-PS100 for selected compounds by 30 s pre-incubation of cells with antagonist compounds prior to administering MCH peptide. Several fixed concentrations of antagonist compounds were prepared in 10-fold increments, and presented to the cells 30 s before introducing a gradient of increasing MCH concentration. Values for compound pA2 were calculated by linear regression of Log(DR−1) MCH EC₅₀ as a function of Log(antagonist concentration), where DR is the dose ratio of MCH EC₅₀ values determined in the presence and absence of antagonist.

The following compounds had K_i values of 100 μM or less in the HT-PS100 assay: Compound Nos. ______. Of these, Compound Nos. ______ had K_i values of 100 nM or less in this assay.

FLIPR® Protocol:

Materials: Pharmacological analysis was conducted using a FLIPR® device (Molecular Devices, Sunnyvale, Calif.). CHOK1-Gqi cells were stably transfected with the rat MCH1 receptor and maintained under G418 antibiotic pressure. FLIPR® assay buffer consisted of phenol red-free DMEM+2.5 mM probenecid. MCH peptide (Amgen, Inc.) was reconstituted in assay buffer and served as the positive agonist control for all experiments. Test compounds were prepared as 10 mM stocks in 100% DMSO and diluted to a top end working concentration of 10 μM in 96 well black, flat bottom, collagen-I coated plates (Becton Dickinson, Bedford, Mass.).

Methods: CHOK1-Gqi cells stably expressing MCH1R were maintained in Dulbeco's modified Eagle's medium (GIBCO/Life Technologies, Rockville, Md.) supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum (HyClone, Logan, Utah) at 37° C., 5% CO₂. Cells were harvested by 10′ treatment with Versene (GIBCO/Life Technologies) followed by trituration, washing twice with cold (4° C.) hybridoma medium (Serum/Protein free, with L-glutamine, sodium bicarbonate, MOPS buffer) (Sigma-Aldrich Corp, St. Louis, Mo.) and replated onto 96 well black, flat bottom, collagen-I coated plates to a density of 10,000 cells/well. The cells were then loaded with the fluorescent calcium indicator Fura-2 (Molecular Probes, Eugene, Oreg.) at 1.6 μM for 60′ at room temperature. The loaded cells were then washed twice with 90 μl/well of wash buffer (1×HBSS, 20 mM HEPES, 2.5 mM probenecid).

Receptor-stimulated intracellular calcium responses were detected using FLIPR® by monitoring increases in the Fura-2 fluorescence response.

Test compounds were screened for MCH1R activity in the FLIPR® for both agonist and antagonist action. Agonist mode challenges were conducted at a maximum gradient concentration of 1 μM. Antagonist activity was tested by 10 min pre-incubation of cells at a compound concentration of defined to be 300× the EC₅₀ of MCH (typically 1 μM), with subsequent introduction of MCH at a concentration 5-fold of EC₅₀ as determined in preliminary experiments. Compounds that showed inhibition of MCH induced MCH1R dependant Ca⁺⁺ responses were automatically tagged for re-interogation, IC₅₀ generation, and Schild analysis.

Schild experiments were conducted on the FLIPR® for selected compounds by co-administering antagonist compounds together with MCH peptide. Several fixed concentrations of antagonist compounds were prepared in 10-fold increments, and presented to the cells in a gradient of increasing MCH concentration. Values for compound pA2 were calculated by linear regression of MCH EC₅₀s as a function of antagonist concentration.

The following compounds had K_i values of 100 μM or less in the rMCH FLIPR® assay: Compound Nos. 1, 5, 6, 15, 22, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 51, 53, 54, 55, 56, 57, 58, 59, and 64. Of these, Compound Nos. 1, 6, 15, 31, 32, 38, 39, 40, and 41 had K_i values of 100 nM or less in this assay.

The following compounds had K_i values of 100 μM or less in the hMCH FLIPR® assay: Compound Nos. 1, 5, 6, 34, 35, 36, 37, 38, 40, 41, 51, 52, 53, 54, 55, 56, 57, 58, 59, and 64. Of these, Compound Nos. 1, 6, 34, 35, 38, 40, 41, 51, 56, and 57 had K_i values of 100 nM or less in this assay.

EXAMPLE 24

Ligand Binding Assay

Binding assays were determined as described below using mouse, rat or human MCH 1 receptors (mMCH1R, rMCH1R, and hMCH1R, respectively) expressed in HEK 293; IC₅₀ values were calculated.

Binding assays were performed in 96-well U-bottom plates. Membranes (100 μg tissue) were incubated at 30° C. for 90 minutes in assay buffer with various peptides in the presence of 0.2 nM 125I native-MCH (Perkin-Elmer Life Sciences, Boston, Mass.) in 100 μL total volume. Non-specific binding was assessed in the presence of 1 μM cold native-MCH. The reaction was terminated by rapid filtration through Unfilter-96 GF/C glass fiber filter plates (FilterMate® 196 Harvester, Packard Instrument Co., Meriden, Conn.) pre-soaked in PBS/0.5% BSA, followed by three washes with 300 μL ice-cold water. Bound radioactivity was determined using a TopCount® microplate scintillation and luminescence counter (Packard Instrument Co., Meriden, Conn.). Nonlinear regression analyses of drug concentration curves were performed using GraphPad Prism® (GraphPad Software, Inc., San Diego, Calif.).

The following compounds had IC₅₀ values of 100 μM or less in the rMCH assay: Compound Nos. 1, 10, 12, 13, 15, 16, 17, 18, 22, 27, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 63, 64, 65, and 66. Of these, Compound Nos. 1, 31, 38, 39, 40, 41, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, and 66 had IC₅₀ values of 100 nM or less in the rMCH assay.

The following compounds had IC₅₀ values of 100 μM or less in the hMCH assay: Compound Nos. 1, 5, 6, 8, 10, 12, 13, 15, 16, 17, 18, 20, 22, 27, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 58, 59, 64, 65, and 66. Of these, Compound Nos. 1, 6, 31, 32, 33, 34, 36, 37, 38, 39, 40, 41, 58, 59, and 66 had IC₅₀ values of 100 nM or less in the hMCH assay.

In view of the above, it will be seen that the several objects of the invention are achieved.

The above description of the embodiments and examples are intended only to acquaint others skilled in the art with the invention, its principles, and its practical application, so that others skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use. The present invention, therefore, is not limited to the above embodiments, and may be variously modified.

With reference to the use of the word(s) “comprise” or “comprises” or “comprising” or “including” or “having” in the above description and/or in the following claims, it should be noted that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that each of those words is to be so interpreted in construing the above description and/or the following claims. When introducing elements of the present invention or the preferred embodiment(s) thereof, the articles “a,” “an,” “the,” and “said” are intended to mean that there are one or more of the elements.

In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous results attained.

As various changes could be made in the above compounds and methods without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.

The entire texts of all U.S. patents and other references cited herein are hereby incorporated by reference into this patent.

Claims

1. A compound of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof:

2. The compound, pharmaceutically-acceptable salt or tautomer of claim 1, wherein: W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl, lower aralkyl, heteroaryl, and lower heteroarylalkyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, lower arylcycloalkyl, and lower heteroarylalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R3 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower heteroarylalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, lower alkoxycarbonyl, and halo; R5 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; R8 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; R11 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; and R12 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano.

3. The compound, pharmaceutically-acceptable salt or tautomer of claim 2, wherein: W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; R4 is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; R8 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; R9 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R10 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; R11 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; and R12 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano.

4. The compound, pharmaceutically-acceptable salt or tautomer of claim 1, wherein X is —OR1.

5. The compound, pharmaceutically-acceptable salt or tautomer of claim 2, wherein X is —OR1.

6. The compound, pharmaceutically-acceptable salt or tautomer of claim 3, wherein X is —OR1.

7. The compound, pharmaceutically-acceptable salt, tautomer or prodrug of claim 1, selected from the group of compounds consisting of 4-[(3,4-dimethylphenyl)oxy]-3-{[(phenylamino)carbonyl]amino}-N-(2-(1-pyrrolidinyl)ethyl)benzamide, 4-[(3,4-dimethylphenyl)oxy]-3-[(3-phenylpropanoyl)amino]-N-(2-(1-pyrrolidinyl)ethyl)benzamide, 4-[(3,4-dimethylphenyl)oxy]-3-({[(phenylmethyl)amino]carbonyl}amino)-N-(2-(1-pyrrolidinyl)ethyl)benzamide, 4-(phenyloxy)-N-(2-(1-pyrrolidinyl)ethyl)benzamide, 3-acetylamino-4-(3,4-dimethylphenoxy)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-propionylamino-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 3-(3-cyclopentylpropionylamino)-4-(3,4-dimethylphenoxy)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-phenylacetylamino-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-(3-phenyl-acryloylamino)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-[(2-phenyl-cyclopropanecarbonyl)amino]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, naphthalene-2-carboxylic acid [2-(3,4-dimethylphenoxy)-5-(2-pyrrolidin-1-yl-ethylcarbamoyl)phenyl]amide, 4-(3,4-dimethylphenoxy)-3-(3-ethylureido)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, N-(2-aminoethyl)-4-(3,4-dimethylphenoxy)-3-(3-phenylpropionylamino)benzamide, 4-methoxy-3-(3-phenylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(naphthalen-2-yl-oxy)-3-(3-phenylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-[3-(2-methoxyphenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 3-[3-(2,4-dichlorophenyl)ureido]-4-(3,4-dimethylphenoxy)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-[3-(4-phenoxyphenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 3-(3-biphenyl-4-yl-ureido)-4-(3,4-dimethylphenoxy)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-[3-(4-isopropylphenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-[3-(2,6-dimethylphenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-(3-naphthalen-1-yl-ureido)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 3-[3-(2,6-diisopropylphenyl)ureido]-4-(3,4-dimethylphenoxy)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 3-[3-(4-bromophenyl)ureido]-4-(3,4-dimethylphenoxy)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-[3-(3-fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-[3-(3-methoxyphenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 3-[3-(2-chlorophenyl)ureido]-4-(3,4-dimethylphenoxy)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-(3,3-diphenylureido)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dimethylphenoxy)-3-(3-methyl-3-phenylureido)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 1,3-dihydroisoindole-2-carboxylic acid [2-(3,4-dimethylphenoxy)-5-(2-pyrrolidin-1-yl-ethylcarbamoyl)phenyl]amide, 4-(4-fluoro-3-methylphenoxy)-3-[3-(3-fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-dichlorophenoxy)-3-[3-(3-fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3,4-difluorophenoxy)-3-[3-(3-fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(4-fluorophenoxy)-3-[3-(3-fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 4-(3-fluorophenoxy)-3-[3-(3-fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 3-[3-(3-fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)-4-p-tolyloxybenzamide, 3-[3-(3-fluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)-4-m-tolyloxybenzamide, 3-[3-(3,5-difluorophenyl)ureido]-4-(3,4-dimethylphenoxy)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 3-[3-(3,5-dichlorophenyl)ureido]-4-(3,4-dimethylphenoxy)-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 3-[3-(3-fluorophenyl)ureido]-4-phenoxy-N-(2-pyrrolidin-1-yl-ethyl)benzamide, 1-[2-(3,4-dimethylphenoxy)-5-(2-pyrrolidin-1-yl-methylpyrrolidine-1-carbonyl)phenyl]-3-phenylurea, 1-{2-(3,4-dimethylphenoxy)-5-[(2-pyrrolidin-1-yl-ethylamino)-methyl]phenyl}-3-(3-fluorophenyl)urea, 1-[2-(3,4-dimethylphenoxy)-5-(2-pyrrolidin-1-yl-methylpyrrolidine-1-carbonyl)phenyl]-3-phenylurea, and 4-(3,4-dichlorophenoxy)-3-[3-(3,5-difluorophenyl)ureido]-N-(2-pyrrolidin-1-yl-ethyl)benzamide.

8. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula II

9. The compound, pharmaceutically-acceptable salt or tautomer of claim 8, wherein: W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, and lower alkoxy; R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl, R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and R12 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl.

10. The compound, pharmaceutically-acceptable salt or tautomer of claim 9, wherein: W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, and hexyloxy; R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; R4 is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R10 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl; and R12 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl.

11. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula III

12. The compound, pharmaceutically-acceptable salt or tautomer of claim 11, wherein: R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and R12 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl.

13. The compound, pharmaceutically-acceptable salt or tautomer of claim 12, wherein: R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; R4 is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R6 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R10 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl; and R12 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl.

14. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula IV

15. The compound, pharmaceutically-acceptable salt or tautomer of claim 14, wherein: R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, wherein R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and R12 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl.

16. The compound, pharmaceutically-acceptable salt or tautomer of claim 15, wherein: R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; R4 is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R10 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl; and R12 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl.

17. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula V

18. The compound, pharmaceutically-acceptable salt or tautomer of claim 17, wherein: R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring.

19. The compound, pharmaceutically-acceptable salt or tautomer of claim 18, wherein: R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R4 is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; and R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring.

20. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula VI

21. The compound, pharmaceutically-acceptable salt or tautomer of claim 20, wherein: R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring.

22. The compound, pharmaceutically-acceptable salt or tautomer of claim 21, wherein: R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl, tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R4 is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; and R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring.

23. A compound of claim 1, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula VII

24. The compound, pharmaceutically-acceptable salt or tautomer of claim 23, wherein: R1 is selected from the group consisting of lower cycloalkyl and aryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, and halo; R2 is selected from the group consisting of lower alkyl, aryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, aryloxy, and halo; R5 is selected from the group consisting of hydrogen and lower alkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen and lower alkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; and R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, and aryl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system.

25. The compound, pharmaceutically-acceptable salt or tautomer of claim 24, wherein: R1 is selected from the group consisting of cyclopentyl, cyclohexyl, phenyl, naphthyl, and biphenyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, hydroxy, methoxy, ethoxy, propoxy, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, phenylethyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, phenylethenyl, phenylpropenyl, phenylcyclopropyl, biphenylcyclopropyl, and naphthylcyclopropyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of dihydroisoindolyl, dihydroindolyl, tetrahydroisoquinolinyl, and tetrahydroquinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, hydroxy, methoxy, ethoxy, propoxy, phenoxy, naphthyloxy, biphenylyloxy, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; and R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and biphenyl, or R8 together with R2 and the nitrogen to which they are attached may form a ring selected from the group consisting of dihydroisoindolyl, dihydroindolyl, tetrahydroisoquinolinyl, and tetrahydroquinolinyl.

26. The compound, pharmaceutically-acceptable salt or tautomer of claim 25, wherein: R1 is selected from the group consisting of phenyl, and naphthyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, chloro, and fluoro; R2 is selected from the group consisting of methyl, ethyl, phenyl, naphthyl, biphenyl, benzyl, phenylethyl, cyclopentylethyl, phenylethenyl, phenylcyclopropyl, or R2 together with R8 and the nitrogen to which they are attached may form a dihydroisoindolyl ring, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, propyl, methoxy, phenoxy, chloro, bromo, and fluoro; R5 is hydrogen or R5 together with R6 and the nitrogen to which they are attached form a pyrrolidinyl ring; R6 is hydrogen or R6 together with R5 and the nitrogen to which they are attached form a pyrrolidinyl ring; and R8 is selected from the group consisting of hydrogen, methyl, and phenyl, or R8 together with R2 and the nitrogen to which they are attached may form a dihydroisoindolyl ring.

27. A pharmaceutical composition comprising a compound, pharmaceutically-acceptable salt, tautomer or prodrug according to any one of claims 1, 7, 8, 11, 14, 17, 20, and 23 and a pharmaceutically acceptable carrier, adjuvant, or diluent.

28. A method of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, the method comprising administering to a subject in need of such treatment or prevention a compound, pharmaceutically-acceptable salt, tautomer or prodrug according to any one of claims 1, 7, 8, 11, 14, 17, 20, and 23.

29. A method of treating or preventing a condition selected from the group consisting of feeding disorders, sexual disorders, reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure, and sleep disturbances, comprising administering to a subject in need of such treatment or prevention a compound, pharmaceutically-acceptable salt, tautomer or prodrug according to any one of claims 1, 7, 8, 11, 14, 17, 20, and 23.

30. The method of claim 29 wherein the condition being treated or prevented is a feeding disorder.

31. The method of claim 30 wherein the feeding disorder is selected from the group consisting of obesity, bulimia and bulimia nervosa.

32. A method of treating or preventing obesity, comprising administering to a subject in need of such treatment or prevention a compound, pharmaceutically-acceptable salt, tautomer or prodrug according to any of claims 1, 7, 8, 11, 14, 17, 20, and 23.